PharmaChem Yearbook 2025 by Retail News

RECOMMENDATIONS FOR GOVERNMENT

Sinéad Keogh, Director, BioPharmaChem Ireland, and Joyce Fitzharris, Chairperson of BioPharmaChem Ireland and President of SK pharmteco, Small Molecule, Europe, explain the five key priorities for the next Programme for Government, as identified at the BPCI Leaders Forum, which are vital for the continued development of Ireland as a global leader in biopharma.

MANUFACTURING REPORT

Ibec’s 2024 Manufacturing in Ireland Report highlights the critical role of the manufacturing sector to Ireland’s economy, outlines CEOs’ confidence in the sector going forward, and reveals nine key priorities for the incoming government.

16 BIOPHARMACHEM IMPACT CONFERENCE & AWARDS

BioPharmaChem Impact 2025 and the inaugural BioPharmChem Awards 2025 will take place on May 8th, 2025, at the Kilashee House Hotel in Co. Kildare.

18 MANUFACTURING ENGINEERING APPRENTICESHIP

The national Manufacturing Engineering Apprenticeship programme is going from strength to strength, writes Jennifer Lynch, Apprenticeships Project Executive at Ibec.

20 STEM ENGAGEMENT

BioPharmaChem Ireland has commissioned two surveys to map out industry supported STEM engagement with primary and post-primary schools across Ireland, explains Eimear Curran, BioPharmaChem Ireland.

22 KEEPWELL MARK

Sarah-Jane Willoughby, Head of Marketing and Strategic Business Lead, Ibec, on how Ibec’s KeepWell standard is leading the way for workplace wellbeing and the future of work.

24 SUSTAINABILITY

Michael Kilkelly, Senior Executive EHS, BioPharmaChem Ireland, argues that the Irish pharma sector’s collaborative spirit should make for a unique and lasting journey towards sustainability.

26 BIOPHARMACHEM SKILLNET

Susan Costello, Network Director, BioPharmachem Skillnet, reflects on what has been a hugely successful and productive 12 months for the BioPharmaChem Skillnet.

28 NIBRT

Talent remains key to unlocking Ireland’s biopharma manufacturing future, writes John Milne, Director of Bioprocessing Training Alliances and Innovation at NIBRT. 4 44 26 10

32 HEALTH PRODUCTS REGULATORY AUTHORITY

Ellen McGrath, Medicine Shortages and Borderline Classification Manager, HPRA, explains how stakeholders will manage medicine shortages under current and future legislative frameworks.

34 SSPC

SSPC, Research Ireland’s cutting-edge research centre, continues to deliver innovative solutions in biopharma via its unique collaborative ecosystem.

36 PHARMACEUTICAL MANUFACTURING TECHNOLOGY CENTRE

The Pharmaceutical Manufacturing Technology Centre (PMTC) continues to address manufacturing issues within the biopharma manufacturing sector.

38 SOUTH EAST TECHNOLOGICAL UNIVERSITY

The Pharmaceutical and Molecular Biotechnology Research Centre at the South East Technological University was the winner of the Research and Development Achievement Award at the 2024 Pharma Industry Awards for their work on ocular drug delivery technologies.

44 CRISPR

Professor Niall Barron, Principal Investigator, Cell Engineering Lab, NIBRT, explains CRISPR technology, its benefits and the ethical challenges it brings to gene editing.

51 ARTIFICIAL INTELLIGENCE

How AI can help Irish Life Sciences companies solve the competitiveness conundrum, by Alan Dickson, Partner, Business Consulting, EY, and Sinead McDonagh, Director Data Analytics & AI, EY Life Sciences.

56 IDA IRELAND

Recent announcements of heavyweight investments point to a bright future for Ireland’s biopharma sector, writes Rory Mullen, Head of BioPharma and Food at IDA Ireland.

58 MERCK

Merck impacts life and health with science, and is committed to delivering breakthroughs that enhance lives globally.

60 BRISTOL MYERS SQUIBB

One of the first pharma companies to launch in Ireland, Bristol Myers Squibb continues to invest in its business here, with a Sterile Drug Product facility at the company’s Cruiserath Campus set to open in 2026.

62 ANALYTICAL SOLUTIONS: ALMAC

With more than 55 years of experience across five global locations, Almac can add real value to drug development and commercialisation programmes.

64 CALIBRATION & VALIDATION: ELLAB

Ellab’s new Whitegate Academy in Co. Cavan is a strategic commitment to Life Sciences and workforce development, offering advanced, tailored training programmes in validation and calibration from spring 2025.

66 SOURCING: NCC

Paul Power, Biopharmaceutical Product Manager, NCC, discusses the challenges of sustainable sourcing and how NCC can assist.

68 LOGISTICS & TRANSPORT: DHL SUPPLY CHAIN

DHL Clinical Logistics are helping to empower pharmaceutical advancements through comprehensive supply chain solutions, including the critical management of clinical trials.

70 ELI LILLY

Eli Lilly’s brand new state-of-the-art Kinsale facility is a blueprint for the future of pharmaceutical manufacturing, not just in Ireland but worldwide.

72 WASTE MANAGEMENT: INDAVER

Indaver is playing a key role in the transition to sustainable waste management.

74 MEASURING DEVICES: ENDRESS+HAUSER

Endress+Hauser’s Compact Line of level and pressure measurement devices were developed specifically for use in the Life Sciences and food/beverage industries.

76 HEALTHCARE LOGISTICS: KUEHNE+NAGEL

Seamus Keane, VP Pharma and Healthcare Europe, Kuehne+Nagel, warns about black swan events and their impact on healthcare logistics.

INGREDIENTS: CAMIDA

Tipperary-based Camida took home the Pharma Supplier of the Year Award at the 2024 Irish Pharma Industry Awards.

HAZARDOUS WASTE SOLUTIONS: SOLTEC

Soltec recently celebrated 30 years in business by winning two prestigious environmental awards.

WIRELESS MONITORING: KELSIUS

Digital transformation and the use of wireless monitoring allows staff to focus on what matters.

WASTE SOLUTIONS: INOPSY

86 SCIENTIFIC EQUIPMENT/TECHNICAL SOLUTIONS

Founded in 1780, Mason Technology is a trusted provider of high-quality scientific equipment and technical solutions to the pharma and biopharma industries.

87 SPECIALIST INTEGRATED CDMO: HOVIONE

Hovione has 60 years of experience as a Specialist Integrated CDMO, with a range

that includes drug substances, drug product intermediates and drug products.

88 INGREDIENTS: BARENTZ

Ingredients distributor Barentz offers pharmaceutical manufacturers a range of ingredients to suit every application.

90 TALENT ACQUISITION: CPL

Headquartered in Dublin, Cpl is a multinational global talent solutions provider.

91 DATA AUTOMATION

For over four decades, Bonner has been a trusted partner for pharma businesses seeking digital transformation.

92 MODULAR CLEANROOMS

Dawsongroup tcs offer modular cleanrooms that are adaptable and compliant controlled environments.

94 DOCUMENTATION: TWI

Twi: making your documentation an asset.

Managing Director: Patrick Aylward

Future-proofing our Biopharma Industry

Sinéad Keogh, Director, BioPharmaChem Ireland, and Joyce Fitzharris, Chairperson from BioPharmaChem Ireland and President of SK pharmteco, Small Molecule, Europe, explain the five key priorities for the next Programme for Government, as identified at the BPCI Leaders Forum, which are vital for the continued development of Ireland as a global leader in biopharma.

On October 18, 2024, BioPharmaChem Ireland (BPCI) convened 80 chief representatives for its annual ‘Leaders Forum’ to discuss shifts in the global landscape. The pandemic underscored the importance of local supply chains and health sovereignty, prompting nations to prioritise domestic manufacturing. As global competitors increase investment incentives, it is crucial for Ireland to adopt transformative policies to maintain its competitive edge.

Ireland’s biopharmachem industry is on a mission: to grasp Ireland’s unique opportunity for global leadership and transform the healthcare and lives of patients across the world. It is clear that our industry now stands at a critical juncture, with rising global competition threatening our position as a global leader in Life Sciences manufacturing. Our ability to compete at a global level is critical to the continued growth and success of Ireland’s biopharma industry. The next government has a pivotal role to play in shaping the sector’s future, determining whether it can maintain its competitive edge, drive economic growth and continue as a cornerstone of the Irish economy, or risk stagnation.

Industry perception of Life Sciences

RECOMMENDATIONS FOR GOVERNMENT

manufacturing, whilst positive, has seen a shift to more “cautious” optimism. Strategic, coordinated investments that drive innovation, talent development and infrastructure are essential to help the industry navigate escalating costs and geopolitical pressures.

Below, we reveal five key priorities, identified at our annual BPCI Leaders Forum. Over the course of the past two months, BPCI have met and engaged with senior policy advisors from across most political parties both pre- and post-election to ensure our priorities for the next Programme for Government are heard.

1. Priority 1: Establish a National Life Sciences Strategy

Our ability to compete at a global level is critical to the continued growth and success of Ireland’s biopharmachem industry. We need to sharpen our competitive edge and future-proof the sector with a strategy that leverages our Life Sciences ecosystem strengths of collaboration, world-class talent and effective leadership. A cohesive national Life Sciences strategy, backed by sufficient resources, will drive industrial policies

that promote cross-sector cooperation. Competitor nations are increasingly using national and cluster ecosystem strategies to gain a coordinated advantage. An Irish Life Sciences Strategy is vital to strategically allocate resources, nurture talent, boost research capabilities and foster an innovationdriven culture.

BioPharmaChem Ireland Recommends: 1.1. Establish and resource a permanent ’Office of Life Sciences’ to drive a national Life Sciences and health technology strategy within the Department of Enterprise, Trade and Employment to drive effective strategic planning and oversee a national Life Sciences strategy, addressing key competitive issues and essential requirements for a thriving ecosystem. Review global best practice in the Life Sciences ecosystem development as a mechanism for strategy/ecosystem development in Ireland.

2. Priority 2: Invest in Skills and Talent

Unlocking the surplus in the National Training Fund (NTF) marks a critical step in Ireland’s

Joyce Fitzharris, Chairperson, and Sinead Keogh, Director, of BioPharmaChem Ireland, pictured at the BPCI’s Annual Leaders Forum in Kilkenny.

RECOMMENDATIONS FOR GOVERNMENT

ability to address key skills needs. A highly skilled workforce is the lifeblood of Ireland’s biopharmachem industry, which offers unique opportunities for skilled talent to work at the cutting edge of healthcare with global reach.

The industry employs over 80,000 people directly and indirectly, over half of whom are third-level graduates. The EGFSN report ’Skills in BioPharma’ forecasts that 21,000 additional jobs are likely to be created in the biopharma sector in Ireland by 2027. Our future success and ability to innovate, compete, and set ourselves apart globally, depends on attracting, retaining, and developing highly skilled talent.

BioPharmaChem Ireland Recommends:

2.1. Investment in Higher Education Institutes promotes industryacademia collaboration by supporting undergraduate education, facilitating new innovative models of delivery and funding greatly needed capital projects, technology and equipment.

2.2. Launch a National Training Voucher Scheme to address the cost of training for employers and empower them to boost in-company training and widen participation in upskilling and reskilling.

2.3. Improve gender balance, equity and inclusion in STEM education at third level and strengthen and resource

career guidance in second level schools for Technology, Engineering and Mathematics professions.

3. Attract Investment and Fostering Innovation

Ireland is a global hub for innovation and manufacturing excellence in biopharma. With our significant research capabilities, dedicated research centres and close collaboration between academia and industry, we have the right foundations for a world-class innovation ecosystem at the leading edge of global science and the delivery of innovative therapies for patients. To remain a global leader in the face of increasing global competition, the sector needs government policy that fosters innovation and drives research and development.

BioPharmaChem Ireland Recommends:

3.1 Continue to scale public investment in research and innovation by prioritising investment for DFHERIS and Taighde Éireann-Research Ireland.

3.2 Accelerate the digital transition by supporting industry in its work to meet national and EU digital transition targets and keep in line with national digital strategies.

3.3 Ensure the R&D tax credit remains relevant and encourages applied and emerging research.

4. Investing in Energy and Infrastructure

According to the National Competitiveness and Productivity Council, Ireland must do more to ensure Ireland remains an attractive place to invest and do business by dealing with outstanding infrastructure deficits, in housing, energy, water and wastewater. Addressing infrastructure deficits that stifle growth, deter investment and hinder the development of large service is essential for maintaining the sector’s competitiveness.

BioPharmaChem Ireland Recommends:

4.1 Embrace the decarbonisation challenge with an ambitious energy strategy that balances decarbonisation, competitiveness and supply security.

4.2 Commit to an ambitious housing policy that addresses housing supply issues to attract and retain talent.

4.3 Enable the delivery of world-class regulatory, transport and utilities by adequately resourcing and streamlining the regulatory, planning and consent local authorities and consent processes.

4.4 Complete commitments related to National Development Plan regarding

Ireland’s biopharmachem industry is on a mission: to grasp Ireland’s unique opportunity for global leadership and transform the healthcare and lives of patients across the world.

Let’s outdo cancer

A world where people with cancer live better and longer lives. That’s Pfizer’s vision. We are accelerating breakthrough cancer medicines that bring new hope to patients everywhere.

Taking cancer on

Pfizer is tackling one of the most challenging health crises of our time. Nothing is more urgent, or more personal, than our goal to outpace, outsmart, and outmaneuver cancer at every turn.

RECOMMENDATIONS FOR GOVERNMENT

major infrastructure projects, particularly in the regions, with strategic projects vital for regional connectivity and the achievement of balanced regional development.

4.5 Accelerate the transition to carbon neutrality by scaling up and expanding industry supports for renewables and energy-efficiency. Provide new financial supports and tax credit incentives to encourage firms to embed eco-design principles when innovating.

5. Drive Sustainability while Supporting Industry in Navigating the Regulatory Environment

Ireland’s biopharma industry is a leader in sustainability, both within Ireland and globally, with the highest manufacturing standards and sustainability performance. Despite a 48.2% increase in production output, energy consumption by BPCI members has decreased by 0.4%. Water consumption has decreased 1.2%. However, the industry is now facing a surge of

overlapping regulations that could delay timely access to, and potentially limit the availability of, essential treatments. By prioritising regulatory reforms that support patient-centric innovation, the sector can continue developing cutting-edge products while advancing towards a sustainable future.

BioPharmaChem Ireland Recommends:

5.1 Partner with the sector to advocate for EU-level regulatory reforms that avoid disproportionate negative impacts on the industry.

5.2 Ensure regulatory agencies and delivery bodies are adequately staffed and resourced to help industry effectively navigate complex new regulatory requirements.

5.3 Partner with sector stakeholders to implement new regulations and capture necessary feedback.

5.4 Re-establish the ‘Better Regulation Unit’ and establish a new arms-length regulatory oversight body.

5.5 Address unfair costs proposed under Urban Wastewater Treatment Directive, working with industry to implement the directive that distributes costs in a fair, proportionate manner.

5.6 Employ a fit-for-purpose EU REACH U-PFAS Restriction on Life Sciences, allowing for derogations to be granted across all parts of supply chains to avoid medicine shortages for patients.

Ireland’s successful biopharmachem sector is built on our world-class talent, enduring commitment to compliance, and close collaboration between industry, the research community and government. Through partnership with government, we can secure Ireland’s position as the global biopharmachem leader, at the leading edge of science, sustainable manufacturing, and healthcare, transforming the lives of patients across the world through our commitment to patient safety, production quality, and equitable access to medicines.

Cara Partners 40 Years and Growing

A leaf from Ginkgo Biloba , believed to be the oldest living species of tree. The seeds and leaves of Ginkgo Biloba have been used in Chinese traditional medicine for over 800 years

Cara Partners manufactures a quantified extract of Ginkgo Biloba for the EU and Chinese market Ginkgo Biloba extract products are used to treat a variety of conditions associated with blood circulation disorders

Manufacturing Sector Performing Strongly Despite Rising Costs

Sharon Higgins, Executive Director of Membership and Sectors at Ibec, pictured at the launch of Ibec’s 2024 Manufacturing in Ireland Report.

MANUFACTURING

Ireland’s manufacturing sector continues to perform strongly despite rising costs, according to Ibec’s 2024 Manufacturing in Ireland Report, ‘Facing Forward: Manufacturing Confidence Amidst Evolving Challenges’.

There is clear evidence of improved efficiency and productivity with the introduction of AI, according to the report, which reveals a steady confidence among manufacturers, with approximately 70% expressing a positive outlook. However, challenges persist, particularly rising operational costs related to wages, raw materials and energy. Despite these hurdles, many manufacturers expect improvements in productivity and profitability.

Confidence in the manufacturing sector shows little or no change from the 2023 survey, with seven in 10 expressing positivity at both national and enterprise level. In terms of cost challenges, over three quarters of all respondents expect increases in wage growth (76%), while just over half (52%) expect increases in raw materials costs, with the same figure (52%) expecting increases in transport costs. Beyond cost increases, almost two thirds of respondents (65%) expressed concern about attracting and retaining talent, while over half of respondents (53%) noted the availability of housing for employees as a major challenge.

A Critical Role in the Economy

The Ibec report details the manufacturing sector’s contribution to the overall economy. In 2023, manufacturing employed over 220,841 individuals, supporting numerous families and generating substantial economic benefits. With total goods exports at €197.25 billion, the sector produced €13.7 billion in wages, €3.03 billion in income tax, and over €10 billion in corporation tax, highlighting its essential role in sustaining public services and infrastructure.

“Manufacturing plays a critical role in the Irish economy, employing a significant portion of the workforce and contributing 44%, over €10 billion, of corporation tax revenue,” noted Sharon Higgins, Executive Director of Membership and Sectors at Ibec. “With the rapid evolution of new technologies, the sector is undergoing significant change, and it is essential to adapt to these developments.”

Priorities for Government

The report outlines nine key priorities that manufacturing organisations have for the incoming Government.

Although operational related costs are expected to continue to increase - wage growth (76%), raw materials (52%), transport (52%), energy (34%)- there is an expectation that productivity (48%), profitability (37%) and domestic sales (24%) will also increase.

1. Help manufacturers develop strong talent pipelines

2. Reduce energy costs

3. Geopolitics and trade uncertainties

4. Protect companies from rising costs

5. Embrace digitilisation and AI

6. Create a taxation environment which rewards innovation and excellence

7. Engage in better regulation

8. Enhance critical infrastructure

9. Set out a key strategy for the sector

Ibec’s 2024 Manufacturing in Ireland Report, ‘Facing Forward: Manufacturing Confidence Amidst Evolving Challenges’.

MANUFACTURING REPORT

Sharon Higgins stressed that the incoming Government must address the competitiveness challenges facing the manufacturing sector “to ensure its continued success during this transformative period. This includes building a robust talent pipeline to drive the sector forward.”

Currently, 65% of companies cite talent availability as a major challenge. “We welcome the recent allocation of €1.5 billion from the National Training Fund, a move we have long advocated for, as part of a multi-annual strategy for capital investment in research and innovation,” Sharon Higgins stressed. “However, greater industry engagement with the education sector is now necessary. Additionally, streamlining work permit and visa processes is vital for attracting the talent needed to sustain the industry's growth.”

The Challenges Ahead

The greatest challenge facing the sector is that of attracting/ retaining workforce. The cost of labour has more than doubled from 8% in 2023 to 19% in 2024 and may encompass both existing costs (wage increases, statutory sick-pay, Work Life Balance leave) and prospective costs (auto-enrolment, Pay Transparency, Living Wage).

The top challenges for manufacturers are:

1. Cost of labour (major challenge for 70%) and attracting and retaining talent (major challenge for 65%)

2. Availability of housing for employees (major challenge for 53%)

3. Cost of energy (major challenge for 47%).

4. Weaker global growth (major challenges for 37%)

5. Cost of raw materials (major challenge for 36%)

6. Sustainability and regulation (major challenges for 37%)

Nine in 10 companies continue to agree that sustainability, defined as “the ability to develop without depleting natural resources or impacting on the environment”, is a priority for their business. Given the

priority attached to sustainability and impending reporting directives, 92% plan to enhance or introduce initiatives in the next 1-2 years to reduce their environmental impact and address customer expectations.

The Impact of AI

AI, or Artificial Intelligence, is defined as the technology that enables computers and machines to simulate human learning in areas such as problem solving, decision making and creativity. Over half of companies, (56%) plan to adopt AI, primarily to improve efficiency, increase innovation and increase profits. 17% plan to enhance existing initiatives and 44% plan to introduce new AI initiatives. 39% say AI is a priority for their business.

AI proved a higher priority for pharmaceutical businesses, with over 54% highlighting it as a priority for their business and 75% planning to adopt AI initiatives over the next 1-2 years. This stands in contrast to engineering firms, where only 25% have identified AI as a priority, with 50% of planning to adopt AI over the same time period.

The number one priority identified for companies is improving profitability (25%), with half (51%) citing it as top three priority, followed by developing new markets (15%), increasing production (14%), access to labour (9%), and cost of labour (8%).

Spiralling Costs

Spiralling costs remain a key concern, right across the industry. “Manufacturers, like many facets of Irish business, are concerned with rising costs,” Sharon Higgins stated. “To help alleviate this concern, we urge the government to adopt a new national energy and industrial strategy that accelerates the roll-out of low-cost renewable generation and storage technologies, invests in the national grid, and supports the electrification of homes and businesses. In the short term, a subvention to offset system charges and the PSO levy would reduce costs and align Ireland with European norms. Expanding industry supports for renewables and energy efficiency is key to a secure, sustainable, and competitively priced energy system that fosters business growth.”

Pictured are (l-r): Paul Condon Corporate affairs, Camida; Maeve Byne, EVP and Site Head, Sterling Pharma Solutions; Brian Killen, Digital Transformation Lead, MSD; Sharon Higgins, Executive Director, Membership and Sectors, Ibec; Sinead Keogh, Director of BioPharmaChem Ireland, Head of Sectors, Ibec; and Siobhan Dean, Deputy Director, BioPharmaChem Ireland.

Helping Irish business go global

Mark Barrett

MANUFACTURING REPORT

Case Study: MSD

The Ibec report includes a number of case studies, including one on MSD, where Brian Killen, Digital Transformation Lead, reveals how digital transformation and sustainability are reshaping the way MSD operates, both in Ireland and globally.

MSD Ireland’s twin transition strategy combines both sustainability and digitalisation in order to achieve a long-lasting impact. MSD uses advanced technologies like AI-powered tools, energy-saving systems, and waste management programmes to support both digital innovation and sustainability goals.

“Digital technologies allow us to track progress against ESG targets in real time,” reveals Brian, citing MSD’s award-winning ‘See Green, Be Green’ programme, which focuses on five important areas of sustainability:

1. Carbon transition: MSD’s 7.3MW solar farm in Ballydine, Co. Tipperary, has reduced the site’s carbon footprint by 2,336 tonnes annually. Similar successes include a solar PV system at the Carlow site, with plans to expand renewable energy projects

across the network by 2025.

2. Waste and water management: Digital systems monitor and minimise waste, while promoting sustainable water usage across all sites.

3. Green chemistry and process development: Transforming processes and collaborating with suppliers to minimise the carbon footprint of MSD’s manufacturing processes.

4. Biodiversity protection: Collaborating with external experts, local communities and employees to support local biodiversity efforts within and nearby MSD facilities.

5. Culture and engagement: Employee-driven innovation creates a sustainability-first mindset across all operations.

MSD’s ESG strategy includes access to medicine, including one of the largest donation programmes globally for diseases like river blindness. The company is also committed to making STEM education much more inclusive, including breaking down barriers across socio-economic and gender lines. “For Ireland to remain competitive, the private and public sectors must work together to foster a highly skilled workforce. This includes addressing barriers in STEM education and ensuring equal opportunities for all backgrounds,” summarised Brian Killen.

Pictured are: James Fulham, Chief Operating Officer, North Cork Creameries; Jackie Murphy, General Manager at Alcon Ireland; Sharon Higgins, Executive Director, Membership and Sectors, Ibec; and Brian Killen, Digital Transformation Lead, MSD; at the launch of the Ibec 2024 Manufacturing in Ireland Report.

Brian Killen, Digital Transformation Lead, MSD.

INNOVATIVE PLASMA THERAPIES

A pioneer in the plasma industry, Grifols manufactures lifesaving plasma-derived medicines to treat chronic and rare conditions, as well as infectious diseases. Learn more about

at www.grifols.com

BioPharmaChem Impact 2025: Realising the Potential of the Ecosystem

Leaders Conference, Awards & Gala Dinner, 08 May 2025

Cultivating the BioPharmaChem ecosystem: Sinéad Keogh, Director, BioPharmChem Ireland, explains why the BioPharmChem Impact Conference 2025 is the highlight of the calendar, and reveals the organisations’s brand new awards programme.

Ireland is often hailed as a land where connections flourish, with only two degrees of separation between individuals. While this inherent closeness is beneficial, it is the purposeful gathering of minds that truly fosters meaningful connections. This is precisely why initiatives like the BioPharmChem Impact Conference are vital. They offer us a unique opportunity to unite our ecosystem and shape the future of BioPharmaChem in Ireland.

At our inaugural conference last year, we gathered an inspiring sellout crowd of 200 leaders, all dedicated to addressing the significant challenges facing our sector, ranging from digitalisation and artificial intelligence to sustainability and talent acquisition. It was a remarkable experience to witness so many passionate individuals collaborate on these critical topics.

We warmly invite you to join us once again on May 8th, 2025, at the Kilashee House Hotel in Co. Kildare, as we continue these essential conversations. This year, we anticipate welcoming over 350 senior

leaders, including influential policymakers, business executives, and esteemed academics, all eager to gain insights and forge strategic partnerships through abundant networking opportunities.

Where Innovation Thrives

The theme for 2025, ‘Realising the Potential of the Ecosystem’, resonates deeply with our collective ambition. It is not merely about growth; it is about nurturing an environment where ideas can blossom and innovation thrives. While Ireland’s biopharma sector is celebrated for its world-class manufacturing capabilities, we must also focus on cultivating other integral facets of the ecosystem. We recognise a tremendous opportunity in expanding the Global Business Services (GBS) ecosystem.

At Impact 2025, we will unveil a comprehensive strategy for GBS, aimed at building an interconnected ecosystem that spans research and development, innovation hubs, and digital services. This initiative

BIOPHARMACHEM IMPACT CONFERENCE & AWARDS

transcends merely filling gaps; it is about creating a fertile ground where innovation can flourish, ensuring that every segment of the value chain is adequately supported and nurtured. Such a holistic approach will enable us to cultivate a truly world-class environment for biopharma.

BioPharmChem Awards 2025

We are thrilled to announce the launch of the inaugural BioPharmChem Awards, a celebration of excellence and innovation within our industry. This programme presents a significant opportunity to recognise the outstanding achievements that are propelling Ireland to the forefront of global biopharma. With six categories aligned to our strategic goals, the awards will honour the exceptional contributions made across the sector:

• BioPharmaChem Company of the Year Award

• Best Talent Strategy of the Year Award

• Sustainable BioPharmaChem Company of the Year Award

• Best Digitalisation/Process Innovation of the Year Award

• BioPharmaChem Partner/Supplier of the Year Award

• Emerging BioPharmaChem Company of the Year Award 2024

These awards are not merely about celebrating success; they are about showcasing our sector to stakeholders and solidifying the message that Ireland is a global leader in biopharma and chemicals. Submissions for the awards will also reinforce BPCI’s ‘Messaging House’ initiative by providing tangible proof points that we can promote to various stakeholders.

At BPCI, we have embarked on this crucial ‘Messaging House’ project to establish a clear and consistent narrative for our sector. This initiative will define our language, tone, and key messages for all communications, ensuring that we speak with one unified voice. In a world inundated with information, consistency in communication is vital for building trust and credibility, especially in our sector, where complex scientific and technical information must be effectively conveyed to policymakers, the media, and the public. We eagerly anticipate launching our ‘Messaging House’ early in the new year and showcasing the excellence of our sector through the Awards programme.

Seeking Partners to Support BioPharmaChem Impact 2025

We invite you to consider sponsoring this transformative event. With an array of sponsorship packages available - Platinum, Gold, and Silver - there is an opportunity for every organisation to play a pivotal role in

shaping the future of our industry. Your support will not only elevate your visibility among industry leaders but also demonstrate your commitment to the growth of the BioPharmaChem sector in Ireland.

Feedback from post-event surveys for BioPharmaChem Impact 2024 has been overwhelmingly positive, with 70% of respondents rating it a 9 or 10 out of 10 when asked about their likelihood to recommend the event to a colleague. An impressive 97% of delegates rated the conference as excellent or very good, with the same percentage expressing satisfaction with the speakers and format, as well as the networking opportunities provided.

Join us in this journey of growth, innovation, and excellence as we cultivate the BioPharmaChem ecosystem together. Let us shape the future, celebrate our achievements, and inspire the next generation of leaders in our remarkable industry.

BioPharmaChem Impact 2025 and the inaugural BioPharmChem Awards 2025 will take place on May 8th, 2025, at the Kilashee House Hotel in Co. Kildare.

Feedback from post-event surveys for BioPharmaChem Impact 2024 was overwhelmingly positive.

BioPharmaChem Impact: a gathering of minds that fosters meaningful connections.

Sinéad Keogh, Director, BioPharmChem Ireland, addressing delegates at BioPharmaChem Impact 2024.

Apprenticeship Programme a Massive Success

The national Manufacturing Engineering Apprenticeship programme is going from strength to strength, writes Jennifer Lynch, Apprenticeships Project Executive at Ibec.

The national Manufacturing Technician and Engineer apprenticeship programmes have grown significantly in recent years, with over 100 companies across Ireland now engaged and five academic providers delivering the programmes.

Initially launched in 2017, the Manufacturing Engineering Apprenticeships were developed by Irish Medtech along with ATU Galway (co-ordinating provider) and representatives from the medtech industry. The programmes were developed to offer access to world class talent to global and homegrown manufacturing organisations and help them achieve growth. They aim to meet the needs of a broad range of manufacturing sectors, from medtech, biopharma and polymer technology, to engineering, machinery, construction and food.

With over 500 apprentices registered since 2017, the programmes are sought after by school leavers, career changers and even those people already employed in a manufacturing facility. We recorded a 40% increase in the number of apprentices registering annually between 2017 and 2024.

Bridging Skills Gaps

Developed by industry for industry, these programmes are designed to meet the needs of employers and bridge skills gaps. The apprenticeships are currently delivered in ATU Galway, MTU Cork, TUS Midwest and ATU Sligo. We are delighted to confirm the programmes will be launched in DKIT Dundalk in summer 2025, providing apprenticeship opportunities for a whole new region.

Employers may decide to recruit externally but it is also a fantastic opportunity for existing employees. The apprentice can sign on to the Manufacturing Technician Apprenticeship (two years, level 6) or the Manufacturing Engineer Apprenticeship (three years, Level 7).

Level 8 Programme Launched

September 2024 also saw the launch of the Advanced Manufacturing Engineering programme (four years, Level 8) in both Galway and Cork, further addressing the skills needs of employers across a number of sectors. This newly developed Honours degree programme provides an important progression route for engineering apprentices and existing technicians who wish to improve their qualifications through the apprenticeship model, building on their level 6 and 7 skills. The programme follows a similar model to level 6 and 7, with a 15-week academic block release and gives candidates exposure to more advanced engineering theories and applications.

In October 2024, Manufacturing Apprentice Jodie Whyte won apprentice of the year in the Engineering category at the Generation Apprenticeship awards. Jodie is working with J&J Vision in Limerick and joined the very first Level 8 Advanced Manufacturing Engineer cohort.

The feedback from companies engaged to date has been outstanding. Company representatives believe the programmes are closely aligned with the most prominent skills needs in manufacturing. The academic modules effectively support the apprentices’ on-the-job learning. The apprentices are very enthusiastic to learn and take a real hands-on approach. Many employers have reported apprentices playing a part in solving complex issues with the manufacturing environment. The modules they study in college are very applicable to their work as a Technician/Engineer.

“Industry collaborating with academia has resulted in a well-designed programme,” noted Claude Costelloe, Zimmer Biomet. “It enables us to deliver a constant pipeline of talent to meet current and future needs of the business.”

David Quaid, Stryker, said, “The Manufacturing Engineering Apprenticeship is a great fit to meet the diverse requirements we have in our organisation. The industry and academia partnership, course content and the mentorship structure are all focused on developing a pipeline of talent to meet the needs of our industry today and into the future.”

Companies across Ireland have a great deal to gain from adopting the apprenticeship model. These programmes can help build your talent pipeline and future-proof your organisation by combining excellent educational qualifications with specialised on-the-job training. The apprentices are fully immersed in the organisation and have time to put their academic learning into practice in a real life manufacturing facility. This model ensures that experienced, work-ready candidates graduate from the programme.

To learn more about the manufacturing apprenticeships and how they can benefit your organisation, please contact trish.breen@ibec.ie

Jennifer Lynch, Apprenticeships Project Executive at Ibec.

McCann FitzGerald LLP

Contact

Fiona O’Beirne Partner, IP & Regulation

+353 1 607 1311 fiona.obeirne@ mccannfitzgerald.com

Adam Finlay

Partner, Data Protection

+353 1 607 1795 adam.finlay@ mccannfitzgerald.com

mccannfitzgerald.com

Conor Cunningham Partner, Litigation

+353 1 607 1225

conor.cunningham@ mccannfitzgerald.com

Laura Treacy

Partner, Competition

+353 1 511 1595

laura.treacy@ mccannfitzgerald.com

STEM ENGAGEMENT

STEM-ming the Skills Gap

BioPharmaChem Ireland has commissioned two surveys to map out industry supported STEM engagement with primary and postprimary schools across Ireland, writes Eimear Curran, BioPharmaChem Ireland.

The security of the future skills and talent pipeline of the Irish BioPharmaChem sector is one of the industry’s most pressing priorities.

With some 21,000 additional jobs within the sector forecasted by 2027, it’s imperative that industry focuses not just on the growth and development of existing talent but nurturing future talent and sparking a lifelong interest in STEM.

A highly skilled workforce is the lifeblood of Ireland’s biopharma industry, which offers unique opportunities for skilled talent to work at the cutting edge of healthcare with global reach. Our future success and ability to innovate, compete, and set ourselves apart globally, depends on attracting, retaining, and developing highly-skilled talent, including greater numbers of PhDs.

National Training Fund

BPCI welcomes the release of €1.5 billion from the National Training Fund which will support universities and training and upskilling for workers. Between 2025 and 2030, €300 million will go to research and innovation, with higher education funding rising from €50 million to €150 million by 2029. Additionally, PhD stipends will increase from €22,000 to €25,000 in 2025, a welcome move for our sector, which employs 25% of all PhDs.

BPCI is working closely with colleagues in industry and across the ecosystem to ensure that people of all backgrounds are aware of the full range of opportunities and careers available.

Surveying BPCI Members on STEM Engagement

BPCI is leading on five of the 10 Recommendations from the Expert Group on Future Skills Needs, Skills For Biopharma Report (April 2025).

To address Recommendation 4.1.1 Promoting Careers in Biopharma: creating a more structured approach for engagement between second level and industry, BioPharmaChem Ireland issued a survey to its members in August 2024 to assess the extent to which companies are involved in STEM education engagement. The survey seeks to establish:

• reasons for involvement;

• which demographics are prioritised and overlooked in engagement; the form of engagement;

• barriers to engagement;

• how companies can be assisted in participation.

The findings have shown strong engagement from industry, with 90% of companies surveyed actively engaging with schools on STEM education initiatives and programmes. Of those organisations, 55% companies have a STEM engagement strategy in place.

The main reason for engagement for the majority of organisations is “to address skills gaps” and to cultivate “the future talent pipeline”.

28% of pharma companies have spent over €10,000 on primary and post-primary STEM Education in 2023.

Eimear Curran, BioPharmaChem Ireland.

STEM ENGAGEMENT

Engagement with primary schools is extremely important to engage children in STEM education early, to help cultivate the future talent pipeline.

One respondent commented that their organisation takes part in STEM education engagement initiatives and programmes: “To inspire the next generation of scientists, engineers and technologists, and to raise awareness about the pharmaceutical industry and career paths available. To support young people in making informed choices about their education and career journey.”

It was also found that the majority of industry STEM education engagement was targeted at secondary schools (30%), with 27% of companies targeting third level and 16% engaging further education.

Furthermore, the results demonstrated that pharma companies are investing in STEM education engagement, with 67% of companies spending over €1,000 on primary and post-primary STEM education in 2023. Of that, 28% of companies invested over €10,000 and 11% of companies spent over €100,000 in school STEM education activities and programmes.

Companies cited the biggest barriers to engagement were a lack of time (33%), and constraints due to site security/sterility (22%).

45% of companies said they intend to increase the level of STEM education engagement in the future.

Targeting Primary and Post-Primary Schools

Following on from the industry survey, to further map out industry supported STEM engagement in Ireland, BPCI, in conjunction with the Department of Education, Department of Enterprise, Trade and Employment, and STEM South West,

launched a survey targeting every primary and post-primary school in the country. The purpose of this exercise is to better understand the needs of schools, how industry can support them more effectively and identify any gaps in provision.

Some 591 schools from across all 26 counties participated in the survey, with 506 primary schools and 85 post-primary schools taking part. The survey was also translated into Irish and 20 Gaelscoileanna contributed to the survey.

Further Engagement Opportunities

The data and responses are currently being analysed but preliminary findings have shown that there are further opportunities for industry to become more involved with schools. 47% of sampled schools engage in extra-curricular STEM programmes; however, a majority of schools (49%) answered that they don’t take part in any of these initiatives.

BioPharmaChem Ireland will publish an Industry-Schools STEM Engagement report in early 2025, outlining key findings and recommendations developed in collaboration with the Department of Education. This will form the basis of a series of best practice sessions to provide additional support for companies interested in engaging more with schools. The survey has also highlighted gaps in participation and will allow industry to target schools and areas which aren’t benefitting from these programmes and initiatives.

BioPharmaChem Ireland will publish an Industry-Schools STEM Engagement report in early 2025, outlining key findings and recommendations.

Ireland Continues to Punch above its Weight

Sarah-Jane Willoughby, Head of Marketing and Strategic Business Lead, Ibec, on how Ibec’s KeepWell standard is leading the way for workplace wellbeing and the future of work.

Employee wellbeing has become more critical than ever, with both current and prospective employees placing greater emphasis on their health, satisfaction and work-life balance. These priorities are influenced by how work is structured and managed.

Wellbeing is just as much a people and business issue. Forward-thinking employers are looking to push wellbeing beyond a silo and embed it into an organisation’s overall people strategy.

When thoughtfully designed, a wellbeing strategy can strike the right balance between employee health and productivity. By addressing wellbeing and performance in an integrated way, organisations can foster healthier, more engaged and more effective teams.

Ibec's KeepWell Mark - National Standards for Workplace Wellbeing

Ibec’s KeepWell Mark is an evidence-based accreditation awarded to companies of all sizes, who have successfully met the criteria for improved employee wellbeing across the eight areas that are assessed under the framework. Organisations leverage the framework insights to inform their people strategies, impacting positively on their culture and in turn driving high performance.

The framework offers employers practical tools and strategies to build or enhance their current wellbeing strategies. To date, hundreds of businesses nationwide across all sectors have been accredited with the KeepWell Mark.

Addressing Modern Challenges with Practical Solutions

Ibec recently updated the KeepWell Mark framework with the introduction of two new pillars, Inclusion & Belonging and Talent Support & Development, alongside enhancing the standards of the existing wellbeing pillars. The revised framework is designed to support thriving workforces now and into the future and addresses the realities of modern work, including the rise of digitisation, remote working, and a highly competitive hiring environment.

The new Inclusion & Belonging pillar focuses on improving psychological safety and leveraging workforce diversity, while the Talent Support & Development pillar prioritises the growth and retention of existing talent.

With a greater emphasis on inclusion, belonging and talent development, the KeepWell Mark remains at the forefront of workplace wellbeing standards in Ireland.

Case Study: Sterling Pharma Solutions

Sterling Pharma Solutions, a global contract development and manufacturing organisation and a KeepWell accredited company, provides a powerful example of the framework’s impact. Seeking independent validation for their wellbeing programmes, Sterling also wanted access to expert support and connections with other businesses committed to wellbeing. The results speak for themselves: employee awareness of wellbeing has increased, with staff now actively engaging in wellbeing conversations and suggesting new initiatives. This has led to

greater employee satisfaction and a stronger commitment to workplace wellbeing.

Commenting on their engagement with the KeepWell Mark, Anita Ryan, Occupational Health Lead for Sterling, said, “Sterling are proud to have achieved the KeepWell Mark; this award recognises that we're aligned with industry best practice and will continue to guide us in supporting our employees to reach their wellbeing potential.”

Create the Conditions for a Culture of Sustained Wellbeing

Workplace wellbeing impacts all aspects of the workforce and how it functions. By linking wellbeing to key business KPIs like costs, engagement, and productivity, employers can embed it into their culture for sustainable performance. Achieving the KeepWell Mark showcases your commitment to a thriving future for both your business and your people If you are interested in hearing more about The KeepWell Mark please contact info@thekeepwellmark.ie or visit www.thekeepwellmark.ie

Pictured are (l-r): Niamh McDonnell, P&O Business Partner, and Anita Ryan, Occupational Health Lead, Sterling Pharma Solutions.

Beyond Responsible Care: A Sustainable & Prosperous Society

Michael Kilkelly, Senior Executive EHS, BioPharmaChem Ireland, on how the Irish pharma sector’s collaborative spirit should make for a unique and lasting journey towards sustainability.

All changed, changed utterly. When Yeats wrote those words just over a hundred years ago, little could he have dreamt of the Ireland of today. As a nation, we have re-imagined ourselves as a modern, forwardlooking people, embracing radical social and economic change; as a society, we have shed the shackles of an inward-looking past; as an economy, we have emerged from the edge of Europe to become a global powerhouse in the Life Sciences sector. Most of this radical change has happened in the last 20 years.

This transformation was driven by a focused and uncompromising government policy on foreign direct investment and support of indigenous innovation, by a consistent pro-business philosophy at the political level, and a strong societal focus on educating our future workforce.

Over those past 20 years, the biopharma sector and its supporting ecosystem has grown dramatically and contributed significantly to the growth of the economy.

Our challenge now is to imagine the next 20 years and beyond, to tackle the challenges of today and anticipate those of the future.

The Carbon Challenge

One of the key challenges facing our industry over the coming years is the transition to a carbon-neutral society. Notwithstanding the real existentialist threat of global warming, European climate law commits Europe to achieve climate neutrality by 2050, with a 55% reduction in net greenhouse gas emissions by 2030. The CSRD, effective in 2023, mandates larger companies to report ESG activities using EFRAG-

defined metrics, promoting transparency and accountability.

All key stakeholders, including employees, communities, investors, educators, government and regulators, have a high expectation from our sector to transition to more sustainable business practices. This is a change that requires widespread collaboration.

A Collaborative Framework

BioPharmaChem Ireland provides a collaborative framework that brings companies together to share experience and thought leadership, with a goal to making the biopharmachem sector in Ireland a world leader in sustainability. Open collaboration is a unique feature of our sector in Ireland and is the most effective way to tackle the complex challenges of sustainability. This gives Ireland Inc. a unique advantage; there is no better example of that than the four 3MW wind turbines installed 10 years ago by the Cork Lower Harbour Energy Group in Ringaskiddy. A combined effort between J&J, DePuy, Novartis (now Sterling) and GSK (now Thermofisher), they have produced over 300M kWh in energy, equivalent to over 100,000 tonnes of CO2 removed.

For the last 20 years, BPCI has promoted a Responsible Care programme within its membership. This is a global voluntary initiative started in Canada in 1995. It is an ethical framework that helps companies continuously improve their environmental, health, safety and sustainability knowledge and performance. It is based on measuring metrics around water, air, waste, energy and health & safety, and sharing them openly, whilst highlighting areas for improvement. Nearly 50 pharma companies in Ireland regularly contribute to this

programme annually. But what was once a voluntary code of practice has morphed into a strategic business imperative.

So BioPharmaChem Ireland is working with members to go beyond Responsible Care to frame a sustainability strategy for our industry to make clear our priorities and to execute a plan to achieve those goals. Our sustainability steering group, drawn from members within our sector, has chosen four areas to focus on. These are:

Data & Standards:

Voluntary standards give a framework for embedding sustainable and ethical activity into core business. Data on those activities provides concrete signposts on their effectiveness. Industry-wide reporting standards need to be harmonised to achieve our zero carbon goals.

A number of companies are now using Science Based Targets (SBTi) to tackle climate change. The initiative aims to encourage and assist companies in setting ambitious and scientifically rigorous greenhouse gas emissions reduction targets to align with the goals of the Paris Agreement. A pivotal benchmark is the greenhouse gas (GHG) emissions reduction goal set to reduce emissions by half by the year 2030. This classifies emissions into three categories:

• Scope 1: Direct emissions that result from activities within an organisation’s control.

• Scope 2: Indirect emissions from electricity, heat or steam that is purchased and used.

• Scope 3 : Any other indirect emissions from sources outside of your direct control. This category covers all the emissions associated not with the company itself, but those for which the organisation is indirectly responsible up and down the value chain. This includes purchased goods and services, use of sold goods, business travel, commuting, waste disposal and water consumption.

Member companies sharing their experience of implementing standards will help other companies adopt these programmes. Recently, over 100 members from 35 companies participated in our best practice-sharing webinar on My Green Labs Certification, a global initiative to embed sustainable practice in all laboratories worldwide.

Energy & Infrastructure:

The biopharma sector is an energy-intensive industry. Falling under Scope 2 of the GHG protocol, reducing carbon footprint is a key consideration. The primary focus on reducing Scope 2 energy emissions is through a combination of energy efficiency, decarbonisation, and electrification of heat.

All our members have extensive energy reduction programmes and most now purchase 100% of their electricity needs from renewable sources. An increasing number have active programmes generating sustainable energy from technologies such as wind turbines, large-scale photovoltaic arrays, biomass, combined heat and power (CHP). Eli Lilly in Dunderrow generates 5.5 million kWh from solar panels and 19.5 million kWh per annum from CHP. Astellas’ site in Killorglin generates 67% of all of its energy required onsite from onsite renewable an 800kW Wind Turbine, a 1.67MW Biomass Boiler and a 120kWp Solar PV array.

A number of companies are now considering electrification of heat using heat-pump technology as an effective way to decarbonise. AbbVie installed four industrial low-GWP heat pumps during 2023, which now deliver an estimated 15% of Scope 1 emissions; three more will be installed in 2024, bringing this up to 33%, and a further four are being evaluated for 2025, bringing it up to 45%. Thermofisher in Ringaskiddy installed a multi-million euro 5 MW heat recovery from process waste gas abatement system and Alexion installed heat pumps which have resulted in annual carbon savings of approximately

498 tCO2e. Takeda’s Grange Castle site has installed a 2.2MW electric element boiler as part of its decarbonisation strategy.

Culture, Communication & Mindset:

Our industry members individually have already achieved a lot in sustainability and plan more great work and our goal is to share our story of sustainability within our companies, within the sector and with the broader community. While the large-scale, capital-intensive projects mentioned previously are very visible, a lot of smaller sustainability projects are being led by employees.

An example of this grassroots, employee-led sustainability engagement programme, within MSD, called ‘See Green, Be Green’ aims to build a sustainable culture from the inside-out by mobilising and empowering colleagues as proactive sustainability ‘change agents’.

Another example comes from Sanofi, where 600 employees from Sanofi Waterford gave 800 hours of their time to volunteer for 30 different organisations and fund-raised over €200K in 2024. They have also partnered with local schools with a TY Sustainable Leadership Programme. These are local initiatives that have a global impact.

Scope 3:

Our goal here is to help our member companies measure the carbon footprint of their value chain in upstream and downstream activities, to put measures in place to reduce that footprint and to share examples of best practice. Here are some examples:

Astellas now use a recycling company in Holland that recycles blister packaging waste. Sending their waste to this company pushes packaging up the waste hierarchy from energy recovery to recycling.

Wuxi are putting a grey water reuse programme on-site which will reduce the amount of water influent on site and reduce the amount sent off-site to be treated elsewhere. As well as this, their rainwater harvesting system saved an impressive 1943m3 in 2023.

Conclusion

Transitioning to a carbon neutral industry is a challenge that can only be achieved through widespread collaboration. Ireland’s pharma industry is in a unique position to become world leaders in this journey as we already have a strongly collaborative ecosystem. We now need to leverage that co-operation even more to get where we need to be. To quote an old electioneering slogan: ‘A lot done, more to do’.

Astellas’ site in Killorglin generates 67% of all of its energy required onsite from onsite renewable an 800kW Wind Turbine, a 1.67MW Biomass Boiler and a 120kWp Solar PV array.

A Year of Growth and Innovation at BioPharmaChem Skillnet

Susan Costello, Network Director, BioPharmaChem Skillnet, reflects on what has been a hugely successful and productive 12 months for the BioPharmaChem Skillnet.

BioPharmaChem Skillnet is dedicated to upskilling Ireland’s workforce in the biopharmachem sector by offering innovative, subsidised training programmes tailored to industry needs. With a focus on fostering a highly skilled and diverse workforce, we collaborate with leading academic institutions, industry partners, and government bodies to drive operational excellence and innovation.

As the biopharma and chemical industries evolve rapidly, the need for a workforce equipped with cutting-edge skills and knowledge has never been greater. Through programmes ranging from quality assurance to leadership development, BioPharmaChem Skillnet ensures that professionals are prepared to meet industry challenges head-on, while contributing to Ireland's reputation as a global hub for pharmaceutical and chemical manufacturing.

Highlights of 2024: Building Momentum

This year, BioPharmaChem Skillnet celebrated numerous milestones across events, collaborations, and impactful programmes:

• Collaborative Achievements:

• Contributed extensively to the Expert Group on Future Skills Needs (EGFSN) report, ‘Skills for Biopharma: Researching and Forecasting the Current and Future Skills Needs of the Biopharma Sector in Ireland to 2027’, where we were featured and referenced 25+ times. This report highlighted key areas for growth and development within the biopharma sector, and we’re proud to be a part of shaping its future.

• Hosted two well-attended webinars in partnership with the Health Products Regulatory Authority(HPRA) on Quality Defects and Recalls and Good Manufacturing Practice (GMP), with an average of 470 participants each.

• Proudly launched our VR Workplace Health & Safety Programme in collaboration with Technological University Dublin.

• Awards and Recognition:

• Our course, ‘Certificate in CPD: Introduction to Biopharmaceuticals & Advanced Personalised Therapies’, was selected as a finalist in the Pharma Education & Training Award category at the Pharma Industry Awards 2024.

• Event Participation & Industry Contributions:

• Participated in Biopharma & Life Sciences Connected Live in Cork early January 2024, where we interacted with a large cohort of the biopharma community.

• Sponsored and engaged at the BioPharmaChem Impact 24 Conference at Fota Island Resort, fostering dialogue on industry advancements.

• Attended CPHI Milan, one of the world’s largest pharmaceutical events, showcasing innovations in biotechnology and sustainable manufacturing practices.

• Joined discussions at the National Pharmaceutical & MedTech Conference in Dublin, exploring how technology drives business growth.

• Represented at the 9 th EuChemS Chemistry Congress, focusing on trends and innovations in chemical research and development.

• Actively participated in the Future Talent Forum and the event on Ireland’s Leadership in Advancing AI and Digitalisation in the Life Sciences, both hosted by Technological University Dublin.

• Sponsored and engaged at the Pharma Industry Awards 2024.

• Collaborated with BioPharmaChem Ireland, SSPC and other key stakeholders on the ‘Future-Ready Workforce’ event, emphasising HR and learning trends.

This year also marked the 25th Anniversary of Skillnet Ireland, a significant milestone in supporting workforce development across the nation. BioPharmaChem Skillnet was honoured to attend the Skillnet Ireland 25th Anniversary Gala Dinner, celebrating two and a half decades of innovation, collaboration and commitment to upskilling Ireland’s workforce. The event highlighted the transformative impact Skillnet Ireland has had on various industries, fostering partnerships and creating opportunities for continuous learning. As one of its proud networks, we are excited to build on this legacy, driving innovation and excellence in the biopharmachem sector.

Innovative Programmes: Meeting Industry Needs

BioPharmaChem Skillnet has introduced pioneering courses to address the skills gap in the BioPharma and chemical sectors:

The Certificate in CPD Neurodiversity in the Workplace (Level 8) was developed with University College Cork’s Adult Continuing Education (ACE).

Looking Ahead to 2025: Driving Excellence

With 2024’s momentum, BioPharmaChem Skillnet is eager to continue its transformative journey in 2025. Key plans include:

• Reintroducing the highly acclaimed Neurodiversity Programme to promote workplace inclusivity.

• Launching the Level 5 Essentials for Pharmaceutical Manufacturing, designed to build a robust talent pipeline for Ireland’s thriving biopharmachem sector.

Our commitment to excellence will drive the evolution of Ireland’s workforce, ensuring the industry remains competitive and future-ready. We are deeply grateful to our partners, collaborators and participants for their support. Together, we are shaping a skilled, resilient workforce ready to lead the biopharma and chemical industries into the future.

The BioPharmaChem Skillnet Team (l-r): Iva Peradenic, Office Administrator; Brendan Kellett, Learning & Development Project Adviser; Susan Costello, Network Director; Marie O’Brien, Accounts Assistant; and Rashika Saxena, Marketing and Business Analyst.

The BioPharmaChem Skillnet team pictured with Sinead Keogh, Director of BioPharmaChem Ireland; Sharon Higgins, Director of Membership & Sectors, Ibec; and Siobhán Dean, Deputy Director of BioPharmaChem Ireland.

Bridging Skills Gaps through Talent Development

Talent remains key to unlocking Ireland’s biopharma manufacturing future, writes John Milne, Director of Bioprocessing Training Alliances and Innovation at NIBRT.

Biopharmaceuticals, complex products derived from living organisms, cells, animals, or plants, are among the most sophisticated and elegant achievements of modern science, offering treatments and increasingly curative outcomes, with groundbreaking new treatments now being delivered to patients based-on cell therapy, gene therapy and innovative vaccines.

Clinical pipelines are increasingly being populated by new therapeutic modalities, with the industry now embracing the potential of new and improved therapies to meet unmet medical needs as they look to build successful and resilient pipelines into the future.

Ireland’s Role in Biopharma

Ireland is continuing to play a critical role in the supply of biopharmaceuticals to global markets through the success of its current manufacturing install base that continues to attract ongoing investment and continues to be served by a world-class workforce.

In the past decade, the biopharmaceutical sector has seen over €10 billion in capital investment in new manufacturing infrastructure, with sites in Ireland now manufacturing a variety of commercially approved products for worldwide supply, often at large-scale and including both drug substance and drug product manufacturing respectively.

A key determinant to this success for Ireland has been the continued supply of qualified personnel across a variety of constituent disciplines, who can successfully transition into the industry and avail of significant career development opportunities on offer in the sector.

Future Workforce Needs in Biopharma

It is evident as we look toward the future that biomanufacturers will continue to require a highly skilled, trained, focused and motivated workforce to meet the emerging challenges and increased complexity of biopharmaceutical manufacture, allied to particular skillsets required to work in highly

regulated environments, subject to the principles of current good manufacturing practice (cGMP).

The biopharma industry is also moving towards the next evolution in industrial and manufacturing processes, incorporating a shift towards a more human-centred approach to manufacturing, referred to as Industry 5.0, which builds on the earlier Industry 4.0 initiative, which emphasised automation, digitalisation and the integration of smart technologies like AI, IoT and big data

respectively. The need to develop personnel competent in digital solutions and the use of more automated technologies will therefore become increasingly important.

The skills agenda and associated workforce readiness solutions will remain critical if Ireland is to continue to attract further investment into the future and maintain its position within the global supply of impactful medicines.

At a recent event hosted jointly by IDA Ireland and NIBRT entitled ‘Future Proofing

John Milne, Director of Bioprocessing Training Alliances and Innovation at NIBRT.

Members of the Biopharma Skills Implementation Group attending a workshop in NIBRT.

Ireland’s Life Sciences Workforce, Strategies for Talent Transformation’, delegates heard that to attract, retain and develop talent, organisations must be “future fit”, that is to be agile, resilient and adaptable, prepared to thrive in a rapidly changing environment by embracing innovation, leveraging technology and promoting a culture of continuous learning and improvement.

Indeed, a resounding message from the meeting was that workforce development isn’t just about meeting immediate demands; it’s a strategic investment in Ireland’s future competitiveness, contributing to Ireland’s recognition as a global hub of talent and innovation.

Ireland’s Response to Biopharma Industry’s Skills Demands Ireland is proactively responding to the

evolving skills needs of the industry. The recently published report from the Expert Group on Future Skills Needs (EGFSN) focusing on the biopharma industry in Ireland has estimated that more than 21,000 additional biopharma jobs could be created by 2027 in a medium growth scenario (Skills for Biopharma Researching and Forecasting the Current and Future Skills Needs of the Biopharma Sector in Ireland to 2027: Expert Group on Future Skills Needs, April 2024).

Average annual recruitment into the sector is forecast to be more than 5,600 out to 2027, according to the same scenario.

The biopharma sector needs to promote careers more effectively, as well as to develop new pathways into careers. The education and training sector must have the capacity to respond to skills needs articulated by industry and additional investment will be needed.

Strengthening STEM education in schools is also essential to underpinning progress.

The study highlighted a variety of opportunities for increasing skills supply to the sector, including micro-credential learning, growing apprenticeships in specific disciplines, and the development of a wider sectoral skills framework. These priorities are reflected in a series of recommendations made in the report and work is underway across the ecosystem to develop implementation plans that will deliver on these key recommendations.

Through the recent Human Capital Initiative (HCI), the Government has focused on strengthening educational provision in sectors where Ireland’s skill demands face deficits. Ongoing Government support for programmes offered through the Skillnet Ireland network and the impactful

NIBRT

Springboard+ initiative will continue to have a positive impact on skills development and overall workforce readiness.

Collaboration between industry, higher education institutes and the advanced training sector will continue to be key to ensure that the demand for skilled workers will match supply into the future.

NIBRT’s role in Biopharma Skills Development

Supported by IDA Ireland, the National Institute for Bioprocessing Research and Training (NIBRT) operates a state-of-the-art pilot production training facility and provides a wide range of training programmes for the biopharmaceutical industry. The facility utilises extensive upstream processing, downstream processing, aseptic fill & finish and associated analytical facilities, disciplines that are highly relevant and will remain core for industry into the future.

NIBRT’s training facility is operated in a GMP-simulated manner, which affords all trainees the opportunity to develop their skills in an industrially relevant environment. Training programmes are delivered to a wide variety of national and international industry clients and to the higher education sector in Ireland to support their expanding academic programmes in biopharmaceutical science and engineering.

The NIBRT curriculum includes content beginning with introductory just in time e-learning solutions hosted on the NIBRT Online Academy (NOA) through targeted

and specialised short courses and on to fully customised courses developed in partnership with industry, focusing on the specific aspects of biologics manufacture and the associated disciplines of quality control and quality assurance (www.nibrt.ie/trainingand-education). Courses are typically a blend of classroom- based theory sessions, contextualised by hands-on practical based sessions in the state-of-the-art production training plant, and online distance learning options are also available to clients.

The Importance of Competency Training in Biopharma

From its decade-plus of engagement with its client base, NIBRT has established that training of individuals to work in biopharma manufacturing-related disciplines is best achieved using competency-based solutions that encourage the trainee to develop critical learning skills in an environment that uses equipment and processes that are aligned to real life scenarios. An effective training for “work” model requires a greater investment than a typical training for “compliance” model, as the latter does not provide the critical knowledge needed to support performance and effective behaviours in manufacturing environments.

Competency-based training at its heart involves a focus on “active learning” principles that encourages the learner to engage in activities that will support and stimulate “higher-order” thinking, problem solving and ideally critical analysis.

The overall approach involves an

integrated perspective that includes the development of requisite knowledge, skills and behaviours, such that the trainee can perform in the actual work environment and this is where the greatest impact is delivered and return on training spend is realised.

The Future Remains Bright

In summary, greater collaboration between enterprise and higher education institutes tasked with providing the Life Science and Engineering graduates of the future will be crucial to success for Ireland. Industry can advise on the specific challenges experienced in regulated manufacturing environments and on the emerging skillsets required across all disciplines to meet the challenges of a rapidly evolving industry. This in turn will help inform curricula development and graduate preparation in certificate, diploma and degree programmes respectively across the Irish ecosystem.

The resilience of the biopharma industry in Ireland will depend on bridging skills gaps through ongoing education and training to support staff hiring and retention initiatives, that will be further underpinned by continuing Government funding of current and future training programmes.

In that way, Ireland will be best placed to meet the challenges and undoubted opportunities that this exciting industry can provide and ensure that we will remain a key provider of life-changing medicines into the future and an industry that our future workforce will be drawn to.

Proudly operating in Ireland for over 10 Years

Alexion, AstraZeneca Rare Disease is a global innovation hub that spans three sites across Ireland focused on the development, manufacturing, supply, and distribution of the Alexion, AstraZeneca Rare Disease portfolio Pairing vast technical capability with deep scientiﬁc knowledge

ALEXION IRELAND IS HOME TO

>1,000

HIGHLY SKILLED COLLEAGUES

Athlone

Dublin

Cork

Managing Medicine Shortages

Ellen McGrath, Medicine Shortages and Borderline Classification Manager, HPRA, explains how stakeholders will manage medicine shortages under current and future legislative frameworks.

This article explores the roles of the Health Products Regulatory Authority (HPRA) and the European Medicines Agency (EMA) in addressing medicine shortages and outlines legislative changes and key measures that are being introduced in response to this complex issue.

Stakeholders involved in the supply of medicines and supply chain management should be aware of pertinent developments and their potential impact on day-to day operations in delivering safe, effective medicines without supply chain interruptions. Key legislation underpins the most significant changes that are on the horizon, complementing all national initiatives to address medicines shortages that are currently planned or ongoing.

The HPRA is responsible for ensuring the quality, safety, efficacy and plays a key role in the availability of authorised medicines in Ireland. In 2018, the HPRA accepted a coordinating role in managing and preventing medicine shortages. The HPRA developed a framework to facilitate a consistent and aligned approach to managing medicine shortages in partnership with key stakeholders.

Since its inception, the national Medicine Shortages Framework (MSF) has been of enormous benefit serving to avoid the

occurrence of potential medicine shortages and, where they have occurred, ensuring appropriate mitigation is in place.

Medicine shortages as a global phenomenon, experienced by all countries, regardless of size or economic status, remain a persistent issue of modern healthcare systems, exacerbated by disruptions, such as the Covid-19 pandemic, geopolitical or extreme weather events. There are currently no signs of shortages abating, despite ongoing efforts of all relevant stakeholders.

Industry information received by the HPRA detailing the root cause for shortages is mainly related to interruption, delays or breakdowns during manufacturing or a product quality issue. Unexpected demand and manufacturing capacity constraints can also cause certain shortages. The well publicised high demand for GLP-1 receptor agonists is an example of a shortage that has occurred as a result of demand outweighing supply, resulting in persistent global shortages and interruptions for patients who are prescribed these therapies.

The pandemic and other health challenges have illustrated that the key to successful shortages management is close co-operation between regulators, health systems, patients and industry.

Understanding the dependencies of health systems on medicines and existing vulnerabilities in supply chains is critical to ensure appropriate and proactive prevention and mitigation strategies.

EMA’s Extended Remit

Enhanced European coordination and the expanded role of the EMA, the EU

Ellen McGrath, Medicine Shortages and Borderline Classification Manager, HPRA.

HEALTH PRODUCTS REGULATORY AUTHORITY

“ The key in moving forward will be to build systems that are both efficient and informative, which will only be possible through collaboration with all stakeholders in an open and transparent manner.”

Pharmaceutical Strategy for Europe and the proposed revision of pharmaceutical legislation are hugely important to developing the European approach, strategically addressing challenges and driving consistency and harmonisation, particularly during crises.

The EMA has been formally mandated to address shortages, on behalf of EU citizens, and the regulatory footing for this new role has been provided for through the introduction of EU Regulation 2022/123 (‘EMA expanded mandate’). There are numerous changes arising out of this mandate. The key ones referenced are of relevance for industry practice and operations, namely the development of the Industry Single Point of Contact (iSPOC) network and the European shortages monitoring platform (ESMP).

Marketing Authorisation holders (MAHs) have overall oversight of the supply of their medicines nationally and globally.

Acknowledging the key role MAHs play in the management and prevention of shortages, active engagement and dialogue with the EMA has been formalised through the iSPOC network. By September 2, 2022, every MAH in the EU had to register an iSPOC and this mechanism is enabling rapid communication between EMA and companies.

The ESMP is set to be introduced from February 2025, which is a centralised electronic platform for pharmaceutical companies and national competent authorities (NCAs) to notify shortages to the EMA. It will also serve as a monitoring tool and a platform through which Medicine Shortages and Safety Steering Group (MSSG) crisis and preparedness activities will be conducted. The ESMP will enable real-time data sharing and enhance the capacity of the EU network to predict and address supply issues collaboratively.

The full roll-out of ESMP beyond the first

phase of implementation carries certain key dependencies, such as the incorporation of structured data. This will ultimately be informed by the overall project work on International Organisation for Standardisation (ISO), identification of medicinal products (IDMP) standards. The EMA is currently working with industry stakeholders on the introduction of ISO IDMP standardised data, creating a central location for master data SPOR (Substance, Product, Organisation, and Referential). When fully developed, ISO IDMP standardised data will also allow for interoperability between the EMA and national shortage monitoring platforms.

Advancing our National Systems

Advancing national stock monitoring systems is required to ensure an effective interface with the ESMP. It is also required nationally to make for more effective prevention and mitigating measures as they afford greater response capacity, with more forewarning of pending issues in supply, with actions that can then be taken in a timelier manner. This will address some of the limitations of the MSF operated by the HPRA currently, with the notification timing to the actual shortage occurrence of 11 days on average. This short timeframe massively reduces the ability of the HPRA to identify and implement actions to prevent the shortage from occurring.

The key in moving forward will be to build systems that are both efficient and informative, which will only be possible through collaboration with all stakeholders in an open and transparent manner. The provision of timely notifications of potential or actual shortages will remain the cornerstone of an effective MSF, and further discreet work will be taken on this locally in 2025, as it requires significant improvement.

The Health (Miscellaneous Provisions) Bill 2024 will also significantly enhance the HPRA’s capabilities to address medicine shortages by providing a solidified legislative requirement for the HPRA to be furnished with information

for the purposes of managing medicines availability by the ‘relevant person’ who is involved in the manufacture or supply of medicinal products. Specific provisions to further develop monitoring and reporting systems are expected to be in place over the course of 2025-26.

Pharmaceutical Strategy

Further to this, the European Commission’s Pharmaceutical Strategy includes a specific intention to address medicine shortages as a component of its four main pillars. Specific initiatives, such as the introduction of the Union list of critical medicines and the requirements under the proposed new European pharmaceutical legislation for an MAH to have in place shortage prevention plans (‘SPP’) are anticipated to further improve supply chain resilience and promote continuity of supply.

An SPP is a risk management process focused on product-specific parameters and is a structured framework within the pharmaceutical quality system that focuses on shortage prevention. Planning for the introduction of these measures is already underway, and the HMA/EMA good practices for industry for the prevention of human medicinal product shortages, published in 2023, can be referred to by manufacturers and wholesalers, to consider aspects to incorporate into SPPs as well as shortage management plans.

Conclusion

Medicine shortages are a global challenge that demand co-ordinated responses across all stakeholders at national and international levels. By combining legislative action, regulatory expertise, and collaborative strategies, Ireland and the EU are strengthening healthcare resilience and safeguarding continued access to medicines.

As Ireland continues to lead in pharmaceutical innovation, the commitment to ensuring the availability of medicines remains paramount.

Medicine shortages are experienced by all countries, regardless of size or economic status, and are exacerbated by disruptions, such as the Covid-19 pandemic, geopolitical or extreme weather events.

Cutting-Edge Research at SSPC

SSPC, Research Ireland’s cutting-edge research centre, continues to deliver innovative solutions in biopharma via its unique collaborative ecosystem.

SSPC, Research Ireland Centre for Pharmaceuticals, hosted at University of Limerick, is a world leading, interdisciplinary hub for (bio)pharma research and innovation. Through its reputation for scientific excellence, close industry partnerships and talent pipeline, SSPC solves industry and societal challenges. SSPC’s unique ecosystem sets it apart, placing Ireland as a trailblazer in (bio)pharma research and talent development.

SSPC won Pharma Research Centre of the Year and the Partnership Alliance Award at the Irish Pharma Industry awards 2024, advocating for the (bio)pharma sector, advancing excellent science, business growth, talent training and retention, operational excellence, and innovativeness. Pictured are Aisling Arthur, SSPC Industry Engagement Manager; Matt Moran, former Director of BPCI, and Professor Damien Thompson, SSPC Scientific Director.

SSPC is uniquely positioned to tackle complex problems and challenges through fundamental science informed by a rich and diverse knowledge base, across the SSPC community, as well as sector-wide stakeholders within the larger ecosystem. SSPC is an academic/ industrial alliance between nine national Research Performing Organisations (RPOs) and 50+ indigenous & global (bio)pharma and Life Sciences companies. Within the Centre, the RPOs, start-ups & spinouts, small & medium enterprises, and multinationals engage in collaborative research and talent development for the Life Sciences sector.

Key deliverables and outcomes include new knowledge and innovations, which support the development and supply of medicines, devices and technologies for the sector and the creation of a sectorfocused PhD and Postdoc talent pipeline. SSPC creates a uniquely global ecosystem of collaboration across the actors to elevate the reputation of the Irish (bio)pharma sector.

Innovative Industry Collaborations

SSPC has significantly enhanced its operational performance by delivering innovative industry collaborations and an ecosystem that supports the (bio)pharma sector nationally and internationally.

• Talent: SSPC has produced 300+ researchers with a 100% employment rate and significant 82% transition into industry. SSPC attracts, trains and retains a high calibre talent for Ireland.

• Investment: SSPC is delivering 12-fold return on Government investment. SSPC has leveraged an additional €50 million investment from industry and other sources, delivering significant economic and human capital impacts.

• Industry: SSPC works with >50+ industry partners and supports a strong indigenous community, with 48% of SSPC industry membership engagement liaising with both the international and Irish sites. The existence of SSPC plays a significant role in the decision by multinational companies to invest/expand in Ireland. SSPC widens engagement and collaboration to establish new areas of excellent science and ideas that increase the attractiveness of Ireland as a location of choice for knowledgedriven (bio)pharma manufacturing.

• Societal Impact: SSPC addresses key societal challenges, particularly sustainability and availability of medicines, for greater global good, supported by education and public engagement initiatives and projects. SSPC’s Education and Public Engagement programme has a global reach of >5.6 million people. Informed by research and in partnership with public stakeholders, the programme supports perception, understanding and trust in (bio) pharma research.

Professor Damien Thompson, SSPC Scientific Director.

“SSPC is committed to producing high-quality graduates with advanced skills, who will serve as catalysts for regional and national growth over the next decade and beyond,” noted Professor Damien Thompson, SSPC Scientific Director. “Their expertise will also play a crucial role in attracting future Foreign Direct Investment (FDI) and enhancing national competitiveness.”

Amneal Ireland Ltd is part of Amneal Pharmaceuticals, inc. (NYSE:AMRX) a fully integrated global essential medicines company powered by a robust U.S generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, we’re rapidly becoming one of the most dynamic, purpose driven pharmaceutical companies delivering more affordable access to essential medicines.

Amneal Ireland is located in Cashel, County Tipperary. Our state of the art 200,000 ft2 facility is dedicated to the development and production of metered dose (MDI) and dry powder (DPI) inhalation products.

We are Amneal and we make healthy possible. Together, we can do more to improve health.

That’s a powerful reason to come to work.

2025 will see continued growth in our Cashel team. If you’re excited about joining a company with a purpose that believes in, encourages and invests in the growth of its people, let’s talk!

To share your interest in joining our Amneal Cashel team, please reference the appropriate are of interest and email CV to careers.cashel@amneal.com

PMTC: Anticipating Your Needs

The Pharmaceutical Manufacturing Technology Centre (PMTC) continues to address manufacturing issues within the biopharma manufacturing sector.

Since its inception in 2013, PMTC has established itself as a progressive, agile, industry-relevant applied research and innovation centre. PMTC focuses on delivering solutions using advanced technology and analytics which address contemporary manufacturing issues impacting on efficiency and sustainability for the pharmaceutical manufacturing sector.

Situated within the Bernal Institute at University of Limerick, PMTC is hosted in a world class facility, comprised of an experienced research team of senior and post-doctoral level researchers with extensive R&D and direct industry experience. In addition to the core research team, PMTC is affiliated with leading RPO's nationally, thus leveraging the best research talent available.

Funded by Enterprise Ireland in partnership with IDA Ireland, PMTC is part of a network of Technology Centres which collectively contribute significantly to supporting Irish companies to be successful, grow their business, create jobs and deliver significant wider economic impact.

Landscape

Biopharma is Ireland’s largest national economy sector, making it the EU’s leading net exporter of medicines, with approximately €90 billion worth of products in 2022.

This underpins a significant crosssection of national infrastructure operation through direct/indirect employment, facility construction, technology consumption and social development.

Products produced in this industrial ecosystem require complex, customised processes and analytical techniques, due to the continuously changing characteristics of novel drugs.

Coupled with an associated broad range of unique regulatory expectations, this requires bespoke Technology Centre support for a myriad of drug product processing development, characterisation, scale-up and life-cycle research needs.

Meeting your R&D Needs

PMTC is biopharma’s progressive, agile,

industry-led applied research and innovation centre with deep domain knowledge and experience.

Through its collaborative industryacademia research network, PMTC delivers productivity-enhancing research-based solutions to industry applications.

These include:

• Cleaning Process Efficiencies: Potential 15% increases in available production time and up to US$200 million reduction in operational costs were identified in the SPOTLESS research project.

• Predictive Process Maintenance: PMTC’s AEPIC research project indicates there is a potential for US$2 million reduction in annual production losses through associated technology application in this area.

• Community Developed Methodologies: Through a collaboration of five major MNCs, two RPOs and consultation with the HPRA, their FoReSight research project published a white paper, risk mitigation based methodology to improve trust in the use of data analytics across the biopharma industry.

Partnership is

Key Collaboration is at the heart of everything they do at PMTC. They are driven by real market needs, which are defined by industry and will have a real-world impact. Strong links have been created by PMTC with sister R&D centres across Enterprise Ireland, Taighde Éireann-Research Ireland and IDA networks where their complementary capabilities have been applied to enhance PMTC’s core biopharma processing competencies. Through its research network of academic

and centre partnerships, PMTC supports a highly collaborative research ecosystem. Here, synergistic partner capabilities are coupled with the core biopharma drug processing and control strategy expertise to deliver impactful industry and funding body value.

Additionally, steady growth in membership value has been demonstrated through increasing year-on-year project workshops, engagement events, network/ community growth, and increasing competitive research funding.

Your Pathway to Success

PMTC has developed a comprehensive, sectorengaged business plan for its next phase of operations. It focuses on significantly growing productivity-oriented research, indigenous company (SMEs) know-how application, integrated testbed and Lab 5.0 characterisation capability, skills and talent development, operational infrastructure, and communityaligned practice of information use.

Core, needs-aligned and biopharmacentric research will address five strategic areas:

1. Pharmaceutical Plant Cleaning and Enhancing Asset Utilisation

2. Advanced (Modular, Continuous) Processing

3. Process Intensification and Improvement

4. Digitalisation and Advanced Data Analytics

5. Sustainability.

For more information: If you would like to know more about the exciting developments at PMTC or become part of their extensive, collaborative membership community, please visit www.pmtc.ie or email pmtc@ul.ie.

Over the past 50 years we have grown to service most of the leading global biopharma clients on their critical production, research and development facilities throughout Europe. We are proud of our reputation for assisting clients in bringing innovative and life improving medicines to market.

Our ability to deliver these services to exacting quality and safety standards and within extremely tight construction schedules has been an essential factor in our ability to forge long term relationships with our clients.

Engineering and Construction Excellence Across Europe

SETU Wins Top Research Award

The Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) at the South East Technological University (SETU) was the winner of the Research and Development Achievement award at the 2024 Pharma Industry Awards for their work on ocular drug delivery technologies.

It has been a busy year for those involved in (bio)pharmaceutical science at the South East Technological University (SETU). The university’s Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) won the Research and Development Achievement award at the 2024 Pharma Industry Awards for their work on ocular drug delivery technologies.

Over 50 projects were completed with industry partners in the preceding 12 months by the PMBRC’s Technology Gateway, the industry wing of the research centre funded by Enterprise Ireland. Seven students were awarded PhDs in 2024 for their research in (bio) pharmaceutical science. And in October 2024, SETU got the green light to launch a new Master of Pharmacy programme which will be the first of its kind in the south-east.

SETU’s emergence as a centre of excellence in (bio) pharmaceutical sciences is the result of decades of hard work and innovation. For Professor Peter McLoughlin, Head (Waterford) of Faculty of Science and Computing and co-founder of the PMBRC, this is the culmination of over 20 years of effort to develop undergraduate programmes and research in this space.

“Originally the legacy institute, Waterford Institute of

Technology, had degree programmes in Applied Chemistry and Applied Biology with Quality Management. The vast majority of graduates from these programmes ended up in the pharma and biopharmaceutical industry and therefore we updated our courses to better reflect graduate and industry needs, rebranding them as degrees in Pharmaceutical Science and Molecular Biology with Biopharmaceutical Science,” recalls Professor McLoughlin. “This updated programme portfolio was further enhanced in 2008 when we received funding from Enterprise Ireland to set up the PMBRC.”

The PMBRC was originally funded by the Enterprise Ireland Applied Research Enhancement (ARE) programme. The first phase of this programme was designed to inject funding into the Institute of Technology (now Technological University) sector to stimulate research activity that would be of benefit to Irish industry.

“The (bio)pharmaceutical industry is a major component of the Irish economy and the south-east region is a hub for pharma and medical device manufacturing, so locating an EI-funded centre in the region made a lot of sense” said Dr Niall O’Reilly, Centre Director of the PMBRC. “The initial seed funding for the PMBRC kick-started a wave of activity, which resulted in support from Science Foundation

Pictured collecting the Research and Development Achievement award at the recent Pharma Industry Awards were (left to right): Dr Niall O’Reilly, Centre Director of PMBRC; Dr Adrienne Flemming, Pharma Awards judging panel; Dr Laurence Fitzhenry, Principal Investigator of the Ocular Therapeutics Research Group (OTRG) in PMBRC; and Tess Ames, Project Manager, OTRG.

Ireland, the Irish Research Council (now both merged into Research Ireland), as well as European and industry funding. We slowly grew the PMBRC to the point where we now have 25 PhD students and 10 members of staff, and a further 20 members of academic staff engaged in research in the centre.”

Diverse Research Activity

The (bio)pharmaceutical research activity in the PMBRC is diverse, ranging from drug discovery and synthesis to finished product formulation. In the past year, researchers have been awarded PhDs for their research in gene therapy, flow chemistry, ocular drug delivery, dry powder inhalers and biopharmaceutical lyophilisation.

The centre also enjoys a strong tradition of multidisciplinary research. For example, molecular biology researchers have teamed up with SETU’s Walton Institute for Information and Communication Science to look at DNA data storage and have published a number of papers in this area recently. Similarly, scientists and engineers in the PMBRC have worked together to develop biosensor technologies and 3-D printed dissolving microneedle arrays for transdermal drug delivery. The PMBRC team also have a wide range of national and international collaborations on five continents.

“The international dimension was very important for us when we were growing the centre,” explained Dr O’Reilly. “It gave us access to world-class expertise and allowed our researchers to get trained on international secondments, bringing that expertise back to Waterford.”

International Collaborations

The PMBRC now leads a number of international collaborations, such as the European-funded ORBITAL-ITN, which develops innovative technologies to treat diseases of the back of the eye, such as diabetic eye disease and age-related macular degeneration.

Key to the success of SETU undergraduate and postgraduate programmes has been its links to industry. “Our offering to industry includes certificate and degree laboratory apprenticeship programmes, level 7 and 8 degrees (both full time and part time, with honours programmes having integrated work placements), level 9 postgraduate/Masters programmes and industry co-funded PhDs,” noted Professor McLoughlin. “Whatever the exit award, our graduates are highly sought after in industry and the close relationship with industry helps us to ensure that our programmes are constantly evolving.” Industry engagement is further enhanced through a (bio) pharma industry board,

which provides a forum for academic/ industry communication.

In parallel, the PMBRC is funded by the Enterprise Ireland Technology Gateway programme, a network of 17 centres of excellence that provides R&D supports to industry. PMBRC industry projects range from short-term quality investigations and consultancy work to longer term projects involving product, process and technology development.

“There is a huge amount of expertise available within the university sector, but sometimes it can be hard for companies to know where to start and how to access that capability,” revealed Dr O’Reilly. “The Technology Gateway breaks down this

“The ongoing development of SETU’s teaching and research capabilities in (bio)pharmaceutical science and pharmacy will play a crucial part in achieving our objectives and supporting the (bio)pharma sector of the south-east to realise its full potential ”

Pictured at the announcement of the new Master of Pharmacy programme in SETU were (l-r): Dr Claire Lennon, Pharmacy Programme Development Lead; Prof. Veronica Campbell, President of SETU; Patrick O’Donovan, TD, Minister for Further and Higher Education, Research, Innovation and Science; and Prof. Peter McLoughlin, Head (Waterford) of Faculty of Science and Computing, SETU.

SOUTH EAST TECHNOLOGICAL UNIVERSITY

barrier, allowing a central point of contact for industry in a given technology area. In addition, if we can’t find the right person in-house, we have contacts in the entire Technology Gateway programme and the wider university sector, so we should be able to find the expertise that you need.”

While the PMBRC Gateway specialises in the (bio)pharma and medical device sectors, their expertise is equally sought after in other industries such as food, veterinary medicine, agri-technology, biofuels, environmental science and engineering. The Gateway works with companies across Ireland, with about half of the client companies being SMEs. “We have a lot of experience in getting funding for our industry collaborations, so whatever the scale of the project, we can find a funding scheme that meets your needs,” said Dr O’Reilly.

Active Spin-Out Companies

Not content to just work with industry, the PMBRC has a number of active spinout companies as well. OcuDel Ltd is a pharmaceutical company developing treatments for ocular diseases in veterinary markets. Their patented nanoparticulate technologies have been shown to enhance the delivery of drugs to the surface of

the eye, compared to conventional eye drop formulations. Their lead product is a treatment for dry eye disease, a painful condition affecting both humans and animals for which current treatments are often ineffective.

Another spin-out, Bioenz Technologies Ltd is an Enterprise Ireland-funded High Potential Start-Up company, focused on enzyme discovery and microbiological solutions. Bioenz is based on over 20 years of research with a proprietary biobank and discovery platform. The company is developing new and improved enzyme and bespoke biocatalyst solutions for more sustainable and impactful environmental, nutritional and therapeutic applications.

New Pharmacy and Veterinary Medicine Programmes

SETU received a major boost in autumn 2024 when the Government announced that it would host new pharmacy and veterinary medicine programmes. For SETU President, Professor Veronica Campbell, these announcements reflect strong support for the University’s long-term ambitions for the south-east region and acknowledge the extensive work that has been done to date

by SETU and PMBRC in building knowledge and capacity through the years, putting SETU in a position to be successful in what was a highly competitive process.

“Pharmacy is a highly sought-after programme of relevance to the southeast that will act as a magnet for talent, consistent with national and regional strategies,” stated Professor Campbell. “As the only university in the region, SETU is delighted to be chosen to provide this new pharmacy programme, which builds on SETU’s established expertise in pharmacy, and (bio)pharmaceutical science and is underpinned by the high calibre research undertaken at PMBRC.”

The new five-year M. Pharm. programme is the result of intense collaboration between a SETU cross-campus team and local stakeholders in University Hospital Waterford, UPMC Medical Centre, industry and community pharmacists, led by Dr Claire Lennon, the Pharmacy programme development lead.

“Consultation with and support from our stakeholders has been pivotal to this success and will ensure our Master of Pharmacy programme prepares graduates for the many areas of modern pharmacy practice,

emergence as a centre of excellence in (bio)pharmaceutical sciences is the result of decades of hard work and innovation,

We are a global pharmaceutical group, listed on the Italian Stock Exchange, with over 4,450 employees. We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors, and the people across the globe we serve.

We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest.

Our site in Ringaskiddy, Cork is dedicated to the manufacturing of Lercanidipine HCl with dedicated Production and Quality units ensuring compliance with the highest specifications.

SOUTH EAST TECHNOLOGICAL UNIVERSITY

meeting the skills needs of the sector,” said Dr Lennon. “There is now an intense period of activity focusing on programme validation within SETU, which will be followed by an application for accreditation to the regulatory body, the Pharmaceutical Society of Ireland. We are also recruiting new academic talent to deliver this programme.”

With all of this activity in SETU, the future of pharmacy and pharmaceutical science in the south-east looks bright. “Our Strategic Plan 2023-2028 positions SETU at the centre of the south-east of Ireland’s innovation region,” summarised Professor Campbell. “The ongoing development of SETU’s teaching and research capabilities in (bio)pharmaceutical science and pharmacy will play a crucial part in achieving our objectives and supporting the (bio)pharma sector of the south-east to realise its full potential. PMBRC’s contribution to this ambition has been vital and we look forward to their continued success in translating research and innovation activity into meaningful impact for the region and beyond.”

Key to the success of SETU undergraduate and postgraduate programmes has been its links to industry.

The (bio)pharmaceutical research activity in the PMBRC is diverse, ranging from drug discovery and synthesis to finished product formulation.

CRISPR: Still Revolutionising Genetic Engineering

Professor Niall Barron, Principal Investigator, Cell Engineering Lab, NIBRT, explains CRISPR technology, its benefits and the ethical challenges it brings to gene editing.

CRISPR technology has revolutionised genetic engineering, by making it faster and more affordable. However, there remain some ethical concerns around its use. Professor Niall Barron, Principal Investigator in NIBRT’s Cell Engineering Lab, talks us through the development of CRISPR, its potential within biopharma and where next for this breakthrough.

CRISPR is an acronym for ‘clustered regularly interspaced short palindromic repeats’, a natural molecular process used by many bacteria to fight off invading viruses that scientists have developed for use in other organisms and cell types to edit their DNA. CRISPR allows scientists to add, remove or change a specific DNA sequence and to turn genes on and off, sometimes without even altering their sequence.

CRISPR gene-editing technology has been around since 2012, and in 2020, Emmanuelle Charpentier of the Max Planck Institute and Jennifer Doudna of the University of California, Berkeley, took home the Nobel Prize in Chemistry for the successful development of CRISPR technology.

“CRISPR blazed onto the scene around 2012 and instantly people started to tweak it, to find better ways of using it to do things and it has really snowballed from there,” explains Niall. “The fact that Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize for it proves that it's had a massive impact, even in that short period of time.”

So what does CRISPR bring to the table? What does it allow scientists and researchers to do that other gene-editing tools or technology couldn't?

To answer this, Niall takes us across the Atlantic to Baylor College of Medicine in Houston, Texas, where he completed postdoctoral research early in his career in the late 1990s. “At the time, I was working in a lab where we were trying to understand the function of nuclear steroid receptor proteins and how they operated in a cell in response to hormones,” he recalls. “Often, the best way to find out what something does is to break it, so you do what's called a knockout. You break that particular gene in a cell or in an animal, in this case it was in mice, and you observe the impact and try to understand the function of that gene. But the technologies, the techniques and molecular biology to achieve that knockout were extremely slow and very difficult to do. It took me over a year just to achieve one knockout. CRISPR makes this process fast and easy; it’s almost off-the-shelf as a lab tool.”

What previously would have taken up to a year can now be delivered within a couple of days: “I can go online and within minutes, I can order in the components to do a CRISPR treatment on a particular cell line. For instance, if I'm doing research on a CHO cell that's making a monoclonal antibody and I want to make that CHO cell last longer in the bioreactor, so it doesn't die as quickly and continues to make my product for another few days, I might try to switch off one of the genes that triggers apoptosis. So I can order the necessary CRISPR components, with a couple of vials containing the CRISPR protein (usually Cas9) and a short RNA ‘guide’ that matches part of that gene sequence in the CHO cell. I mix them together, transfer

them onto my CHO cells, wait a couple of days and then screen for the cells where the Cas protein has cut the gene, damaging its genetic coding and, thus ‘knocking it out’. It’s very straightforward.”

Breaking Into DNA

CRISPR at its simplest, like other gene-editing technology (zinc finger nucleases, TALENs etc), introduces a double strand break in DNA. When fixing this break, the cellular repair machinery will sometimes make a mistake, resulting in a gene knockout, allowing the scientist to then study the effect of that broken gene on cellular function.

Aside from speed and ease of use, the other big advantage of CRISPR is specificity, Niall reveals: “If you think of a human genome, you are looking at approximately three billion base pairs of DNA, which is an awful lot of territory to cover, especially if you're only

interested in one single base pair change, a single mutation that maybe causes a disease. The obvious thing to do is to repair that mistake [in the DNA], to change that T into an A or a G to rectify whatever the mistake might be. But the problem is targeting that one base amongst three billion base pairs and not accidentally hitting something else as well.”

Niall acknowledges that CRISPR has not solved this issue entirely and some challenges remain around off-target effects. “In in the biopharma industry, for example, you may be using Chinese hamster ovary (CHO) cells to make recombinant proteins at scale. If I am doing genetic manipulation on a CHO cell that I'm only ever going to grow in a bioreactor, as long as it doesn't affect my drug product, it doesn't hugely matter if I hit something else as well in the genome, because the cell line is already full of mutations and is developing more all the time. If I'm using CRISPR as a therapy in

its own right, however, I better be sure I'm not causing more harm than good by fixing that mutation but breaking something else, maybe fixing beta-thalassemia but causing cancer.”

There have been incremental improvements over the last decade or more in terms of increasing both specificity and efficacy, however, Niall insists, and the technology continues to evolve.

The Cost Advantage

The other advantage that CRISPR brings is its cost compared to other gene-editing technologies. One of the main gene-editing technologies that pre-dates CRISPR is zinc finger nucleases, which are “essentially proteins that you design with a specific shape so that they bind to a very specific sequence of DNA bases”. Designing the zinc finger protein to target a specific region of DNA takes specialist expertise and skill, making it expensive when compared to CRISPR.

CRISPR has the potential to develop new gene therapies, which could prove particularly effective in treating or even preventing diseases that have a genetic basis, like sickle-cell anaemia, cystic fibrosis, muscular dystrophy and many others.

While CRISPR began life being used to knockout genes, and is still extremely useful in this area, it can also be used for knock-in, Niall explains: “This uses the CRISPR technology itself to introduce those breaks in the DNA and in doing so, you give yourself an opportunity to deliver something else in there, like a good copy of the gene that's missing.” He cites the examples of haemophilia or sickle-cell anaemia.

“CRISPR is still only in its infancy,” Niall states. “It is more broadly used in research and non-therapeutic applications, and is still at a very early stage in terms of its therapeutic application. There is huge excitement about CRISPR, lots of spin-out companies and lots of clinical trials involving ex-vivo applications, whereby you take the patient’s cells out and perform the CRISPR manipulation outside the body before reintroducing the engineered cells, rather than delivering the CRISPR treatment into the patient, in a similar manner to CAR-T cell therapy.”

An Ethical Quandary

However, some scientists have warned that CRISPR technology, while potentially bringing huge scientific benefits such as the chance to eliminate diseases like cystic fibrosis, also brings an ethical quandary, whereby its use could spill over into the realm of eugenics. In 2018, a Chinese researcher, He Jiankui, shocked the world when he used CRISPR to alter the genomes of twin baby girls, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect white blood cells. The scientist

Professor Niall Barron, Principal Investigator, Cell Engineering Lab, NIBRT.

Astellas Ireland Co., Ltd.

Kerry Plant

Killorglin Co. Kerry

Astellas Ireland Co., Ltd.

Damastown Road

Damastown Industrial Park

Mulhuddart

Dublin 15

“ Anything that can be passed to the next generation needs to meet the absolute pinnacle of ethical, moral and technical standards. Moral and ethical challenges are a societal concern that we all need to decide together. This happens all the time with the advance of technology.”

was subsequently imprisoned but has since resumed research on human embryo genome editing.

“One of the first things you'd have a concern about is interfering with the germ line,” Niall insists. “Anything that can be passed to the next generation needs to meet the absolute pinnacle of ethical, moral and technical standards. Moral and ethical challenges are a societal concern that we all need to decide together. This happens all the time with the advance of technology.”

He cites the example of CAR-T technology, which was introduced for patients “who had exhausted absolutely all other options and in most cases only had four to six weeks left to live. So even if you inadvertently cause another mutation (there’s no evidence this is the case, by the way) that appears in 10 years, you have bought the patient those 10 years; those are the kind of moral or ethical decisions that doctors have to deal with. The same challenges apply to CRISPR. What's the risk? What's the benefit? What’s the cost? This will change from application to application and all the time, researchers are working on improving the technology.”

One area of research, and one which Niall believes might assuage ethical or targeting concerns involves editing the RNA that comes from the genome rather than the genome itself: “Rather than going after the genome and doing something permanent that may have unintended consequences, you can administer the CRISPR medicine to target the RNA. If I make a mistake in RNA, I'll make a few bad proteins and there could be minor side effects, but most of my edits will knock-down or improve the protein that I'm trying to target. This is about getting away from using CRISPR to modify a person's actual DNA and rather just modifying the steps afterwards, which are transient.”

The technology is changing all the time as scientists make new developments, with Niall citing the example of David Liu at Harvard, who he predicts will win a Nobel Prize in the coming years: “David Liu has developed the technology known as

base editing and prime editing, using the targeting ability of CRISPR to bring other molecular machinery to a very specific location in the genome and modify it, so it effectively localises a ‘cut and replace’ function to put in a string of bases replacing the bases already there, or to switch a C to a T or A to a G. Base editing is a very specific way of making a localised change in the genome and there is huge excitement around applications for this technology.”

Concerns Over Patents

Niall feels that some of the major biopharma companies have been reluctant to use CRISPR because of concerns over patents. “Until companies have a clear view of who owns any technology, who they need to pay a licence to, they’re not going to risk committing to something using CRISPR. So they might use CRISPR to see if something works, and then they go back to the original cells and use zinc finger nucleases or other technologies because they know exactly who owns the licences and who has to be paid.”

The other great challenge, not just with CRISPR but with all new medicines, is delivery. “How do you target delivery to the correct organ in the individual in an efficient manner so it doesn't all end up being cleared by the liver or going to the wrong organs and either being ineffective or worse still, causing some consequences that you never anticipated?” concludes Niall. “Delivery remains one of the great challenges in medicine in terms of achieving that specificity, so that medicines are targeted, localised, with either no side effects or as few target effects as possible: that’s the holy grail.”

CRISPR allows scientists to add, remove or change a specific DNA sequence and to turn genes on and off, sometimes without even altering their sequence.

CONTRAST MEDIA: GE

GE HealthCare: Over 30 Years in Ireland

GE HealthCare has been supporting patients across the globe for over three decades from its Irish base in Carrigtohill, Co. Cork.

GE HealthCare’s pharmaceutical imaging agent manufacturing facility at its Ireland Campus in Carrigtohill, Co. Cork, has been supporting patients for more than 30 years. During that time, the site has seen significant growth – it started production in 1993 with 43 employees, producing three million doses annually for customers in western Europe. Today, more than 760 employees work at the site, producing over 32 million doses annually for customers and their patients across the globe.

The site manufactures injectable diagnostic imaging agents (contrast media) used in X-ray and Computed Tomography (CT) procedures around the world. Contrast media helps improve the visibility of specific organs, blood vessels or tissues during imaging procedures. This aids clinicians in making better informed decisions regarding monitoring and treatment of patients.

Increasing Demand

The company estimates that demand for its iodinated contrast media products will increase significantly over the coming years, largely due to an increase in the use of CT imaging procedures. To help address this increasing demand, GE HealthCare invested $30 million into additional production capacity at the Carrigtohill site to support the company’s ambition to produce an additional 30 million patient doses per year by the end of 2025, compared to 2022.

Eugene Barrett, GE Healthcare Ireland Site Leader, who leads the team at the Cork facility, said: “We know that our products play an important role in helping clinicians diagnose patients and put in place the most appropriate treatment options available. As a team, we’re driven by that purpose to deliver on our promises to our customer because patients rely on us each and every day to have

their scheduled X-ray and CT procedures.

“The opening of our newest production line has been a great success and means that our products can help even more customers and patients. That’s only possible because of the commitment of everyone on the team,” Eugene continued. “We’ve come a long way over the last 30 years and we’re looking forward to the next 30 years and the opportunities there will be for us to make an even bigger impact for our customers and their patients but also for our local community, as an employer seeking to grow further.”

A Global Leader in Imaging Agents

The Carrigtohill site is part of GE HealthCare’s Pharmaceutical Diagnostics segment, a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE HealthCare imaging agents have been routinely used across MRI, X-ray/ CT and ultrasound to enhance clinical images and support diagnosis.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, dedicated to providing integrated solutions, services and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalised, connected and compassionate care, while simplifying the patient’s journey across the care pathway.

For more information about roles currently open at GE HealthCare, visit: https://jobs.gecareers.com/healthcare/global/en/

We can provide the best tailor made cooling  solution to suit your requirements

SPECIALIST REFRIGERATION ENGINEER

Utilising the most energy efficient technologies and  assisting our clients to be fully compliant with the current  legislative and environmental guidelines. We provide a  complete solution of Mechanical Equipment, Fire Rated  We can provide the best tailor made cooling

We can provide the best tailor made cooling

SPECIALIST REFRIGERATION ENGINEERING

SPECIALIST REFRIGERATION ENGINEER

We can provide the best tailor made cooling

SPECIALIST REFRIGERATION ENGINEER

SPECIALIST REFRIGERATION ENGINEERING

Utilising the most energy efficient technologies and assisting our clients to be fully compliant with the current legislative and environmental guidelines. We provide a complete solution of Mechanical Equipment, Fire Rated Insulation and a wealth of application knowledge to our clients.

SPECIALIST REFRIGERATION ENGINEERING

Utilising the most energy efficient technologies and assisting our clients to be fully compliant with the current legislative and environmental guidelines. We provide a complete solution of Mechanical Equipment, Fire Rated Insulation and a wealth of application knowledge to our clients.

PRODUCTS & SERVICES

We can provide the best tailor made cooling

With a vast knowledge of the refrigeration industry and  the Pharmaceutical sector in particular, we are the first  choice for our large client base when it comes to servicing,  maintaining, and replacing all  equipment  from large capacity chillers to medical storage  cabinets and temperature control systems.

PRODUCTS & SERVICES

assisting our clients to be fully compliant with the current  legislative and environmental guidelines. We provide a  complete solution of Mechanical Equipment, Fire Rated   wealth of application knowledge to our

• Site survey & system  recommendation

• Supply, installation & commissioning

• Project management

• Energy Saving Packages

• Energy Saving Pack

• Monitoring Systems

PRODUCTS & SERVICES

• Site survey & system  recommendation

• Monitoring Systems

PRODUCTS & SERVICES

Utilising the most energy efficient technologies and assisting our clients to be fully compliant with the current legislative and environmental guidelines. We provide a complete solution of Mechanical Equipment, Fire Rated Insulation and a wealth of application knowledge to our clients.

• Plant service and maintenance

• Supply, installation & commissioning

• Site survey & system  recommendation

PRODUCTS & SERVICES

• Supply, installation & commissioning

• Site survey & system  recommendation

• Supply, installation & commissioning

• Project management

• Site survey & system  recommendation

Unit 26

• Supply, installation & commissioning

We can provide the best tailor made cooling  Unit 26

With a vast knowledge of the refrigeration industry and  the Pharmaceutical sector in particular, we are the first  choice for our large client base when it comes to servicing,  equipment  from large capacity chillers to medical storage

• Supply, installation & commissioning

• Plant service and maintenance

PRODUCTS & SERVICES

• Site survey & system  recommendation

• Project management

With a vast knowledge of the refrigeration industry and the Pharmaceutical sector in particular, we are the first choice for our large client base when it comes to servicing, maintaining, and replacing all types refrigeration equipment from large capacity chillers to medical storage cabinets and temperature control systems.

• Site survey & system  recommendation

• Supply, installation & commissioning

• Energy Saving Packages

• Project management

• Energy Saving Packages

• Project management

• Monitoring Systems

With a vast knowledge of the refrigeration industry and the Pharmaceutical sector in particular, we are the first choice for our large client base when it comes to servicing, maintaining, and replacing all types refrigeration equipment from large capacity chillers to medical storage cabinets and temperature control systems.

• Supply, installation & commissioning

• Project management

• Monitoring Systems

• Project management

• Monitoring Systems

• Energy Saving Packages

• Plant service and maintenance

Cross Technical Solutions Ltd.

9/10 Broomhill Road, Tallaght, Dublin 24

PRODUCTS & SERVICES

• Energy Saving Packages

• Monitoring Systems

• Plant service and maintenance

• Energy Saving Packages

With a vast knowledge of the refrigeration industry and the Pharmaceutical sector in particular, we are the first choice for our large client base when it comes to servicing, maintaining, and replacing all types refrigeration equipment from large capacity chillers to medical storage cabinets and temperature control systems.

• Energy Saving Packages

9/10 Broomhill Road, Tallaght, Dublin 24

PRODUCTS & SERVICES

Cross Technical Solutions Ltd., 9/10 Broomhill Road, Tallaght, Dublin 24

PRODUCTS & SERVICES

Co. Dublin - Ireland

• Monitoring Systems

• Supply, installation & commissioning

• Project management

• Plant service and maintenance

• Monitoring Systems

PRODUCTS & SERVICES

• Plant service and maintenance

• Energy Saving Pack

PRODUCTS & SERVICES

• Site survey & system  recommendation

PRODUCTS & SERVICES

• Supply, installation & commissioning

• Project management

• Energy Saving Packages

• Monitoring Systems

Co. Dublin - Ireland

Tel (+353) 01 405 6777

• Site survey & system  recommendation

• Project management

• Site survey & system  recommendation

• Supply, installation & commissioning

• Energy Saving Packages

• Plant service and maintenance

• Site survey & system  recommendation

• Monitoring Systems

With a vast knowledge of the refrigeration industry and the Pharmaceutical sector in particular, we are the first choice for our large client base when it comes to servicing, maintaining, and replacing all types refrigeration equipment from large capacity chillers to medical storage cabinets and temperature control systems.

• Energy Saving Packages

• Plant service and maintenance

• Site survey & system  recommendation

• Supply, installation & commissioning

• Site survey & system  recommendation

• Supply, installation & commissioning

Tel (+353) 01 405 6777

• Site survey & system  recommendation

Tel (+353) 01 405 6777

• Project management

• Supply, installation & commissioning

• Project management

• Supply, installation & commissioning

Fax (+353) 01 4136932

Fax (+353) 01 413 6932

• Project management

• Energy Saving Packages

• Project management

• Energy Saving Packages

jmcgrath@ctsolutions.org

PRODUCTS & SERVICES

• Monitoring Systems

jmcgrath@crosstechnicalsolutions.ie

• Monitoring Systems

www.crosstechnicalsolutions.ie

• Energy Saving Packages

www.crosstechnicalsolutions.ie

jmcgrath@crosstechnicalsolutions.ie www.crosstechnicalsolutions.ie

• Energy Saving Packages

Cross Technical Solutions Ltd. 9/10 Broomhill Road, Tallaght, Dublin 24

• Energy Saving Packages

PRODUCTS & SERVICES

• Plant service and maintenance

• Monitoring Systems

• Site survey & system  recommendation

Co. Dublin - Ireland

• Monitoring Systems

• Supply, installation & commissioning

• Site survey & system  recommendation

• Plant service and maintenance

Tel (+353) 01 405 6777

• Plant service and maintenance

• Project management

Fax (+353) 01 4136932

• Project management

• Energy Saving Packages

• Supply, installation & commissioning

jmcgrath@crosstechnicalsolutions.ie www.crosstechnicalsolutions.ie

• Energy Saving Packages

• Monitoring Systems

• Plant service and maintenance

sales@crosstechnicalsolutions.ie www.crosstechnicalsolutions.ie

• Supply, installation & commissioning

We can provide the best tailor made cooling  Co. Dublin ‐ Ireland

• Plant service and maintenance

We can provide the best tailor made cooling  sales@crosstechnicalsolutions.ie www.crosstechnicalsolutions.ie

With a vast knowledge of the refrigeration industry and  the Pharmaceutical sector in particular, we are the first  choice for our large client base when it comes to servicing,  types refrigeration  equipment  from large capacity chillers to medical storage

sales@crosstechnicalsolutions.ie www.crosstechnicalsolutions.ie

We can provide the best tailor made cooling  solution to suit your requirements , Cookstown Industrial Estate Cookstown, Tallaght, Dublin 24 Co. Dublin ‐ Ireland

Tel (+353) 01 405 6777

Fax (+353) 01 4136932 sales@crosstechnicalsolutions.ie

Tel (+353) 01 405 6777

Fax (+353) 01 4136932

AI and the Competitiveness Conundrum

How AI can help Irish Life Sciences companies solve the competitiveness conundrum,

by Alan Dickson, Partner, Business Consulting, EY, and Sinead Mc Donagh, Director

Data Analytics

AI, EY Life Sciences.

Biopharma and Life Sciences companies in Ireland and across the globe are facing what might be described as a competitiveness conundrum. Demand for innovative medicines and treatments has never been higher and even the world’s leading biopharma giants are struggling to meet it. On the other hand, health systems are struggling with escalating costs owing to ageing populations and other inflationary pressures and are, in turn, seeking price reductions from pharma suppliers. Meanwhile, the increasing burden of regulation is driving costs upwards for the global Life Sciences sector.

At the same time, the very nature of healthcare is undergoing profound change. The era of the blockbuster medicine is effectively a thing of the past. While there is no let-up in research and development activity and the amount of new treatments coming through the pipeline, the economics have changed quite fundamentally.

The model has been inverted and instead of a small number of drugs treating large numbers of patients, multiple treatments are being developed to treat ever smaller patient groups. The implications are clear for the unit cost of production of new medicines.

If the Life Sciences industry is to meet the expectations of health systems and other customers at the same time as delivering on patient needs and changing regulatory requirements, it will need to do a lot more with the same.

The competitiveness conundrum presents particular challenges for the Irish biopharma industry. Ireland has been steadily progressing

up the manufacturing value chain for the past three decades and more. The country is no longer a low-cost location for manufacturing, nor does it wish to be. It now ranks among the world’s foremost knowledge economies and its manufacturing base reflects that.

Indeed, research analysts consistently name Ireland as a world leading location for advanced and digital manufacturing. The Irish operations of many global biopharma firms are lighthouse sites for their parent companies due to their advanced capabilities. That is a global standing we relinquish at our peril and we must not only retain current standards but continually improve if we are to stay ahead of the curve.

There is no going back. Cost cutting at the expense of the value add created would be counterproductive in the extreme for the biopharma industry here. And therein lies the nub of the challenge.

Choosing the Right Manufacturing Location for Biopharma

The global biopharma and Life Sciences sector is highly dynamic. As new medicines and treatments come through R&D pipelines and receive regulatory approval, companies must decide where to locate their manufacture. In an environment where customers are seeking more for less, manufacturers need to become ever more efficient and productive.

This is not a simple proposition in the highly regulated biopharma world where there is zero tolerance for process faults. Drugs are increasing in complexity, while their batch sizes are falling rather

ARTIFICIAL INTELLIGENCE

Alan Dickson, Partner, Business Consulting, EY.

than growing, in line with global healthcare spending. As treatments become more specialised and personalised, they also become more expensive to produce. Production facilities that can offer even slight cost advantages will have a distinct edge when competing for new manufacturing mandates.

In that respect, we need to acknowledge the labour cost environment in Ireland. The availability of highly skilled and qualified talent has long been one of Ireland’s key attractions for inward investment by advanced manufacturing sectors like biopharma. That comes at a price, which the industry has been willing to pay, up until now. While there is no question of attempting to reduce labour costs, it is clear that efficiency needs to improve quite significantly if the industry here is to remain competitive.

Keep Sustainability High on the Agenda

Sustainability is another key factor in the decision-making process. Biopharma company leaders are choosing their capital investments now for the next five years and sustainability requirements are front-of-mind for them. Regardless of how sophisticated or advanced a manufacturing facility is, it will not attract new investment if it is not top ranking in terms of its green credentials.

1. Shaping the future with AI AI, and particularly Generative AI, can provide a solution to the competitiveness conundrum. Used the right way, it can create competitive advantage, re-engineer processes and enhance risk controls. It can assist Irish Life Sciences companies to continue to increase the value they deliver. But it should not be seen as some kind of miracle panacea. Its application requires careful consideration and

planning to ensure that the investment of time and financial resources does not go to waste.

At EY AI Labs, we look at AI implementation in advanced and digital Life Sciences manufacturing settings through the lens of the four separate components required for a successful outcome. The first of those is an examination of what AI can do today and the potential benefits it can bring

tomorrow. That means looking at particular use cases where it can be applied to optimise processes and make efficiency gains.

In one recent instance, we worked with a leading global biopharma company to identify yield gains of between 3% and 5% across its manufacturing network. We are also working with a number of other global companies to use AI to future-proof new facilities which are currently under development.

2. People’s Adoption of AI

The next critical component is the people aspect. A primary factor in the unsuccessful deployment of AI is often its underutilisation or incorrect use. There’s a natural fear that many people have of technology that they believe has the potential to replace them in their role.

If organisations want people to use these new tools and exploit their capabilities, they need to help them by providing training and explaining what their roles will look like in five years’ time when AI is fully in place. This will not only help to allay fears but will allow people to embrace the technology and enjoy using it.

3. Streamlining Manufacturing Processes

The next component relates to shop floor manufacturing processes. AI solutions must be tailored to what actually happens on the shop floor. If not, the engineers and production

Sinead Mc Donagh, Director Data Analytics & AI, EY Life Sciences.

EST. 1989

EU & NORTH AMERICA

730+ EMPLOYEES

Over three decades supporting Pharmaceutical & Biologics clients in Europe & North America with technical and engineering expertise.

LotusWorks’ di erentiator is in our partnership approach, quality of client care, safety, compliance, and operational excellence. We are proud of our long-standing relationships as a strategic partner of choice to global Pharmaceutical & Biologics manufacturers.

managers won’t use it and its capacity to optimise and automate processes will be lost.

4. Digital System Integration

The last component is digital system integration. The AI must be integrated with other systems in the facility to get the data it requires. That integration must extend to the supply chain to make it as efficient and resilient as possible.

An AI enabled digital control tower can provide end-to-end visibility across supply chain and manufacturing and support inventory optimisation. In addition, the technology can be used to better predict future demand by time, SKU and region and translate those insights into ongoing capacity requirements across the supply chain to enable better planning.

Beyond digital manufacturing and supply chain optimisation, AI can help address other key challenges faced by the biopharma industry today. Regulation is one example. There is so much manufacturing regulation out there and more on the way that people need to think about. In a case where humans are responsible for sign-off on compliance, AI can help to ensure that all relevant regulations have been taken into account and adhered to.

The technology also has applications for sustainability. What AI is brilliant at doing is collecting data, finding insights and providing recommendations of what should be done to achieve the desired improvements in performance. That doesn’t just apply to productivity but to resource consumption in areas like energy and water. It can also automate some aspects of sustainability reporting.

How

EY’s

AI Labs can be the Gamechanger

AT EY, we have set up the AI Labs, which is a multidisciplinary centre of excellence for driving innovation through the application of AI technology, machine learning and advanced analytics.

The EY Wavespace AI Lab was established in Dublin in 2022 as part of a global network of over 50 EY Wavespace locations and is the European hub for innovation in Life Sciences. The AI Lab provides a location and capability for our clients to collaborate, plan and prototype how they can take full advantage of this transformative technology. This is brought to life with a series of Life Sciences AI case studies and demos, showing the art of the possible today.

The AI Lab team works with clients on

each of the components mentioned above to assist them in driving innovation and efficiencies through the applications of AI technology in an advanced manufacturing environment.

Most importantly, each workshop is designed with the specific needs and goals of the client in mind. No two sessions are the same, and while all four essential components are discussed, the emphasis and focus on each one varies according to the particular circumstances of the client.

Our team of experts looks at every aspect of AI and GenAI deployment right along a company’s value chain to co-create solutions that will help them solve the competitiveness conundrum.

Ultimately, the challenge is to make sure that the advanced manufacturing Life Sciences plants we already have continue to lead the world, and to provide value adding solutions which ensure that companies looking at locations for their next advanced manufacturing plant will continue to choose Ireland.

In meeting that challenge, we need to understand that AI will not replace jobs here in Ireland. We need to invest in innovation and technology to make sure the people using the AI are here in Ireland. That is the key to protecting what we have and generating further growth in the future.

If you are interested in how AI can transform your business and want to learn more through our workshops, we would be delighted to hear from you. Please feel free to reach out to Sinead McDonagh, our Life Sciences AI Lab Lead, at Sinead.McDonagh@ie.ey.com to discuss further.

We need to invest in innovation and technology to make

for biopharma globally.

AI, and particularly Generative AI, can provide a solution to the competitiveness conundrum.

sure at Ireland remains at the top table

Bright Future for Biopharma

Recent announcements of heavyweight investments point to a bright future for Ireland’s biopharma sector, writes Rory Mullen, Head of BioPharma and Food at IDA Ireland.

In December 2023, IDA Ireland celebrated Ireland’s Life Sciences industry at an event in Dublin’s National Concert Hall. Special recognition was given to US pharmaceutical company Pfizer, with global Chairman and CEO Albert Bourla receiving an award from the then Taoiseach Leo Varadkar TD, to mark the company’s presence in Ireland for more than 50 years and its commitment to sustained investment here.

The Life Sciences sector accounts for one third of the employment by IDA client companies and it remains an exemplar of innovation and impact in the economy. Overall, the employment base of IDA Ireland client companies remained stable during 2023 and total employment was over 300,000 for the second year in a row. With more voters than ever heading to the polls across the globe this year, the international investment landscape throughout 2024 has continued to be volatile, particularly regarding national industrial strategies in strategic sectors, including biopharmaceuticals. The ramping up of trade tariffs being mooted by some, along with an increased emphasis on State Aid for industrial projects, on top of the uncertainty around inflation, interest rates and energy costs, brought about by geopolitical events in Ukraine, Gaza, and Lebanon, is exacerbating this volatility.

In Ireland, whilst the number of Foreign Direct Investment (FDI) projects in the first half of 2024 was slightly down on 2023, levels of investment remained strong from new and existing investors. A total of 131 investments were won in the first half of the year, with associated employment potential of over 8,000 jobs.

This performance underlines the country’s ongoing reputation as a competitive, stable and resilient place in which to do business. Ireland consistently wins international investment due to our highly educated and talented workforce and because of our stable, pro-business environment. We have a welcoming environment for FDI across the country and IDA Ireland will continue to work with all our client companies to ensure that they progress on the paths of digitalisation and decarbonisation that are essential to ensuring future competitiveness.

Exports by IDA’s multinational client companies grew to €383.1 billion in 2022 and the biopharmaceutical sector was a key driver of this. In addition to expenditure in the Irish economy, IDA Ireland clients make

A Thriving Industry

The biopharma industry continued to thrive in Ireland during 2024. The projects that were announced in recent years are currently being built out and validated. Currently there is over €5 billion being invested across 15 biopharma sites throughout Ireland. Rising geopolitical tensions have focused companies on the geographical resilience of their supply chains and this has enhanced Europe’s attractiveness for biopharma manufacturing projects.

Direct employment in the sector in Ireland is continuing to grow and there are now more than 50,000 direct employees in IDA’s biopharmaceutical client companies.

Investment Highlights of 2024

In the last year, total investment of an additional €1.5 billion has been announced. These new, nationwide investments will ensure that the recent growth in employment in the sector will continue.

a considerable contribution to the public finances. Sectors dominated by IDA Ireland client companies account for an estimated 70% of corporation tax receipts and also make a significant contribution to income tax receipts.

Highlights over the last 12 months include the announcement by Eli Lilly in September to invest an additional $1 billion in the new manufacturing site it is developing in Limerick to increase production of biologic active ingredients for the company’s promising portfolio of treatments for Alzheimer’s disease.

Also, in September, Cara Partners announced an additional investment of €130 million in their facility in Cork that

Rory Mullen, Head of BioPharma and Food at IDA Ireland.

Matthew Klein, CEO of PTC Therapeutics, officially opens the company’s new Dublin office.

at the opening of NIBRT’s advanced therapies facility are Kate Cotter, Director of Training Delivery NIBRT; Rachel Shelly, Divisional Manager, Life Sciences & Food, and Talent, Transformation & Innovation, IDA Ireland; Tánaiste Micheál Martin TD; Julie O’Neill, NIBRT Chairperson; and Darrin Morrissey, CEO, NIBRT.

specialises in the extraction of API from natural herbal material. There were many other announcements during the year, such as those by PCI Services in Stamullen, Co. Meath, ThermoFischer in Cork, and PTC Therapeutics in Dublin.

In February of this year, BMS announced the investment of $400 million into its Dublin 15 Cruiserath Campus towards the build and design of a Sterile Drug Product (SDP) facility, which will support the manufacturing and supply of existing medicines across a range of therapeutic areas, including oncology, immunology and haematology.

Last March, Astellas - the global Japanese pharmaceutical company specialising in transplant, kidney, bladder, and cancer drugs - broke ground on their new €330 million Fill Finish facility on a 45-acre site in Tralee, Co. Kerry. This will complement their existing facility in Killorglin and demonstrates their commitment both to the region and the country.

Ensuring Ireland is an Attractive Investment Location

As we continue to win investment across both the small molecule and biologics manufacturing sectors, we need to ensure that we remain an attractive investment location for all new modalities, including Advanced Therapeutic Medicinal Products (ATMPs) currently being developed by the industry. Advanced therapeutics is a broad category of innovative biological medicines that includes cell therapies, gene therapies, mRNA and DNAbased therapies and other novel biologicbased medicines and vaccines. These new advanced therapies are set to transform the ways in which we can help patients.

Earlier this year, Tánaiste Micheál Martin TD officially launched The National Institute for Bioprocessing Research and Training’s (NIBRT) new state-of-the-art advanced therapies research and training facility. This expansion increases NIBRT’s capacity and capability to conduct manufacturing-focused research and training in advanced therapeutics.

The Irish Government remains fully committed to the ongoing development of the biopharma sector in Ireland. During 2024, Digital Manufacturing Ireland Centre (DMI) in Limerick progressed its work with biopharma

companies and the Government’s Expert Group on Future Skills Needs completed its work with recommendations to ensure that Ireland is well positioned to meet the strong growth in talent requirements for the industry.

The Department of Health continues to take the lead on Ireland’s input to the EU pharma strategy and has brought together a cross departmental group to ensure that the Government takes a holistic view of the strategy.

A Strong Future

IDA Ireland will continue to work closely with global biopharma companies to ensure that their activities in Ireland excel. I am consistently impressed by the culture within our biopharma client companies, which is so focused on the delivery of innovative medicines that transform lives.

We believe that Ireland has a strong future in biopharma and that we will remain a global leader in manufacturing and process development for many years to come and the advanced management and innovation services activities that our client companies are increasingly establishing here will grow and develop.

IDA Ireland partners with our client companies to support them across their talent development, innovation and sustainability journeys and we look forward to working with BPCI members to ensure that the biopharma sector in Ireland reaches its full potential as a global development and manufacturing and management hub for the industry.

Congratulations to Sinead Keogh on the completion of her first year as Director of Biopharmachem Ireland and we wish all in BPCI and its members every success in 2025.

Pictured

Pictured as Eli Lilly announced a $1 billion expansion of its Limerick manufacturing site are: Minister for Enterprise, Trade and Employment Peter Burke TD; Senator Tim Lombard; Dave Ricks, CEO, Eli Lilly and Company; Tara Tibbs, Sr Vice President and Kinsale General Manager; and Michael Lohan, Chief Executive Officer of IDA.

Making a Difference Merck :

Merck impacts life and health with science, and is committed to delivering breakthroughs that enhance lives globally.

Merck is a vibrant science and technology company with over 63,000 employees in 66 countries, spread across three businesses: Life Science, Healthcare, and Electronics. They are committed to delivering breakthroughs that enhance lives globally, from helping discover novel therapies to addressing unmet medical needs and powering the digital world of tomorrow.

Merck also deliver personalised treatments for serious diseases and enable people to achieve their dream of becoming parents. Their tools, services and digital platforms make research simpler, more exact, and enhance breakthroughs more quickly. Their solutions accelerate access to health by ensuring tests are accurate and the medicines we take can be trusted.

Merck are the company behind the companies advancing digital living. Their science sits inside technologies that are changing the way we access, store, process and display information. Their innovations are unlocking the power and potential of data to open new possibilities to transform life as we know it.

Merck in Ireland

Merck’s Cork site is part of their Life Science business, which aims to impact life and

health with science. The Merck Life Science Centre in Cork is a unique manufacturing facility within the company’s global network of 55 manufacturing and testing sites. A dedicated team of more than 700 scientists, engineers, and technical experts are involved in manufacturing critical products for use in diagnostics, drug discovery and therapeutics. Their Cork site continues to grow and increase its manufacturing capacity and in 2022 announced an outlay of over €440 million over the next five years in Merck’s largest ever single site investment. It will also lead to the creation of more than 370 permanent jobs in Cork by 2027.

From working on virus filters and UF filters for DNA sample preparation to diagnostics products such as lateral flow membranes, pregnancy, HIV and Dengue fever tests, Cork focuses on:

• Biotools: The Biotools department makes filtration and medical devices, manufacturing 120 million devices annually for the pharmaceutical industry.

• Membrane: As the Merck Centre of Excellence, membranes are manufactured and incorporated into filtration devices to remove harmful bacteria and viruses from life-saving medicines. Often, Merck’s membrane is the last component a treatment will touch before being administered to a patient.

The company’s new site in Blarney, which is due to commence commercial operation in 2026, will produce filtration devices for customers, producing both traditional and novel treatments and therapeutics.

Making a Difference

As well developing products to improve people’s lives, the Merck Cork team is committed to making a difference in the local community. Through initiatives such as hosting an annual School Science competition, sponsoring period products and career panel discussions in local schools and working with local outreach programmes, the team passionately pursues creating a level playing field for future generations in the workforce.

Together with their colleagues, customers and stakeholders, Merck impacts life and health with science.

Pictured as Merck announced a €440 million investment in their Cork site are (l-r): Cllr Gillian Coughlan, Cork Mayor; Martin McAuliffe, Managing Director and Head of Cork Operations, Merck; then Taoiseach, Micheál Martin TD; Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science; Michael Lohan, CEO, IDA Ireland; Sara Yussefi, Global Head of Life Science Communications and Business Services, Merck Group; and Ivan Donzelot, Head of Integrated Supply Chain Operations, Merck Life Science.

We are a

Investing in Ireland

One of the first pharma companies to launch in Ireland, Bristol Myers Squibb continues to invest in its business here, with a Sterile Drug Product (SDP) facility at the company’s Cruiserath Campus set to open in 2026.

Bristol Myers Squibb was one of the first pharmaceutical companies to launch in Ireland, opening an Active Pharmaceuticals Ingredient Plant in Swords, Co. Dublin in 1964. This leading global biopharma company is on a mission to discover, develop and deliver innovative medicines for patients with serious diseases in areas including oncology, haematology, immunology, cardiovascular, fibrosis and neuroscience.

In 2024, Bristol Myers Squibb celebrated 60 years in Ireland. In that time, it has significantly grown its presence in Ireland, expanding its network of Irish sites to include a distribution centre in Shannon, County Clare, and the global headquarters for External Manufacturing in Blanchardstown Corporate Park, which is also the home to Bristol Myers Squibb European Treasury Centre, Commercial Operations, Global Procurement, and Global Manufacturing Science & Technology.

The Cruiserath Campus

In 2017, Bristol Myers Squibb opened a new state-of-the-art multi-product cell culture, biologics drug-substance manufacturing facility in Cruiserath, Dublin 15. The campus spans more than 125 acres and is the first Bristol Myers Squibb biologics drug substance facility outside of the United States with the capability to have multiple products produced at one time, providing consistent, high-quality and compliant products for patients across the world.

Following a $1 billion investment, the Cruiserath Campus is now the site of release for all finished drug products into the EU and the rest of the world. It is also home to a Global Biologics Laboratory, responsible for release testing for all commercial biological drug products.

More recently, Bristol Myers Squibb invested $400 million towards the build and design of a Sterile Drug Product (SDP) facility at the Dublin 15 Cruiserath Campus. As the company’s first European Biologics SDP facility, it will support the manufacturing and supply of existing medicines and serve as a launch excellence facility for pipeline assets.

A Significant Milestone

This large-scale investment represents a significant milestone for Bristol Myers Squibb Ireland. It will significantly expand manufacturing and laboratory capacity in Cruiserath, as the campus adds new technologies and capabilities supporting SDP manufacturing. The co-location of drug

substance and drug product manufacturing alongside existing global testing capabilities provides Bristol Myers Squibb increased flexibility in supplying medicinal products to patients through their commercial brands and clinical pipeline. Additionally, it will ensure Bristol Myers Squibb’s presence in Ireland continues to play a critical role in the global production, development and supply network.

With the new SDP facility at the Cruiserath Campus due to open in 2026, it is anticipated there will be a further 350+ roles created in Ireland as part of this investment, bringing the total number of Bristol Myers Squibb direct employees at the campus to more than 1,000, marking the beginning of an exciting new chapter for Bristol Myers Squibb in Ireland.

This article was funded by Bristol Myers Squibb. NO-IE-2400094

Bristol Myers Squibb’s latest investment is expected to add 350+ new jobs in their Irish operation.

Bristol Myers Squibb celebrated 60 years in Ireland in 2024.

We are in the business of breakthroughs—the kind that transform patients’ lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we’ll never give up our search for more hope, for more people, around the world.

Expert Analytical Solutions: Foresight for Success

With more than 55 years of experience across five global locations, Almac can add real value to drug development and commercialisation programmes.

Almac employs over 700 highly skilled analytical scientists across five global locations working in regulatory-approved GMP laboratories.

With 55+ years of experience, their expert teams develop 1,000+ analytical methods and validate 250+ methods annually. Drawing upon an extensive range of analytical technology, combined with a wealth of analytical knowledge, Almac can add real value to your drug development and commercialisation programmes.

Within Almac’s specialised testing laboratories, they have significant experience in a wide range of analytical techniques delivered by highly skilled analytical scientists, ensuring all testing is conducted with the highest level of accuracy and reliability.

Analytical Solutions

Almac support drug substance and drug product analytics across all clinical phases, from early pre-clinical/clinical development to commercial release:

Test Articles Services

Raw materials

• Drug substance / API

• Small molecule

• Peptides

Biologics

• Drug product

• Small molecule

• Peptides

Biologics

• Over encapsulated drug

• Medical devices

• Conjugates

Highly potent

• Controlled substances

• Method development

• Method validation

• Method transfer

• Stability Study programmes

• Release analysis: all lifecycle stages

• Spectroscopy services (inc. structural elucidation and impurity identification)

• Biodistribution Studies by ICP-MS

• Investigational analysis

• Reference standard management

• Microbiological testing

• Physical sciences

• Analytical support for clinical trial supplies

Analytical Solutions for Biologics

Almac offers a diverse suite of analytical methods with applications across the biologic development space, with extensive experience in the analysis of drug substance, drug product and reference material, from pre-clinical phase through to commercial manufacture for monoclonal antibodies (mAb) and mAb-like molecules, antibody drug conjugates, biosimilars and biobetters, recombinant proteins, cell/gene therapies and long peptides.

Almac look deeper so you don’t have to:

Specialised instrumentation and techniques: most recently they have invested in state-of-the-art chromatography, spectroscopy, and

biologics testing equipment, including the Raman TRS100 system, which allows faster assay of tablets, capsules, and other dosage forms.

Digitisation upgrade: a multi-million-euro digitisation upgrade, including enhancements to their existing laboratory information management system (LIMS), promotes seamless information sharing across multiple teams, departments and facilities, offering clients a reliable, optimised and streamlined solution.

People: Almac’s expert teams conduct continuous training and collaboration with local academia fosters talent, offering clients the very best partnership possible now, and for the future.

Ongoing investment: guaranteeing best-in-class services, Almac continue to invest in expanding their analytical labs, technology and people. Most recently, their new lab space at their global headquarters site has enabled Almac to increase capacity, with additional upgrades featuring across all sites.

Why choose Almac?

Highly experienced and dedicated teams: their teams bring a wealth of experience and dedication, ensuring expert solutions for every project.

Industry leading project management: Almac excel in project management, setting high standards for efficiency and effectiveness.

Flexibility to meet your growing needs: their flexible approach allows Almac to adapt and meet your evolving requirements seamlessly by leveraging their five global sites.

Reputation for quality: Almac is a quality-driven organisation and makes the commitment to clients, large and small, to deliver highquality results every time.

Results-driven: their focus is on achieving tangible, impactful results that drive the success of your product.

Collaborative partnership: Almac believe in building strong, collaborative partnerships to achieve the mutual goal of drug development and commercial success.

Continual investment in their people, facilities, capabilities, and technology: they continuously invest in their team, infrastructure and technology to stay at the forefront of innovation and capability.

For more information, visit www.almacgroup.com

Ellab Invests in Calibration and Validation Training Academy

In the second half of 2024, a construction site in Whitegate, County Cavan, buzzed with activity as Ellab was building an innovative, cutting-edge global training academy dedicated to the development of engineers and technicians in the critical fields of calibration and validation. This investment underscores the company’s long-term strategy to support the Life Sciences sector, while fostering significant career growth opportunities for its global workforce.

With the Life Sciences industry rapidly expanding, the Whitegate Academy will play a key role in upskilling talent, helping to meet growing demands in Ireland and abroad. The academy will serve not only as a local training hub but as a global resource for Ellab’s employees, offering both on-site and virtual training programmes designed to standardise and elevate the technical expertise of its teams.

Founded in 1949, and headquartered in Denmark, Ellab has consistently been at the forefront of innovation and quality, with the company’s stated mission being to reduce the time to market and risk of product loss for biotech and pharma companies across Europe, the US and Asia. They achieve this through three main business lines focused on validation, calibration and environmental monitoring.

Ellab’s presence in Ireland began in 2020 with its acquisition of an instrumentation products and services supplier and in the following years, expanded that presence with the acquisition of three further validation and calibration companies.

Meeting Industry Needs with Focused Training

Calibration and validation are two technical disciplines that sit at the heart of quality

assurance in Life Sciences manufacturing. These processes ensure that life-saving products meet stringent regulatory requirements, thereby guaranteeing patient safety and product effectiveness.

Recognising the sector's continuing need for specialised skills, Ellab is creating an academy to address the shortage of professionals equipped to handle these critical tasks. The academy will offer advanced, tailored training programmes in both validation and calibration, with a full suite of onsite equipment in a facility designed to replicate a pharma and biotech processing environment.

“Our investment in Ireland is about more than just facilities; it’s about creating a futureready workforce,” explained Ludvig Enlund, CEO of Ellab, of the vision behind the academy. “Calibration and validation are central to the Life Sciences ecosystem, and we’re committed to building the talent needed to support this crucial sector globally.”

Supporting the Life Sciences Sector in Ireland

Ireland has become a global leader in Life Sciences, attracting major multinational investments due to its skilled workforce and strategic geographic location within

Europe. However, with rapid growth comes the challenge of ensuring a steady supply of specialised talent to sustain industry momentum.

Ellab’s investment responds to this challenge by directly contributing to the growth and stability of the Life Sciences sector in Ireland. The Whitegate training academy will help address the sector's increasing demands by training the next generation of engineers and technicians, while also upskilling current employees.

“Ireland is already a key player in the Life Sciences industry, but to maintain that position, we need to ensure that the workforce keeps pace with evolving technology and industry requirements,” said Paul O’Hare, Managing Director of Ellab Ireland. “This academy will make Ireland not only a centre of operations but a centre of expertise.”

A Global Resource for Talent Development

Although located in Ireland, the training academy’s influence will extend far beyond the country’s borders. Ellab has designed the academy to be a global resource, offering a mix of in-person training at the Ireland facility and online courses, accessible to employees across Ellab’s international footprint.

Ellab’s Whitegate Academy will offer a full suite of onsite equipment in a facility designed to replicate a pharma and biotech processing environment.

CALIBRATION & VALIDATION:

Expecting to open its doors to its first cohort of trainees in spring 2025, the academy’s curriculum will reflect the highest international standards required for highly regulated environments, equipping Ellab’s employees with consistent, standardised knowledge and practical skills, regardless of their location. This approach ensures that the company’s global workforce is aligned in their understanding of calibration and validation processes, which is critical for delivering a uniform, high-quality service to Life Sciences clients worldwide.

Jacob Kristoffersen, Global Vice President of Ellab’s Field Services, noted, “Our new training academy is a global initiative. We’re focused on empowering our teams, no matter where they are, with the same high level of expertise. By centralising our training in Ireland but making elements of it accessible globally, we’re promoting consistency and excellence across our operations.”

Strategic Response to Recruitment Challenges

By establishing a world-class training facility, Ellab is taking a proactive approach to meeting current and future recruitment needs. The academy will not only attract new talent to the field in the form of graduates but also provide continuous development opportunities for existing employees. This strategic investment in workforce training ensures that the company

can maintain a steady pipeline of qualified engineers and technicians ready to meet client needs in a continuously evolving sector.

“In an industry that’s evolving as fast as Life Sciences, staying ahead of the skills curve is critical,” said Ludvig Enlund. “By addressing these recruitment challenges

head-on, we’re not only securing our future but supporting our clients.

Long-Term Career Opportunities for Employees

By creating a clear path for professional development, the academy enhances Ellab’s ability to attract and retain top talent. It also signals the company’s commitment to investing in its people, offering them long-term career opportunities in a global organisation.

“We see this as a major step in providing meaningful career opportunities,” said Paul O’Hare. “This academy will be a catalyst for professional growth, giving our employees the chance to develop specialised skills in an industry that’s full of exciting potential.”

Strategic Investment in the Future of Life Sciences

By making this investment in Ireland, Ellab is positioning itself at the forefront of Life Sciences innovation, ensuring that it can continue to provide world-class services to its clients around the globe.

By addressing critical skills shortages, supporting global talent development, and fostering career opportunities, the Whitegate academy is set to play a pivotal role in shaping the future of both the company and the industry.

As Ludvig Enlund concluded, “This isn’t just an investment in training; it’s an investment in the future of our industry. We’re proud to launch this academy in Ireland and excited about the impact it will have on our company, our employees, and the Life Sciences sector as a whole.”

Ellab’s new academy will play a key role in upskilling talent in the realm of calibration and validation, two technical disciplines that sit at the heart of quality assurance in Life Sciences manufacturing.

Expecting to open its doors to its first cohort of trainees in spring 2025, the academy’s curriculum will reflect the highest international standards required for highly regulated environments.

SOURCING: NCC

Navigating Sustainability in Pharma

Paul Power, Biopharmaceutical Product Manager, NCC, discusses the challenges of sustainable sourcing and how NCC can assist.

The pharmaceutical industry faces increasing pressure to reduce its carbon footprint and contribute to a more sustainable future. Driven by stringent EU regulations like the Corporate Sustainability Reporting Directive (CSRD) and the Corporate Sustainability Due Diligence Directive (CSDDD), pharmaceutical companies must now report and reduce their entire value chain’s environmental impact, including Scope 3 emissions. Additionally, growing consumer demand for environmentally friendly products is pushing companies to adopt a holistic approach to sustainability.

Understanding the Scope of the Problem

To fully grasp a company's environmental impact, it's essential to consider the three categories of emissions:

• Scope 1: Direct emissions from owned or controlled sources, such as company vehicles or on-site energy generation.

• Scope 2: Indirect emissions from purchased electricity, heating and cooling.

• Scope 3: Indirect emissions that occur in the value chain, including upstream and downstream activities like raw material sourcing, transportation and product use.

A significant portion of a pharmaceutical company's carbon footprint, estimated at around 70%, stems from Scope 3 emissions, particularly the sourcing and production of raw materials (Source: Sumudu Dehipawala, Ellie Goldman, Emily Hwang, Prem Shah, Ayushi Shroff, and Matthew O’Hara, The pharmaceutical industry’s carbon footprint and current mitigation strategies: A literature review, Trinity Life Sciences, August 16, 2023).

This is due to the complex global supply chains involved in the pharmaceutical industry, often spanning multiple countries, continents and industries. Additionally, the energy-intensive nature of many manufacturing processes contributes to substantial carbon emissions.

Navigating the Challenges of Sustainable Sourcing

While the importance of sustainable sourcing is clear, it presents several challenges for pharmaceutical companies. These challenges include complex supply chains, a lack of transparency, difficulty in sourcing pharma-grade products, and additional costs related to audits, certifications and premium pricing. By addressing these challenges and prioritising sustainable sourcing, pharmaceutical companies can significantly reduce their environmental impact, enhance their brand reputation, and contribute to a more sustainable future.

NCC: Your Partner in Sustainable Sourcing & Material Supply

As a leading supplier of sustainable materials, NCC is committed to helping pharmaceutical companies navigate the complexities of sustainable sourcing. We have extensive experience in sourcing sustainable raw materials that match the specific requirements of our pharma customers. Our comprehensive services offer a range of solutions to reduce your Scope 3 emissions and improve your overall sustainability profile.

By partnering with NCC, you can reduce your carbon footprint, demonstrate your company’s commitment to environmental responsibility, and avoid costly on-site modifications by focusing on sustainable raw materials. Our expertise in sustainable sourcing, combined with our commitment to ethical and responsible practices, makes us the ideal partner for your sustainability journey. Together, we can build a more sustainable future for the pharmaceutical industry.

For more information, visit ncc.ie, email hello @ ncc.ie or call (01) 613 1400.

Paul Power, Biopharmaceutical Product Manager, NCC.

Sustainable pharma sourcing, simplified.

Did you know that an estimated 70% of a pharma company’s carbon footprint comes from scope 3 emissions?1 By switching to sustainable raw materials, you can significantly reduce your environmental impact.

At NCC, we make this transition seamless with our dedicated teams specialising in Sustainable Sourcing, Supply Chain Management, and Regulatory Compliance.

Join us in creating a greener future for the pharmaceutical industry.

Learn more about our sustainable sourcing solutions today:

1Sumudu Dehipawala, Ellie Goldman, Emily Hwang, Prem Shah, Ayushi Shroff, and Matthew O’Hara, The pharmaceutical industry’s carbon footprint and current mitigation strategies: A literature review, Trinity Life Sciences, August 16, 2023.

DHL Delivering PatientCentric Clinical Logistics

DHL Clinical Logistics are helping to empower pharmaceutical advancements through comprehensive supply chain solutions, including the critical management of clinical trials.

DHL Quantum is a new carbon-neutral site, opened in January 2024, located close to the existing Life Sciences and Healthcare site at Dublin Airport, which is ideal for global and European export while supporting Irish manufacturing plants.

In the fast-paced and highly regulated world of pharmaceuticals, the successful management of clinical trials is pivotal. Factors such as increasing complexity, evolving treatment protocols, technological advancements, and data security challenges, play a pivotal role in driving the growth of logistics and distribution services in the clinical trial supplies market.

Recognising this, DHL Clinical Logistics has developed a suite of specialised services designed to support pharmaceutical customers through every phase of their clinical trials. From initial planning to final delivery, DHL ensures the integrity, security, and efficiency of clinical trial supplies and data.

DHL Supply Chain Ireland operates in accordance with Irish Life Sciences regulations as enforced by the Health Products Regulatory Authority (HPRA). Additionally, DHL aligns its operations with the standards and guidelines established by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), where applicable.

Customer-Centric Approach – Patient-Centric Focus

DHL places a strong emphasis on customer

satisfaction. Key components of their patientcentric approach include 24/7 customer support, providing round-the-clock assistance to address any issues or concerns that may arise during the transportation and handling of clinical trial materials. Understanding that each clinical trial is unique, DHL offers flexible services tailored to meet the specific needs of each customer. A tailored, study-specific supply and distribution plan can help improve efficiencies and establishing a partnership approach ultimately supports a meaningful experience for the patient.

With a focus on comprehensive supply chain management, DHL operates as a Lead Logistics Partner. This involves integrating their customers' clinical logistics distribution and vendor network into DHL’s global clinical trials depot network, resulting in operational and commercial simplification, tailored to the unique needs of clinical trials. This includes:

Regulatory Expertise & Regulatory Compliance:

Navigating the complex regulatory landscape is one of the most significant challenges in clinical trials. Different countries have varying regulatory

requirements, which can complicate the process for multinational studies. Ensuring compliance with these regulations demands substantial time and resources, often leading to delays in trial initiation and completion.

With a deep understanding of global regulatory requirements and compliance, DHL collaborates with pharmaceutical companies to navigate and design customised logistics strategies that align with their specific trial needs, considering factors like trial size, multiple locations across multiple time zones, network design, recruitment and participation. With DHL Supply Chain operating globally in the clinical trials arena, with a presence in over 220 countries and territories, it is essential that local, in-market regulations are fully understood and adhered to. To continually improve regulatory compliance, DHL stays up to date with local regulations by working closely with regulatory bodies to ensure compliance with guidelines, as set by bodies like the Federal Drug Administration (FDA) and European Medicines Agency (EMA).

Ensuring the integrity of temperaturesensitive pharmaceuticals is also critical within the trial process. DHL provides cutting-edge cold chain logistics, including temperature controlled passive shippers, monitoring, and real-time temperature tracking. Additionally, they manage returns of clinical trial materials and assets, maintaining efficiency and compliance throughout the trial process.

“ The global Clinical Trials market size is projected to be worth $106 billion (€100 billion) by 2032.”

Storage and Inventory Management:

DHL's storage solutions adhere to Good Manufacturing Practices (GMP), offering secure and compliant environments for pharmaceutical products. Plus, managed by their customised clinical web-based portals, DHL’s advanced inventory management systems ensure accurate tracking and availability of clinical trial supplies.

With a 31-warehouse network driven by DHL's global standards, alongside a single online access point for digital services, they ensure consistent visibility, traceability, communication, issue management and reliability across all locations.

Data Management and Reporting:

The crucial and pivotal role of Data Management and Reporting in Clinical Trials cannot be understated in the success and integrity of clinical trials. The volume of data generated in clinical trials is enormous, and managing this data effectively is a significant challenge. Ensuring data accuracy, integrity, and security is vital for the validity of the trial results.

Among the key aspects and importance of these functions are:

• Ensuring that data collected is precise and reflects the true outcomes of the trial.

LOGISTICS & TRANSPORT:

• Standardising data collection methods across all trial sites to maintain uniformity.

• Implementing rigorous checks and validation processes to prevent and correct errors.

• Maintaining comprehensive and organised records that are readily available for regulatory audits and inspections.

• Utilising advanced systems for real-time Electronic Data Capture (EDC), which enhances accuracy and reduces lag time.

• DHL global standards in data protection and information security aim to mitigate risks and safeguard patient safety.

• Organising data in a way that facilitates efficient statistical analysis.

• Utilising a standardised approach to reporting, communication, and control tower capabilities, DHL provides customers with visibility wherever they operate. This includes comprehensive interim and final reports on billing, operational performance and quality control, aiding in informed decision-making about the trial’s progress and outcomes.

Enabling continuous monitoring of data to identify trends, anomalies, or adverse events promptly.

• Providing a clear and comprehensive assessment of the trial’s effectiveness and safety outcomes.

• Ensuring transparent and efficient communication between sponsors, investigators, and regulatory bodies.

• Facilitating secure and seamless data sharing among authorised stakeholders.

• Early identification of data inconsistencies or adverse events that could impact the trial.

• Implementing corrective mitigation processes to address identified risks and ensure the trial's integrity.

In summary, effective data management and reporting are the backbone of clinical trials, ensuring the reliability of findings, compliance with regulations, and ultimately, the safety and efficacy of new treatments. These processes are indispensable for the successful execution and credibility of clinical research.

One of the significant challenges in managing a clinical trial supply chain is the lack of real-time visibility. The supply chain is often complex, with multiple stakeholders involved. Without proper visibility, it becomes increasingly challenging to track the movement of material, leading to delays and increased costs.

DHL’s advanced IT systems provide realtime visibility into the status and location of clinical trial shipments, and with comprehensive reporting, detailed reports and analytics help customers monitor the performance and compliance of their logistics operations.

“At DHL our Clinical Service Centre allows us to consolidate operations under one single point of contact, while drawing on the breadth and depth of expertise across the whole DHL Group network,” explains John Halpin, Business Development Manager - Life Sciences & Healthcare Ireland, DHL Supply Chain Ireland.

Innovation in Clinical Trial Logistics

DHL is committed to leveraging the latest innovations to enhance its clinical logistics services. This includes:

Digitalisation: Leveraging a range of digital tools to enhance the accuracy and efficiency of logistics operations, DHL employs electronic documentation, blockchain for enhanced data security, robotic process automation, and cloudbased reporting and incident management systems, among other advanced technologies.

DHL Clinical Logistics has developed a suite of specialised services designed to support pharmaceutical customers through every phase of their clinical trials.

Artificial Intelligence: Implementing AI-driven solutions for predictive analytics, optimising routes, and ensuring timely deliveries.

Sustainability: The growing importance of sustainable practices is also central to the clinical supply chain’s evolution. DHL is dedicated to reducing its environmental impact through sustainable practices, including carbon-neutral shipping options, eco-friendly reusable shippers and loggers and carbon neutral facilities.

The adoption of virtual and decentralised clinical trials is increasing, driven by advancements in digital health technologies, remote monitoring tools, and patient-centric approaches. These trials offer greater flexibility, convenience and inclusivity for participants, while reducing costs and accelerating trial timelines.

DHL Clinical Logistics stands out as a reliable partner for pharmaceutical companies, offering a comprehensive and innovative approach to clinical trial logistics. By ensuring the safe, timely, and compliant delivery of trial materials, DHL supports the advancement of medical research and the development of new therapies, ultimately contributing to better health outcomes worldwide.

DHL’s storage solutions adhere to Good Manufacturing Practices (GMP), offering secure and compliant environments for pharmaceutical products.

Where Innovation Meets Excellence

Eli Lilly’s brand new state-of-the-art Kinsale facility is a blueprint for the future of pharmaceutical manufacturing not just in Ireland but worldwide.

Over four decades ago, Eli Lilly and Company began a mission to unite innovation with advanced pharmaceutical manufacturing in Kinsale, setting a standard of excellence that continues to break boundaries. Today, having added two more Irish facilitiesGlobal Business Solutions in Little Island, Cork (established in 2010), and Lilly Limerick (launched in 2023), Lilly Ireland has become far more than just manufacturing; it’s now a cornerstone in Lilly’s global purpose to make life better for people around the world.

Prestigious Award Wins

The latest feather in Lilly’s cap is a state-ofthe-art facility in Kinsale that is already making waves in the industry. Recognised globally with the prestigious Overall Award for Facility of the Year and the Innovation Award from the International Society for Pharmaceutical Engineers, the new continuous manufacturing building is a testament to Lilly’s commitment to excellence. Sitting in Lilly Kinsale’s expansive manufacturing campus, nestled in picturesque West Cork, it is a leap forward not just for Lilly, but for biopharmaceuticals on a global scale. Specialising in peptide production, the facility reflects Lilly’s unwavering focus on creating medicines that tackle some of the most challenging diseases. Peptides are critical in the treatment of numerous conditions, and the demand for these advanced therapies continues to rise. Lilly is committed not only to meeting this demand but doing so with a strong emphasis on safety, environmental responsibility and speed.

More Than Just a Building

At its core, it is more than just a building; it is a blueprint for the future of medicine manufacturing. Advanced automation lies at the heart of its operations, ensuring precision in even the most complex manufacturing processes.

“Every element of the facility is optimised to maintain the highest standards of safety and quality control, minimising human error and guaranteeing consistent, reliable outcomes”, noted Lorraine O’Shea, Associate Vice President and Small Molecule Plant Manager. “This attention to detail isn’t just about operational efficiency; it’s about protecting the trust of patients who depend on these treatments.”

Yet the new facility's excellence extends beyond technical innovation. Sustainability is deeply embedded, showcasing what modern pharmaceutical manufacturing can look like. The facility incorporates low-energy HVAC systems, advanced water recycling technologies, and rigorous wastereduction protocols, significantly reducing its environmental footprint. These efforts reflect a forward-thinking philosophy: the belief that delivering life-saving treatments and safeguarding the planet are interconnected responsibilities.

The story of this facility is one of bold innovation, environmental stewardship, and an unwavering dedication to improving lives. It is a symbol of what the future of medicine can be: driven by purpose, guided by responsibility, and powered by innovation. As Lilly Kinsale continues to set a new global standard, it stands as a promise of the company’s enduring mission to shape a healthier, more sustainable world.

CEO Dave

and

Lilly

Ricks

Peter Burke TD, Minister for Enterprise, Trade and Employment, are pictured alongside Lilly employees and local councillors and guests at the official opening of its latest award-winning continuous peptide facility at Lilly Kinsale in September 2024.

Lorraine O'Shea, Associate VP - Small Molecule Plant Manager, Lilly Kinsale.

At Lilly, we are constantly advancing the way we discover, develop and manufacture medicines to bring innovative new treatments to the people who need them.

Sustainability as a Competitive Advantage

Indaver is playing a key role in the transition to sustainable waste management.

As the Irish pharmaceutical industry strives for greater sustainability, the management of hazardous waste has become a critical component of its strategy to meet climate goals, improve carbon management, and enhance overall environmental performance. The industry’s commitment to greener operations coincides with growing regulatory pressure and societal expectations to minimise waste and reduce carbon footprint, making it essential to adopt innovative solutions that align with these objectives. Indaver, a total service provider in waste management, treatment and a supplier of sustainable energy and materials, is playing a key role in this transition.

Supporting Carbon Reduction and Energy Efficiency

Carbon management is a crucial focus for pharma companies striving to meet both regulatory demands and internal climate targets. Indaver’s waste-to-energy solutions are key to reducing the carbon footprint of pharmaceutical operations. At their thermal treatment plants across Europe, including the Meath facility in

reducing environmental impact in the region, offering scalable solutions for carbon reduction. The expertise gained at Rivenhall can also drive similar projects in Ireland, enhancing cross-border collaboration for a more sustainable pharma supply chain.

Hydrogen: Decarbonising Pharma’s Future

In Ireland, Indaver’s Duleek facility is set to take a significant step toward decarbonisation with the planned construction of a 10MWe Hydrogen Generation Unit (HGU). This innovative unit will produce hydrogen fuel from renewable energy generated at the facility. By capturing excess energy when demand is low, the unit will maximise the value of non-recyclable waste, providing a clean energy alternative for sectors like transport and manufacturing.

For the pharma industry, hydrogen presents a promising solution to decarbonising

Ireland, Indaver generates electricity from waste, much of which is renewable. In 2023, these plants produced enough electricity to power over 265,000 households.

A more Sustainable Pharma Supply Chain

Indaver’s new facility at Rivenhall, Essex, UK, scheduled for operation in 2026, will treat over 595,000 tonnes of residual waste, with more than 50% of the energy recovered being renewable. The project’s inclusion of recycling facilities, heat distribution systems, and carbon capture potential further strengthens its role in advancing a circular economy. It aims to further cut emissions by capturing and storing CO2 from waste treatment processes.

While based in Essex, Rivenhall supports Ireland’s sustainability goals by

energy use, while reducing reliance on fossil fuels. As policy makers, technology providers and industries collaborate, hydrogen is expected to become a cornerstone of Ireland’s sustainable energy future.

Plastics-to-Chemicals: Closing the Loop on Plastic Waste

Indaver’s Plastics2Chemicals (P2C) installation, now in commissioning at the Port of Antwerp, offers a pioneering solution. About 65,000 tonnes of end-of-life plastics are converted into high-quality raw materials for reuse in food packaging. It is projected to save 225,000 tonnes of CO2 each year, making it a major advancement for both waste reduction and carbon emissions.

A Pharma Industry Fit for the Future

The Irish pharma industry can greatly benefit from Indaver's sustainable waste solutions. With all of the above solutions, Indaver supports industry goals and broader efforts to cut carbon emissions and advance a circular economy.

Indaver’s: Plastics2Chemicals installation in commissioning, Antwerp, Belgium.

Indaver’s integrated waste management facility at Rivenhall, Essex, UK.

Compact Design, Maximum Efficiency

Endress+Hauser’s Compact Line of level and pressure measurement devices were developed specifically for use in the Life Sciences and food/beverage industries.

The new compact product line from Endress+Hauser enables higher productivity, ease of use and offers optimal production scalability. The product line is specifically designed for use in the Life Sciences and food and beverage industries. The product line covers many hygienic applications, consisting of three measuring principles for measuring pressure, continuous levels and point levels. The new products offer optimal solutions for small vessels and a standardised, user-friendly design.

The customers’ needs completely drove the development of the new product line. Thanks to the compact sensor design, the small process connections and the outstanding performance, the measuring devices are flexible in scale. The sensors can be used in small vessels and pipes and in bigger process tanks. The products’ 360-degree hygienic design and IP69 ingress protection class enable efficient cleaning. The fully welded stainless-steel devices can also remain in place during cleaning and sterilisation processes of plants or tanks. This saves time, simplifies cleaning procedures and helps to avoid contamination. Thanks to a touch display, settings can be made intuitively and within minutes, directly on the device. As the display is gap-free, there is no risk of contamination.

Solving a Wide Range of Applications

Whether the pressure of your process pipe

The new compact product line from Endress+Hauser offers optimal solutions for small vessels and a standardised, userfriendly design.

needs to be measured when cold, medium-like milk is transferred, the level of base ingredients must be monitored continuously or an overfill protection for process tanks is needed, the compact line offers the right measuring device to solve those tasks.

In pressure measurement technology, the new Cerabar PMP43 impresses with a wide range of sensor variants with fully-welded, hygienic process connections, which are used in the food and beverage industry and the Life Sciences sector.

With the Liquiphant FTL43, point levels in almost all pumpable liquids can be detected using the proven vibronic technology. A significant advantage is the wide range of applications that do not require adaptation to different media.

The new Micropilot FMR43 free space radar sensor is designed for continuous, contactless level measurement. Thanks to its exceptional performance, the measuring device ensures reliable measurement, even under rapidly changing or turbulent process conditions. The hygienic industry’s requirement for even smaller process tanks was also considered during the development of the new devices.

In addition to the proven 80 GHz technology, a one-half-inch process connection can be realised thanks to a 180 GHz frequency option, which allows use in the smallest process tanks. The variety of the mentioned technologies benefit various applications and help to drive the standardisation of measurement solutions at the same time.

Improved Plant Performance

The new compact product line can increase production process productivity. The Heartbeat Technology functionalities developed by Endress+Hauser, combined with reliable and

comprehensive diagnostics, process and device monitoring, can detect process anomalies such as foam formation or build-up at an early stage. This reduces the risk of plant shutdowns. Additionally, qualitative device health verifications are performed in less than three minutes without disassembly or process interruptions.

Using the traceable in-situ verification function of Heartbeat Technology, calibration intervals can be optimised. An example is the Micropilot FMR43 and the Radar Accuracy Index (RAI); the RAI evaluates the reference measurement accuracy during traceable verification according to ISO 9001 to analyse a possible measurement drift compared to the validated state via factory calibration. In this way, plant operators always have transparency regarding the accuracy of the measuring devices.

Easy to Operate

The new measuring instruments of the compact product line simplify measuring tasks in every respect. The entire product line uses an identical user interface across all technologies. This makes installing, commissioning and operating the devices easier and more intuitive than ever. Numerous digital wizards guide users through commissioning and parameterisation. This saves valuable time and helps to prevent human errors.

All analyses, controls, maintenance, or function checks can be conveniently performed remotely via smartphone or tablet using Bluetooth Technology and the SmartBlue app from Endress+Hauser. In addition, the devices can also be integrated into engineering systems or software tools for parameterisation and control via digital communication with an IOLink or HART connection, for example.

For more information please visit: https://eh.digital/48kwOvs

Process improvement is like sailing. With an experienced partner, you can achieve more.

Optimizing processes and maximizing efficiency is important to remain competitive. We are the partner that helps you master yield, quality, and compliance. With real-time inline insights and close monitoring of crucial parameters, we support manufacturers to optimize processes, reduce waste, and increase yield.

Navigating the Unpredictable

Seamus Keane, VP Pharma and Healthcare Europe, Kuehne+Nagel, warns about black swan events and their impact on healthcare logistics.

Imagine a world where one single, unforeseen event can cripple the healthcare industry, leaving millions without access to essential medical supplies. This is not a dystopian future; it is the reality of black swan events. These dramatic incidents, characterised by their extreme rarity and severe impact, can disrupt critical healthcare supply chains in ways that demand heightened focus on customer experience (CX) to ensure recovery and continuity.

Repercussions of Black Swan Events on Healthcare Logistics

The Covid-19 pandemic and the Red Sea crisis are stark examples of black swan events that have severely disrupted global healthcare supply chains. The pandemic disrupted global supply chains on an unprecedented scale, causing shortages of critical healthcare products. Logistics service providers (LSPs) struggled to keep pace with the sudden surge in demand, while grappling with border closures, labour shortages and manufacturing shutdowns. This event underscored the fragility of just-in-time inventory systems and the need for greater supply chain resilience in the healthcare industry.

Similarly, the Red Sea crisis, which due to geopolitical tensions, has led to the suspension

of shipping through the Red Sea and the re-routing of ships around Africa and the Cape of Good Hope, has caused significant delays, affecting the delivery of medical supplies to various regions, illustrating how disruptions in one part of the world can have far-reaching effects on healthcare systems globally. The Red Sea crisis has emphasised the need for healthcare LSPs to develop contingency plans for geopolitical risks and to diversify their supply chains to avoid over-reliance on a single route or region.

Mitigating Black Swan Events

While operational resilience and supply chain continuity are critical during crises, the role of CX is often overlooked. During the Covid-19 pandemic, companies that prioritised open communication, provided real-time shipment updates, and swiftly addressed delays, became trusted partners to healthcare providers, alleviating logistical burdens and allowing them to focus on patient care. Similarly, the Red Sea crisis has shown that logistics service providers with customercentric strategies can offer secure alternatives and maintain trust.

Enhancing CX to Build Resilience against Black Swans

During black swan events, proactive communication and transparency by LSPs can significantly ease the burden on healthcare providers, allowing them to better navigate crises. Flexibility and responsiveness in CX strategies enable rapid adaptation to changing circumstances, while strong partnerships and collaboration built on trust ensure that all parties can effectively address challenges. Additionally, investment in technology, such as real-time tracking, automated notifications and advanced analytics, enhances CX and provides crucial support during unpredictable events.

CX as a Strategic Imperative

In an industry where the timely delivery of healthcare products can mean the difference between life and death, CX is not just a competitive advantage; it is a strategic imperative. By focusing on customer-centric strategies, LSPs will not only navigate black swan events more effectively but will also thrive in their aftermath, fostering long-term partnerships and allowing healthcare providers to remain focused on their core mission: patient care.

Seamus Keane, VP Pharma and Healthcare Europe, Kuehne+Nagel.

The Covid-19 pandemic was a black swan event that severely disrupted global healthcare supply chains.

No matter where along a product’s lifecycle you operate—from product discovery to patent expiry—choose a partner you can rely on to consistently apply the highest GxP compliant quality standards.

ireland.sales@kuehne-nagel.com healthcarelogistics.kuehne-nagel.com Healthcare Logistics

For all your shipping needs:

■ Personalised medicines

■ Medical devices

■ Pharmaceuticals

■ Vaccines

■ Animal health products

■ Consumer healthcare products

Contact our Healthcare Logistics experts to learn more:

Camida wins Pharma Supplier of the Year

Camida were winners of the much-coveted Pharma Supplier of the Year Award at the 2024 Irish Pharma Industry Awards.

Camida was recognised for its commitment to quality, innovation and reliability in the pharmaceutical supply chain, and the Pharma Supplier of the Year title was bestowed on the company for its exceptional contribution to the industry. The prestigious award highlights Camida’s strong customer-focused approach and unwavering dedication to operational excellence, which has cemented its position as a trusted partner for leading pharmaceutical companies worldwide.

“This award is a testament to the hard work and dedication of the entire Camida team,” said David Anchell, founder and Managing Director of Camida. “We are honoured to be recognised and celebrated among such an esteemed group of industry leaders, and we remain committed to supporting our clients with agile, sustainable and innovative solutions that meet the highest standards in pharmaceutical manufacturing and development.”

Reputation for Excellence

Founded in 1988 and headquartered in Clonmel, Co. Tipperary, Camida has built a solid reputation for excellence, partnering with clients across the globe to source and supply high-quality ingredients tailored to their specific needs. With a strategic focus on speed, agility, transparency, and a strong emphasis on customer service, Camida continues to support the pharmaceutical industry to bring safe, effective products to market, thus enhancing lives worldwide.

The Pharma Industry Awards, held annually, bring together Ireland’s top pharmaceutical companies to celebrate outstanding achievements across the sector. The awards are widely regarded as a benchmark for excellence and innovation within the global pharmaceutical industry.

Irish Pharma Industry Awards judge Nuala Calnan presents Pharma Supplier of the Year Award to Camida's Clodagh Phelan.

Simplifying Procurement

For over three decades, Camida has been simplifying the sourcing, procurement and distribution requirements of its valued clients in the pharma, ingredients and industrial sectors. Many of the major players in Europe and around the world work with Camida to improve efficiency and reduce complexity when securing raw materials.

“Camida is all about perfect chemistry, maintaining long-lasting relationships with suppliers and customers to source and supply specialised chemicals to a wide range of industries globally,” David Anchell explained. “Our team consistently meets and exceeds the highest industry standards and conforms to the most stringent international protocols. Camida is entirely customer focused, and we are committed to speed, accuracy and quality. We offer clients a proven track record,

zero obligation to purchase, and an expert team keen to do business, and thankfully it works exceptionally well for companies of all sizes, even those with the most complex procurement needs!”

Camida is a customer service-driven supplier of specialised chemical products to a range of industries. The team aspires to meet the highest industry standards and conform to the most stringent international protocols. Camida is a homegrown success story with a global client network, primarily in the pharma, food and industrial industries. Camida has been consistently giving back through sponsorship and participation of sporting organisations and events in its hometown of Clonmel and the wider Tipperary area.

Tipperary-based Camida took home the Pharma Supplier of the Year Award at the 2024 Irish Pharma Industry Awards.

SEARCH YOUR IS OVER

From Organic Intermediates to Biochemicals, from Performance Chemicals to Food Ingredients, Camida can source, manage and deliver your needs.

Whether your business is in pharmaceuticals, ingredients, biotechnology or surface coatings, we meet the highest industry standards and conform to the most stringent international protocols.

Tap into our global network and over 35 years experience in sourcing specialised chemicals.

We understand your needs, we provide solutions, above all, we exceed your expectations.

Visit www.camida.com, email us at info@camida.com or phone us at +353-52-6125455.

Soltec: Reasons to Celebrate

Soltec recently celebrated 30 years in business by winning two prestigious environmental awards.

Soltec (Ireland) Ltd is celebrating 30 years in providing hazardous waste solutions to the pharmaceutical industry. This milestone coincided with a bumper year for the company, as they opened a new distillation treatment facility and won two prestigious environmental awards.

Excellence in Sustainability

This year, the company was recognised for its contributions to the circular economy, winning two highly respected environmental awards. The company was awarded the top accolade at the 2024 Pakman Awards, the Overall Pakman Award, for their dedication in providing sustainable solutions in the waste management sector. Soltec also won the Waste Recycling and Recovery Facility of the Year Award, for their commitment to advancing waste management practices in support of a circular economy.

Soltec’s business involves accepting and recovering chemical waste from the pharmaceutical industry. Through this recovery

process, they produce new chemicals, products and materials for re-entry to the economy. This business model focuses on a sustainability strategy, the foundations of which align with the principles of the circular economy. In fact, 91% of the waste Soltec manages is recovered and recycled.

Zoe Kavanagh, CEO of Repak, praised Soltec, “for their exceptional leadership in environmental sustainability”.

The Pakman Awards are the leading national environmental awards that recognise excellence in recycling and waste management among businesses and organisations in Ireland.

New Distillation Treatment Facility

Soltec marked its 30th year in business with an event attended by Minister for Enterprise, Trade and Employment, Peter Burke TD. Not only was the company celebrating three decades in business, it also opened a new distillation treatment facility, the culmination of a €6.8

million investment programme to expand Soltec’s capacity to accept, treat and recycle hazardous waste from around the country. Soltec has increased its capacity to treat hazardous waste by 300% (from 5,000 tonnes in 2019 to 20,000 tonnes in 2024).

In opening the new facility, the Minister noted how “firms like Soltec are a vital component of our sustainability measures, to improve our economy”.

Mark Christal, Head of Sustainability, Enterprise Ireland, described the opening of Soltec’s new state-of-the-art distillation plant as “testament to the company’s ambition and mission to support businesses and manufacturers to make sustainability their prime focus, recycling as much of their byproducts and waste as possible.”

Speaking at the event, Director David Corcoran noted that Soltec is the only company in Ireland that can repurpose residual chemical waste into new products using distillation and the new facility increases the company’s capacity to attract new clients, particularly in the pharma sector.

At the 2024 Pakman Awards (l-r): Michael Corcoran, Managing Director, Soltec; Zoe Kavanagh, CEO, Repak; David Corcoran, Director, Soltec; Minister of State Ossian Smyth; Patricia Corcoran, Richard Kelly, and Diarmuid Griffin of Soltec.

Minister for Enterprise, Trade and Employment, Peter Burke TD pictured with directors David Corcoran and Michael Corcoran at the opening of Soltec’s new distillation plant.

Providing sustainable solutions through recycling hazardous waste.

Securing cost-effective treatment options for our industry partners.

Reducing Ireland’s carbon footprint.

30 YEARS EXPERIENCE IN TREATMENT AND RECYCLING

IRELAND’S ONLY PROVIDER OF SOLVENT DISTILLATION SERVICES

Kelsius’ Wireless Monitoring Solutions

Digital transformation and the use of wireless monitoring allows staff to focus on what matters.

The eras of digital transformation are most often defined relating to the development of the internet and mobile technologies: pre-internet, post-internet, and the arrival of a truly mobile era from 2007 onwards. By then, few if any of even the most insightful futurists would have predicted the trajectory of the next era. As the pandemic arrived, along with the global hardship that it brought about, this too defined an era of digital transformation seen not least in the pharmaceutical and biopharmaceutical sectors.

Improving Efficiencies Using Wireless Technology

For many such manufacturers, digital transformation in the form of wireless monitoring has proven to help improve efficiencies in their operations by saving technicians time, removing the need for manual records, and providing data and reports at the touch of a screen for analysis and regulatory compliance.

The recently launched Kelsius app allows users to receive alerts via push notifications on a mobile device.

Facing New Global Challenges

Post-pandemic, a confluence of factors has affected how we work and live. Global stability was never guaranteed, but it has rarely seemed as unstable as the last few years. Traditional supply chains cannot be depended upon. Meanwhile, the need for sustainable practices has become more and more urgent as resources become scarcer and the environment struggles to meet the demands put upon it.

In Life Sciences, these factors have put increasing pressures on manufacturers to bring life-saving medicines and therapeutics to market quickly. In addition, challenges such as regulatory compliance, the cost of research, cybersecurity and attracting talent, continue to be at the forefront of strategic, as well as operational, decision making for pharmaceutical and chemical manufacturers.

CoolCheck from Kelsius is an automated monitoring system that provides monitoring for temperatures, humidity, oxygen and carbon dioxide. The 24-hour wireless system provides the user with real-time data through a sensor network suitable for facilities of any size, in any number of locations. Adopting the automated system means that users are not required to undertake manual monitoring. The sensors feed data into a portal which will alert the user in real time if any issues arise.

Never Miss an Alert

The recently launched Kelsius app allows users to receive alerts via push notifications on a mobile device should issues arise. Alerts can be delivered automatically by email or voice call. Alerts can be configured from sensors placed anywhere in the facility. The broad scope of applications includes fridges, freezers, incubators, water baths, liquid nitrogen tanks and more. Supervisors and

managers can remotely monitor alerts, including what corrective actions were undertaken by who, when and where.

Safe, Secure, Sustainable

With an increased focus today on cybersecurity, CoolCheck provides a safe and secure environment that is GDPR-compliant. Kelsius applies a range of security protocols to its technology, with controls in place to validate or reject access to customer portals, including multi-factor authentication, roles and permissions.

Daily and incremental back-ups allow data to be restored to any five-minute period and archived data is accessible any time for audits or inspections, with data retention of 30+ years.

Kelsius also prides itself on offering sustainable solutions that help its customers to contribute to their own sustainability targets, by removing paper, reducing waste and saving energy. Kelsius has been ranked amongst the top 11% of companies assessed by sustainability rating company Ecovadis.

Guaranteed Irish

Talk to Kelsius about how CoolCheck can help you to enhance your digital transformation to save staff time, reduce costs and ensure regulatory compliance. As a Guaranteed Irish company, they are trusted by companies and industries across Ireland who use their systems to protect their products, protect their customers and protect their reputation.

For more information, visit www.kelsius.com, email sales@kelsius.com or phone (074) 916 2982.

A Kelsius carbon dioxide monitor.

A Kelsius temperature and humidity sensor.

Providing Circular Side Stream Solutions

Purifying water and recovering materials with mobile & modular installations

InOpSys is committed to providing circular waste or side stream solutions for the chemical and pharmaceutical industry, by building and operating mobile & modular purification installations on the customer site. Using a train of selective technology combinations, InOpSys efficiently closes water and material loops and thus helps the industry reach their sustainability goals by reducing waste and CO2 emissions.

Alternative

for linear destruction

The costs associated with waste and emissions can thus be reduced and value can be created by the recovery of materials (e.g. precious metals like Pd, Pt, …). InOpSys wants to do better than linear destruction (e.g. incineration) of hazardous side or waste streams in times of water and material scarcity.

Award-winning concept for API removal & metal recovery

InOpSys offers solutions to treat water and solvent streams, for:

• Active Pharmaceutical Ingredient (API) removal & recovery

• Metal removal & recovery (e.g. precious metals)

• Micropollutant removal

Awards:

• Imagine Chemistry Challenge AkzoNobel (2017)

• Belgian Business awards for the Environment (2018): first prize

• Solar impulse foundation (2021): efficient solution label

Selective and very high rate of removal

InOpSys uses a decentralised model, creating installations on-site, close to the side stream source. This allows working with unmixed and well defined side streams, and avoids transport as a plus.

InOpSys is a one-stop shop, because they do not focus on one single technology, but on a hybrid combination of different technologies. Thanks to this “relay team” of technologies, very high removal rates

can be achieved in a more efficient way compared to monotechnology solutions. This also allows InOpSys to remove pollutants in a selective way, leaving easily biodegradable components untouched.

CAPEX-free service

The customers are unburdened as InOpSys takes ownership from start to finish, and

offers its service in a CAPEX-free way. InOpSys finances the installation via a pay-per-use model, which spares customers an investment which is not interesting enough according to their internal return on investment guidelines.

Contact details www.inopsys.eu • info@inopsys.eu

+32 (0)495 653 821

One of the running on-site installations which recovers valuable Palladium, used as a homogeneous catalyst by the customer, and purifies the waste water, closing the loops.

circular chemistry can save the world.

we believe in circles. advantages.

circular chemistry

we believe in circles. advantages.

SELECTIVE REMOVAL

circular chemistry can save the

Mason Technology:

Established Expertise in Scientific Solutions

Founded in 1780, Mason Technology is a trusted provider of high-quality scientific equipment and technical solutions to the pharma and biopharma industries.

Comprehensive Scientific Solutions

As partners to 50+ leading manufacturers, including Mettler Toledo, Edwards Vacuum, BUCHI, Huber, Evident, Shimadzu, Eppendorf, and Buchiglasuster, they provide a broad range of products and solutions in chromatography, weighing, microscopy, spectroscopy, biotechnology, general laboratory, and software. Their science-trained sales teams design tailored solutions to meet your unique requirements.

Expert Support for Optimal Equipment Performance

Their experienced service engineers offer end-toend technical support for your equipment, from Installation and Commissioning to tailored

Validation Services (IQ, OQ, PQ, RQ) and INAB-accredited Calibration. They ensure compliance with manufacturer standards and regulatory demands throughout your equipment’s lifecycle.

Specialised Software Support

Their software specialists provide consultation and Computer System Validation (CSV) services, ensuring compliance with Data Integrity and 21 CFR Part 11 requirements for cGXP environments.

A Trusted Partner for Quality and Compliance

With continuous ISO certifications since 1994, Mason Technology is your reliable partner in achieving scientific excellence.

Your Trusted Partner

A leading provider of high-quality scientific equipment, innovative solutions, and technical services to the pharmaceutical, biopharma, chemical manufacturing, and medical device sectors.

Your Safe Pair of Hands

Committed to quality, we have maintained continuous ISO certification since 1994, reflecting our dedication to excellence and regulatory compliance.

Hovione: Endto-End Solutions from One Site

Hovione has 60 years of experience as a Specialist Integrated CDMO (Contract Development and Manufacturing Organisation), with a range that includes drug substances, drug product intermediates and drug products. With four FDA inspected sites in the US, Macau, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey, the company provides branded pharmaceutical customers with services for the development and compliant manufacture of innovative drugs and is able to support highly potent compounds.

For generic pharmaceutical customers, the company offers niche off-patent API products. Hovione also provides proprietary product development and licensing opportunities for drug products. In the inhalation area, Hovione is the only independent company offering a complete range of services. As a leader in spray drying, Hovione has the largest capacity, the best scale-up science and the most experienced team to take your project from development to market.

With a view to helping customers solve complex problems, Hovione has invested in building know-how and expertise in particle design and formulation development for highly sophisticated

inhalation APIs. They apply QbD principles in every carrier-based or composite particles formulation development endeavour, ensuring early-on scalable processes to their partners.

Hovione offers end-to-end solutions at a one-site-stop, from drug substance to drug product intermediate to drug product, which means API synthesis, particle engineering, formulation and powder filling can all be developed, characterised and GMP manufactured on the same site. These integrated services can minimise risk, save cost and time on development and manufacturing processes.

For more information, please see www.hovione.com.

Barentz: a Broad Portfolio to Suit all Applications

Ingredients distributor Barentz offers pharmaceutical manufacturers a range of ingredients to suit every application, including challenging formulations.

Barentz is a global life science ingredients distributor specialising in human nutrition, pharmaceuticals, personal care and animal nutrition, creating unique synergies across all fields of expertise.

Founded in 1953, Barentz is now present in over 65 countries, with a global team of more than 2,000 local experts, dedicated to 22,000 customers and with a turnover of €2.1 billion. Driven by the powerful blend of entrepreneurship, partnership and knowledge, Barentz is known as the global Life Sciences ingredients distributor and creates and delivers “Always a better solution”.

Barentz acquired Forum Products in 2011 and rebranded it as Barentz Ireland in 2019. Barentz’s success lies in building long-lasting relationships with suppliers and customers, based on trust, transparency and reliability, where going the extra mile to provide customer satisfaction is part of the company’s DNA.

A broad portfolio of premium quality and high-performance ingredients

EXCIPIENTS

Fillers

Binders

Diluents

Disintegrants

Glidants

Lubricants

API s

Antihypertensives

Antiarrhythmics

Sedatives

BIOPHARMA INGREDIENTS

Mineral salts

Taste masking

Flavours

Sweeteners

Solubilisers

Sugars

Controlled release

Anthelmintics

Diuretics

Mineral salts for Atypical & Speciality APIs

– low in endotoxin grades Amino Acids

Mannitol

Sorbitol

Excipients for Nutraceuticals

Oils, fats, and waxes

Preservatives

Emulsifiers

Permeation enhancers

High quality ingredients and technical expertise

Barentz has a skilled team of technical sales managers offering a broad portfolio of ingredients to suit every application. They are on hand to select the optimum combination of ingredients to assist with solving the formulation challenges and manufacturing demands of customers.

Barentz represents some of the world’s foremost producers of excipients, APIs, nutraceutical and biopharma ingredients, including Roquette, Meggle, Dr Paul Lohmann, IFF, Ajinomoto, Abitec, Ashland, Asahi Kasei, Sandoz & Moehs. Barentz supplies a range of customers producing specialist pharma, generics, OTC, CMOs/ CDMOs, biopharma, medical devices, nutraceutical and healthcare supplements.

Why Barentz is the right business partner for you

Barentz offers clients:

• In-house technical scientists, providing specialist advice on ingredient choices and functionality;

• Local sales office, staffed with technical sales managers and support staff;

• Local, regional & central (HUB) warehousing;

• Combined order management and sampling service with harmonised ERP/ CRM systems;

• Fully implemented QA systems, ISO9001:2015 and GDP certified.

For more information, contact Barentz Ireland Ltd, Block S, Grants View, Greenogue Business Park, Rathcoole, Co. Dublin, D24 XN60

Tel: (01) 4039518

Dextrose

E-mail: pharmaireland@barentz.com Web: www.barentz.com

Cpl: Your Trusted Partner for Talent

Headquartered in Dublin, Cpl is a multi-national global talent solutions provider. Their vision is to be the world’s best at transforming clients through sustainable total talent solutions. This is a living strategy embedded in every aspect of the organisation.

Cpl’s distinct edge in the talent solutions industry is rooted in their unwavering commitment to excellence, sustainable growth, and delivery capability, with solutions that span the entire talent spectrum.

Cpl have been instrumental in fostering growth across the Life Science industry from its inception to the billion-dollar powerhouse it is today.

Through their Life Science Recruitment Division, Cpl guide companies across growth

stages, from start-ups to fully operational manufacturing sites, excelling in talent acquisition and fostering a culture of retention.

Diverse client range

Their Talent Evolution Group offers customised RPO and MSP solutions for diverse clients, including multinational pharmaceutical companies, medical device manufacturers, and specialised biotech firms, whether they are looking to rapidly scale, optimise manufacturing or ensure compliance.

PharmaChem ad 131x180mm v2.pdf 1 23/10/2024 13:03:34

Cpl’s Future of Work Institute (FOWI) employs best and next practices, independent research, and creative engagement to develop world-class frameworks and approaches for innovative people and workforce strategies.

Their expert Life Science Recruitment Teams, specialised Talent Evolution Group, and FOWI are committed to fulfilling BPCI’s mission of:

• Identifying talent needs aligned with BPCI’s national GBS strategy;

• Assisting clients in acquiring digital talent and skills;

• Providing a skilled workforce to maintain labour-intensive assets in Ireland.

When it comes to your life science talent needs, Cpl are committed to support your journey.

For more information, visit Cpl.com or email Info@cpl.ie.

Applying Data-Driven Manufacturing with Bonner

The industrial landscape is undergoing a digital revolution, and Bonner is working closely with pharma clients, providing essential tools to prevent inefficiency and maximise productivity.

The team at Bonner understands the challenges faced by Life Sciences and manufacturing facilities still relying on manual processes and isolated data. These siloed methods limit real-time insights, reducing optimisation efforts and fuelling costly inefficiencies.

Transforming Data into Actionable Insights

Bonner enables you to unlock the true potential of your data. With systems that provide you with real-time and postrecording visualisation and analysis, you can

Why upgrade and automate?

• Streamline Workflows: Identify and eliminate bottlenecks to ensure smooth production runs and plant-wide integrations.

• Maximise Equipment Uptime: Improve area efficiency and minimise production losses, ultimately boosting Overall

Advanced SCADA Systems

Bonner specialises in implementing systems that seamlessly integrate with your existing infrastructure. Their expertise extends beyond data acquisition to include advanced SCADA systems. Bonner’s advanced data driven manufacturing solutions assist businesses in minimising downtime, reducing maintenance costs and optimising efficiency through analysis of complex data sets. Informed decisions driven by up-to-date information mean processes can be adapted to changing conditions.

It’s also important for facilities to be able to seamlessly connect multiple process lines or machines to one orchestration control system, allowing for advanced control and reporting, with the advantage of streamlining workflows.

A Proven History of Success

For over four decades, Bonner has been a

Advanced Cleanrooms from Dawsongroup tcs

Dawsongroup tcs offer modular cleanrooms that are adaptable and compliant controlled environments.

Dawsongroup tcs Ireland offer advanced modular cleanroom solutions that cater to the specific needs of the pharmaceutical and chemical industries. These cleanrooms are designed to meet the highest standards of air cleanliness and contamination control, adhering to both ISO and GMP regulations. By ensuring full compliance with these standards, they provide an environment that supports sterile manufacturing, research and development, and quality control processes.

One of the key advantages of Dawsongroup tcs’ modular cleanrooms is their adaptability. The modular design allows for rapid installation, minimising downtime and enabling businesses to quickly set up or reconfigure their environments as needed. This flexibility is essential for companies with dynamic production requirements, as it allows for easy expansion or modification of the cleanroom space without significant disruptions to ongoing operations. Whether you need to scale up for increased production or adapt the space for a different application, their cleanrooms offer a future-proof solution that can evolve with your business.

In addition to their adaptability, these modular cleanrooms are customisable to meet specific operational needs. From airflow and filtration systems to interior layout and materials, every aspect can be tailored to ensure that your cleanroom is optimised for the unique demands of your processes. This customisation ensures that you can maintain the highest level of cleanliness and compliance, no matter how specialised your requirements.

ATEX Rooms: Safe Handling and Storage of Hazardous Substances

Dawsongroup tcs Ireland also provides ATEX-rated modular rooms designed to safely handle, store and process hazardous or explosive materials. Built to meet stringent ATEX directives, these rooms offer a secure and compliant environment for industries that deal with volatile substances, such as pharmaceuticals and chemicals. Their ATEX rooms ensure that the risk of explosions or chemical accidents is minimised, providing

a controlled space that safeguards both personnel and processes.

The modular nature of these ATEX rooms means they can be customised to suit the specific needs of your operation, whether that involves production, processing, or storage of flammable compounds. Dawsongroup tcs engineers work closely with clients to design rooms that meet the exact requirements of your operations, ensuring compliance with European safety standards while enhancing operational efficiency.

Cold-rooms at Dawsongroup tcs Ireland are engineered to offer precise temperature control, with temperature ranges from +60°C to -70°C to accommodate a variety of needs.

With integrated safety features such as explosion-proof lighting, ventilation systems, and pressure-relief mechanisms, their ATEX rooms are built to provide robust protection in even the most challenging environments. This ensures not only regulatory compliance but also the safety and well-being of your workforce.

Incubators and Cold-Rooms: Precision Temperature Control with a Focus on Sustainability

The modular incubators and cold-rooms at Dawsongroup tcs Ireland are engineered to offer precise temperature control, ensuring the stability and integrity of temperaturesensitive products such as vaccines, biologics and active pharmaceutical ingredients (APIs). These units are critical for pharmaceutical storage and testing, with temperature ranges from +60°C to -70°C to accommodate a variety of needs.

Sustainability is a key focus in their cold-room solutions. They utilise low Global Warming Potential (GWP) refrigerants and CO₂-based systems to significantly reduce environmental impact. This commitment to

sustainability not only helps clients meet their own environmental goals but also enhances operational efficiency. By using energyefficient systems, their cold-rooms help reduce energy consumption and operational costs, while maintaining the highest levels of temperature control.

Designed for reliability and sustainability, these cold-rooms and incubators are ideal for businesses looking to protect sensitive products, while also minimising their carbon footprint. Their solutions offer the perfect balance of precision, compliance and environmental responsibility, ensuring your business remains both competitive and sustainable in the long term.

For more information, visit dawsongroup.ie

Dawsongroup tcs modular cleanrooms are adaptable and customisable to meet specific operational needs.

Every solution complies with MHRA, GMP/GDP regulations, and HSE requirements, offering safety and reliability. Additionally, our systems include a 30-minute LPCB fire rating for enhanced protection, ensuring you meet industry standards with confidence.

Our flexible hire options are designed to optimise your processes and maximise uptime, allowing you to adjust capacity to meet demand. With precise temperature control ranging from +60°C to -70°C, we ensure your operations stay efficient and adaptable.

Dawsongroup offers innovative, awardwinning modular solutions for the healthcare industry, including temperature-controlled storage, ISO 5-8 cleanrooms, and instant structures for vaccination centers and labs. These solutions ensure precise environmental control across development, manufacturing, and distribution processes.

TWi: Making Documentation an Asset

Three of the biggest content challenges for Life Sciences in 2025 are:

1. Effectively Leveraging Generative AI (genAI)

Before it’s possible to extract value from AI, it’s vital that you have your content in order. It needs to be consistent, accurate and structured in such a way AI can make sense of it.

2. Improving Speed to New Markets

When it takes eight months to launch into a new market because your content isn’t ready for translation, and you don’t have structured content components that can update after a single approval; TWi got that down from eight months to two months per new territory for a client.

Are

review processes slowing

3. Increasing Regulatory Scrutiny

As regulations tighten and draw more scrutiny, it’s important that you have control over your content. Content in pre-approved components can be reused across many documents (and their translations too), creating huge time efficiency, as well as drastically reducing human error. TWi provides documentation for biopharma, pharma and MedTech

CHEMICAL SUPPLIERS

Camida Ltd

ACIDS & ALKALIS

AQS Environmental Solutions

Associated Chemicals Ltd

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Chemifloc Ltd

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

GI Chemicals

Greenfield Global

Heterochem Dist Ltd

Micro-Bio Ireland Ltd

National Chemical Company

Q1 Scientific

Solv-Echem Ireland Ltd

Univar

ACTIVATED CARBONS

Associated Chemicals Ltd

Brenntag Ireland

Chemco Ireland Ltd

Fisher Scientific Ireland Ltd

National Chemical Company

Univar

ACTIVE PHARMACEUTICAL INGREDIENTS

AbsorboPak

Barentz

Corcoran Chemicals Ltd

Mallinckrodt Pharmaceuticals

Mason Technology

SK Pharmteco

BIOCHEMICALS

Alexion

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Carbon Group

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

GI Chemicals

Mason Technology

Pharmalex

Univar

BIOCIDES

Associated Chemicals Ltd

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

Heterochem Dist Ltd

Mason Technology

Univar

CATALYSTS

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Fisher Scientific Ireland Ltd

Ortec Inc.

National Chemical Company

SK Pharmteco

CHIRAL COMPOUNDS

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Fisher Scientific Ireland Ltd

Hovione Ltd

National Chemical Company

SK Pharmteco

EXCIPIENTS

A&C Your Global GMP Partner

Associated Chemicals Ltd

Azelis

Barentz

Brenntag Ireland

Chemco Ireland Ltd

Corcoran Chemicals Limited

Greenfield Global

Heterochem Dist Ltd

Mason Technology

Micro-Bio Ireland Ltd

National Chemical Company

Ortec Inc.

Univar

FINE CHEMICALS

Actylis

AbsorboPak

Arran Chemical Company

Associated Chemicals Ltd

Azelis

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Corcoran Chemicals Limited

Fisher Scientific Ireland Ltd

Greenfield Global

Heterochem Dist Ltd

IDA Ireland

Micro-Bio Ireland Ltd

National Chemical Company

Ortec Inc.

SK Pharmteco

Solv-Echem Ireland Ltd

GASES

National Chemical Company

HETEROCYCLICS

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Corcoran Chemicals Ltd

National Chemical Company

INDUSTRIAL CHEMICALS

Corcoran Chemicals Ltd

GI Chemicals

Mason Technology

INORGANIC CHEMICALS

Associated Chemicals Ltd

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Chemifloc Ltd

Corcoran Chemicals Limited

Fisher Scientific Ireland Ltd

GI Chemicals

Heterochem Dist Ltd

Micro-Bio Ireland Ltd

National Chemical Company

Ortec Inc.

Solv-Echem Ireland Ltd

Univar

LABORATORY REAGENTS

Associated Chemicals Ltd

Bonner

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

Heterochem Dist Ltd

IDA Ireland

Mason Technology

Solv-Echem Ireland Ltd

MISC CHEMICALS

AbsorboPak

Arran Chemical Company

Associated Chemicals Ltd

Azelis

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Chemifloc Ltd

Corcoran Chemicals Limited

Fisher Scientific Ireland Ltd

Greenfield Global

Heterochem Dist Ltd

Mason Technology

National Chemical Company

Solv-Echem Ireland Ltd

Univar

OILS, FATS AND WAXES

Associated Chemicals Ltd

Brenntag Ireland

Carbon Group

Corcoran Chemicals Limited

Heterochem Dist Ltd

Mason Technology

ORGANIC INTERMEDIATES

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

Heterochem Dist Ltd

Hovione Ltd

IDA Ireland

Mason Technology

National Chemical Company

Ortec Inc.

SK Pharmteco

Univar

ORGANOMETALLICS

Arran Chemical Company

Associated Chemicals Ltd

Camida Ltd

Mason Technology

National Chemical Company

REAGENTS

Associated Chemicals Ltd

Camida Ltd

Corcoran Chemicals Ltd

Fisher Scientific Ireland Ltd

Heterochem Dist Ltd

IDA Ireland

Mason Technology

National Chemical Company

Source BioScience

SILANES

Arran Chemical Company

Associated Chemicals Ltd

Brenntag Ireland

Camida Ltd

Fisher Scientific Ireland Ltd

Heterochem Dist Ltd

Ortec Inc.

Univar

SOLVENTS

Brenntag Ireland

Camida Ltd

Carbon Group

Chemco Ireland Ltd

Corcoran Chemicals Limited

Fisher Scientific Ireland Ltd

Greenfield Global

Heterochem Dist Ltd

National Chemical Company

Univar

SURFACTANTS

Associated Chemicals Ltd

Brenntag Ireland

Camida Ltd

Carbon Group

Corcoran Chemicals Limited

Fisher Scientific Ireland Ltd

Greenfield Global

Heterochem Dist Ltd

TREATMENT CHEMICALS

Corcoran Chemicals Ltd

GI Chemicals

Micro-Bio Ireland Ltd

GENERAL SUPPLIERS

AGITATORS

CPI Technology Ltd

Quitmann O’Neill

AIR / ROAD / OCEAN FREIGHT

AbsorboPak

Dawsongroup | TCS Ireland

Hazchem Training Ltd

Kuehne + Nagel

Portakabin Ireland

UPS Healthcare

AIR FILTRATION / MONITORING / INGREDIENTS

CMS Chemstore Engineering Ltd

ALUMINIUM PRODUCTS

Foltech Engineering Ltd

Quitmann O’Neill

ANALYSIS SERVICES

Almac Sciences Ltd

ATG Scientific Ltd

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

Corcoran Products Ltd

Eurofins Biopharma Product Testing

GI Chemicals

IDA Ireland

Particular Sciences Ltd

Reading Scientific Services Ltd

SK Pharmteco

ANALYTICAL EQUIPMENT

ATG Scientific Ltd

Endress & Hauser (Ireland) Ltd

Fisher Scientific Ireland Ltd

LABPLAN

Mason Technology

Particular Sciences Ltd

Scientific Instruments Ireland

ASSOCIATIONS

GS1 Ireland

AUTOCLAVES

Fisher Scientific Ireland Ltd

Scientific Instruments Ireland

Mason Technology

AUTOMATION

Bonner

Endress & Hauser (Ireland) Ltd

LABPLAN

O’Flynn Medical Ltd

Portakabin Ireland

ProSys Containment and Sampling Technology

Tekpak Automation Ltd

BALANCES

Bonner

Fisher Scientific Ireland Ltd

Mason Technology

Scientific Instruments Ireland

BARCODE VERIFICATION

GS1 Ireland

Holfeld Graphics

Horan Automation

Tekpak Automation Ltd

BARCODING / LABELLING / TRACEABILITY

Corcoran Products Ltd

GS1 Ireland

Holfeld Graphics

Horan Automation

Tekpak Automation Ltd

BIOINTERACTION ANALYSIS

ATG Scientific Ltd

BIOLOGICS

Mason Technology

MSD Ireland

BIOPHARMACEUTICALS

AbsorboPak

Alexion

Alkermes Pharma Ireland Limited

Almac Sciences Ltd

Barentz

BS&B Safety Systems Ltd

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

Eurofins Biopharma Product Testing

Horan Automation

IDA Ireland

Janssen

Mason Technology

Micro-Bio Ireland Ltd

MSD Ireland

Pharmalex

Portakabin Ireland

Reading Scientific Services Ltd

BIOPHARMA / BIOTECH SUPPLIERS

BS&B Safety Systems Ltd

Mason Technology

BIOPHARMA / BIOTECH SUPPORTS

Flexachem Manufacturing Ltd

BIOTECHNOLOGY

Almac Sciences Ltd

Charles River Microbial Solutions

DHL Supply Chain

IDA Ireland

Labplan

Mallinckrodt Pharmaceuticals

Mason Technology

Micro-Bio Ireland Ltd

MSD Ireland

Particular Sciences Ltd

Pharmalex

BLENDERS

Fisher Scientific Ireland Ltd

Ortec Inc.

BLISTERING / DE-BLISTERING

Holfeld Graphics

Horan Automation

BPRV

BS&B Safety Systems Ltd

CPI Technology Ltd

BURSTING/RUPTURE DISCS

Horan Automation

CABINETS

Dawsongroup | TCS Ireland

Fisher Scientific Ireland Ltd

Foltech Engineering Ltd

Horan Automation

Mason Technology

Source BioScience

CAD

Horan Automation

CALIBRATION

Ballinlough Pharma Solutions

Bonner

Dawsongroup | TCS Ireland

Labplan

LotusWorks

Mason Technology

CARTONING SYSTEMS

Tekpak Automation Ltd

CASE ERECTING / PACKING

Horan Automation

Tekpak Automation Ltd

CASE SEALING

Horan Automation

CENTRIFUGES

AQS Environmental Solutions

CPI Technology Ltd

Fisher Scientific Ireland Ltd

Labplan

Mason Technology

CHEMICAL CONSULTANTS

Corcoran Chemicals Limited

Hazchem Training Ltd

Mason Technology

CHILLED WATER

Astatine

Cross Technical Solutions

CHROMATOGRAPHY

Charles River Microbial Solutions

Fisher Scientific Ireland Ltd

Labplan

Mason Technology

SK Pharmteco

CLEANROOMS

Charles River Microbial Solutions

Cross Technical Solutions

Dawsongroup | TCS Ireland

Fisher Scientific Ireland Ltd

Horan Automation

KUKA Robotics Ireland Ltd

Mason Technology

Ortec Inc.

Portakabin Ireland

CLEANING SERVICES / EQUIPMENT

AQS Environmental Solutions

Portakabin Ireland

CLINICAL RESEARCH

ORGANISATION

Charles River Microbial Solutions

COLD CHAIN CONSULTATION

DHL Supply Chain

COLD CHAIN PACKAGING

Alexion

CRS Pharma Solutions

DHL Supply Chain

Horan Automation

Kuehne + Nagel

Quitmann O’Neill

UPS Healthcare

COMPRESSED AIR / COMPRESSORS

Ballinlough Pharma Solutions

COMPUTER SYSTEMS

Charles River Microbial Solutions

Chemishield

Westbourne IT Global Services

CONDENSORS

Ballinlough Pharma Solutions

CPI Technology Ltd

Cross Technical Solutions

Dawsongroup | TCS Ireland

Flexachem Manufacturing Ltd

Mason Technology

CONDITION MONITORING

AbsorboPak

Bonner

Charles River Microbial Solutions

Flexachem Manufacturing Ltd

Foltech Engineering Ltd

LotusWorks

Q1 Scientific

CONSTRUCTION MANAGEMENT

Astatine

Dawsongroup | TCS Ireland

Portakabin Ireland

Tandem Project Management Ltd.

CONSULTANCY

Astatine

Dawsongroup | TCS Ireland

Hazchem Training Ltd

Horan Automation

Reading Scientific Services Ltd

Tandem Project Management Ltd

CONTENT STRATEGY

TWi

CONTRACT DEVELOPMENT & MANUFACTURING

Hovione

Ortec Inc.

SK Pharmteco

CONTRACT DEVELOPMENT & MARKETING

Charles River Microbial Solutions

Hovione

CONTRACT PHARMA SERVICES

Alkermes Pharma Ireland Limited

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

Eurofins Biopharma Product Testing

Hovione

Mason Technology

Ortec Inc.

Pharmalex

Reading Scientific Services Ltd

CONTROL SUBSTANCES CONVEYORS

Horan Automation

Tekpak Automation Ltd

COOLING SYSTEMS

Astatine

Ballinlough Pharma Solutions

CPI Technology Ltd

Cross Technical Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Mason Technology

DATA ACQUISITION

Bonner

Charles River Microbial Solutions

IDA Ireland

Labplan

DEHUMIDIFIERS

Cross Technical Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Mason Technology

DESIGN

Ballinlough Pharma Solutions

Horan Automation

Nelipak Healthcare Packaging

Pharmalex

Quitmann O’Neill

Tandem Project Management ltd

Tekpak Automation Ltd

DISPERSERS

Fisher Scientific Ireland Ltd

Horan Automation

DISTILLATION

Fisher Scientific Ireland Ltd

Labplan

Mason Technology

DOCUMENTATION SOLUTIONS

Charles River Microbial Solutions

Kuehne + Nagel

TWi

DRAINS

AQS Environmental Solutions

Foltech Engineering Ltd

DRUMS / CONTAINERS

AbsorboPak

CMS Chemstore Engineering Ltd

Complas Packaging Ltd

Corcoran Products Ltd

Interpac

National Chemical Company

Quitmann O’Neill

ECONOMIC DEVELOPMENT AGENCY

IDA Ireland

EDUCATION & TRAINING

Charles River Microbial Solutions

GS1 Ireland

Mason Technology

Pharmalex

Reading Scientific Services Ltd

Science Foundation Ireland (SFI)

TWi

Westbourne IT Global Services

EFFLUENT MONITORING / TREATMENT

Carbon Group

Mason Technology

ELECTRICAL

Portakabin Ireland

Tandem Project Management ltd.

ELECTRONIC COMPONENTS

Horan Automation

ENERGY EFFICIENCY / MANAGEMENT

Astatine

Horan Automation

Sustainable Energy Authority of Ireland

ENGINEERING SERVICES

Astatine

Bonner

Charles River Microbial Solutions

Chemishield

Dawsongroup | TCS Ireland

Endress & Hauser (Ireland) Ltd

Horan Automation

LotusWorks

Mason Technology

Tandem Project Management ltd

Tekpak Automation Ltd

ENVIRONMENTAL CONSULTING

Charles River Microbial Solutions

CMS Chemstore Engineering Ltd

Mason Technology

Quitmann O’Neill

ENVIRONMENTAL MONITORING

Bonner

Charles River Microbial Solutions

Mason Technology

ENVIRONMENTAL SERVICES EQUIPMENT

AQS Environmental Solutions

Charles River Microbial Solutions

CMS Chemstore Engineering Ltd

GI Chemicals

Mason Technology

O’Flynn Medical Ltd

Portakabin Ireland

Quitmann O’Neill

Source BioScience

EVAPORATORS

Cross Technical Solutions

Dawsongroup | TCS Ireland

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

Labplan

Mason Technology

EXPLOSION PROOFING

CMS Chemstore Engineering Ltd

Henley Forklift Group Limited

Mason Technology

EXPLOSION PROTECTION / PANELS

BS&B Safety Systems Ltd

CMS Chemstore Engineering Ltd

Henley Forklift Group Limited

EXTRUDERS

BS&B Safety Systems Ltd

FACILITY DESIGN

ATG Scientific Ltd

Dawsongroup | TCS Ireland

Pharmalex

Tekpak Automation Ltd

FACILITIES MANAGEMENT

AbsorboPak

AQS Environmental Solutions

Foltech Engineering Ltd

O’Flynn Medical Ltd

Quitmann O’Neill

FILLING EQUIPMENT

Horan Automation

Ortec Inc.

Quitmann O’Neill

Tekpak Automation Ltd

GENERAL SUPPLIERS

FILTERS

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

Mason Technology

FILTRATION

Associated Chemicals Ltd

Fisher Scientific Ireland Ltd

Mason Technology

FIRE DETECTION / PREVENTION / PROTECTION

BS&B Safety Systems Ltd

FLAME ARRESTERS

BS&B Safety Systems Ltd

Flexachem Manufacturing Ltd

FLEXCO PLATES

Holfeld Graphics

FLOW CONTROL

Bonner

Endress & Hauser (Ireland) Ltd

Flexachem Manufacturing Ltd

Horan Automation

Mason Technology

FLUID HANDLING

Horan Automation

Interpac

Labplan

ProSys Containment and Sampling Technology

Quitmann O’Neill

FUME CUPBOARDS

Fisher Scientific Ireland Ltd

Foltech Engineering Ltd

Mason Technology

FURNACES

Fisher Scientific Ireland Ltd

Mason Technology

Scientific Instruments Ireland

GAS DETECTION

Bonner

CMS Chemstore Engineering Ltd

Fisher Scientific Ireland Ltd

GAS SUPPLY

Corcoran Products Ltd

Scientific Instruments Ireland

GAUGES

BS&B Safety Systems Ltd

Fisher Scientific Ireland Ltd

GENERATORS

Dawsongroup | TCS Ireland

Mason Technology

Scientific Instruments Ireland

GLASSWARE

Associated Chemicals Ltd

Fisher Scientific Ireland Ltd

Mason Technology

Quitmann O’Neill

GRINDING

Fisher Scientific Ireland Ltd

HAZARDOUS WASTE DISPOSAL

INGREDIENTS

Chemishield

Indaver Ireland

Interpac

Quitmann O’Neill

HEALTHCARE LOGISTICS

Kuehne + Nagel

HEALTH & SAFETY / FIRST AID

Charles River Microbial Solutions

Hazchem Training Ltd

Tandem Project Management ltd.

HEAT EXCHANGERS

BS&B Safety Systems Ltd

Cross Technical Solutions

Flexachem Manufacturing Ltd

Labplan

HEATERS

Ballinlough Pharma Solutions

CMS Chemstore Engineering Ltd

Mason Technology

HOMOGENISERS

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

HOSES

Mason Technology

HUMIDITY / HUMIDIFIERS

AbsorboPak

Ballinlough Pharma Solutions

Cross Technical Solutions

Dawsongroup | TCS Ireland

Interpac

Mason Technology

Source BioScience

HYGIENIC DIAPHRAGM VALVES

Flexachem Manufacturing Ltd

INCUBATORS

Ballinlough Pharma Solutions

Charles River Microbial Solutions

Cross Technical Solutions

Dawsongroup | TCS Ireland

Fisher Scientific Ireland Ltd

Mason Technology

ProSys Containment and Sampling Technology

INJECTION MOULDING

Horan Automation

Quitmann O’Neill

INSPECTION EQUIPMENT

Holfeld Graphics

Horan Automation

Mason Technology

O’Flynn Medical Ltd

Tekpak Automation Ltd

INSTRUMENTATION

ATG Scientific Ltd

BS&B Safety Systems Ltd

Charles River Microbial Solutions

Endress & Hauser (Ireland) Ltd

Horan Automation

Labplan

LotusWorks

Mason Technology

Scientific Instruments Ireland

Charles River Microbial Solutions

Westbourne Global IT Services

INVESTMENT

IDA Ireland

INVESTMENT PROMOTION AGENCY

IDA Ireland

ISOLATORS

Foltech Engineering Ltd

ProSys Containment and Sampling Technology

LABELLING

CMS Chemstore Engineering Ltd

DHL Supply Chain

Horan Automation

Tekpak Automation Ltd

LAB IT

Mason Technology

Westbourne Global IT ServicesS

UPPLIERS

LABORATORY EQUIPMENT / SUPPLIERS

ATG Scientific Ltd

Charles River Microbial Solutions

Chemishield

CMS Chemstore Engineering Ltd

Fisher Scientific Ireland Ltd

Labplan

Mason Technology

Micro-Bio Ireland Ltd

O’Flynn Medical Ltd

Particular Sciences Ltd

Portakabin Ireland

ProSys Containment and Sampling Technology

Scientific Instruments Ireland

Solv-Echem Ireland Ltd

LABORATORY MOBILE BENCHES

ATG Scientific Ltd

LABORATORY SERVI CES

Charles River Laboratories Ireland Ltd

CMS Chemstore Engineering Ltd

Eurofins Biopharma Product Testing

GI Chemicals

Mason Technology

Nelipak Healthcare Packaging

Reading Scientific Services Ltd

Westbourne Global IT Services

LIFT TABLES

Horan Automation

LIQUID FILLING & CAPPING

ATG Scientific Ltd

Horan Automation

Tekpak Automation Ltd

LOGISTICS

AbsorboPak

AQS Environmental Solutions

Ballinlough Pharma Solutions

Charles River Laboratories Ireland Ltd

Chemco Ireland Ltd

Dawsongroup | TCS Ireland

DHL Supply Chain

Kuehne + Nagel

Portakabin Ireland

Quitmann O’Neill

Solv-Echem Ireland Ltd

UPS Healthcare

MACHINE TOOLS

Horan Automation

Lister Machine Tools Ltd

MAINTENANCE

AQS Environmental Solutions

Bonner

Cross Technical Solutions

Endress & Hauser (Ireland) Ltd

Horan Automation

LotusWorks

Mason Technology

Particular Sciences Ltd

Source BioScience

MANUFACTURERS

Abbvie

Amneal

BS&B Safety Systems Ltd

Horan Automation

Hovione

IDA Ireland

Micro-Bio Ireland Ltd

Portakabin Ireland Ltd

Quitmann O’Neill

Source BioScience

Tekpak Automation Ltd

MATERIALS HANDLING / FORKLFTS / PALLET TRUCKS

AbsorboPak

Ballinlough Pharma Solutions

Henley Forklift Group Limited

Horan Automation

Interpac

Portakabin Ireland

Toyota Material Handling Ireland Ltd

MECHANICAL ENGINEERING SERVICES

Foltech Engineering Ltd

LotusWorks

Portakabin Ireland

Tandem Project Management ltd

Tekpak Automation Ltd

MECHANICAL & PROCESS ENGINEERING

Endress & Hauser (Ireland) Ltd

Foltech Engineering Ltd

Horan Automation

LotusWorks

Tandem Project Management ltd.

MEDICAL DEVICE MANUFACTURE

B. Braun Medical

Charles River Microbial Solutions

Horan Automation

LotusWorks

Mallinckrodt Pharmaceuticals

Mason Technology

Ortec Inc.

Tekpak Automation Ltd

MEMBRANE FILTRATION SYSTEMS

Microfiltration: Fisher Scientific Ireland Ltd

Nanofiltration: Fisher Scientific Ireland Ltd

Ultrafiltration: Fisher Scientific Ireland Ltd

Reverse osmosis: Fisher Scientific Ireland Ltd

METERS

Fisher Scientific Ireland Ltd

Mason Technology

MICRO QC

Charles River Microbial Solutions

Mason Technology

Reading Scientific Services Ltd

MICROSCOPES

Fisher Scientific Ireland Ltd

Mason Technology

Particular Sciences Ltd

MICROWAVE TECHNOLOGY

Mason Technology

Scientific Instruments Ireland

MILLING

Fisher Scientific Ireland Ltd

Mason Technology

SK Pharmteco

MIXERS

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

Mason Technology

NOISE / ODOUR CONTROL

AbsorboPak

Associated Chemicals Ltd

ATG Scientific Ltd

Flexachem Manufacturing Ltd

NON-HAZARDOUS WASTE DISPOSAL/RECOVERY

Indaver Ireland

NON-HAZARDOUS WASTE MANAGEMENT

Indaver Ireland

NON-HAZARDOUS WASTE TREATMENT

Indaver Ireland

OEM MANUFACTURING

B. Braun Medical

Foltech Engineering Ltd

IDA Ireland

Mason Technology

PACKAGING / BLENDING UNDER GMP

National Chemical Company

PACKAGING / DESIGN

Charles Tennant & Co Ltd

Complas Packaging Ltd

Holfeld Graphics

IDA Ireland

Interpac

Kuehne + Nagel

Limerick Packaging

Nelipak Healthcare Packaging

Quitmann O’Neill

Tekpak Automation Ltd

UPS Healthcare

PACKAGING / MACHINERY

AbsorboPak

Horan Automation

IDA Ireland

Interpac

NPP Group Ltd

Limerick Packaging

Nelipak Healthcare Packaging

Quitmann O’Neill

Smurfit Kappa Ireland

Tekpak Automation Ltd

PALLETS

Ballinlough Pharma Solutions

Interpac

Quitmann O’Neill

Tekpak Automation Ltd

PALLETISING / DEPALLETISING

Tekpak Automation Ltd

PARTICLE SIZING SURFACE AREA

Particular Sciences Ltd

Reading Scientific Services Ltd

PHARMACEUTICAL FABRICATION

Charles River Microbial Solutions

IDA Ireland

ProSys Containment and Sampling Technology

PHARMACEUTICAL MANUFACTURE

Abbvie

Amneal

LotusWorks

Mallinckrodt Pharmaceuticals

Mason Technology

SK Pharmteco

PICK & PLACE MACHINES

Tekpak Automation Ltd

PIPES / CORES

Mason Technology

Quitmann O’Neill

Smurfit Kappa Ireland

PLASTIC CONTAINERS

Mason Technology

Interpac

Nelipak Healthcare Packaging

PrimePac Ltd

Quitmann O’Neill

PLASTIC CORES / TUBES

Quitmann O’Neill

Smurfit Kappa Ireland

PNEUMATICS

Flexachem Manufacturing Ltd

Horan Automation

Mason Technology

POWDER HANDLING

AQS Environmental Solutions

Dawsongroup | TCS Ireland

Foltech Engineering Ltd

Interpac

Mason Technology

ProSys Containment and Sampling Technology

Quitmann O’Neill

PRESSURE MEASUREMENT / SWITCHES / VESSELS

BS&B Safety Systems Ltd

Flexachem Manufacturing Ltd

Horan Automation

Mason Technology

PRESSURE RELIEF

BS&B Safety Systems Ltd

Flexachem Manufacturing Ltd

PRINT PACKAGING

Horan Automation

Limerick Packaging

Quitmann O’Neill

PROCESS CONTROL

Bonner

BS&B Safety Systems Ltd

Charles River Microbial Solutions

Dawsongroup | TCS Ireland

Horan Automation

Mason Technology

GENERAL SUPPLIERS

O’Flynn Medical Ltd

Scientific Instruments Ireland

PROCESS DESIGN

Bonner

BS&B Safety Systems Ltd

Pharmalex

Tandem Project Management ltd.

PROCESS & MECHANICAL ENGINEERING CONTRACTORS

Bonner

PROJECT MANAGEMENT

Astatine

Chemishield

Horan Automation

Pharmalex

Reading Scientific Services Ltd

Tandem Project Management Ltd

PROTECTIVE CLOTHING / APPARATUS

O’Flynn Medical Ltd

ProSys Containment and Sampling Technology

PUMPS

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

Horan Automation

Mason Technology

Quitmann O’Neill

QC RELEASE TESTING

Charles River Laboratories Ireland Ltd

QUALITY & COMPLIANCE

AbsorboPak

Charles River Microbial Solutions

Chemifloc Ltd

LotusWorks

Mason Technology

Pharmalex

ProSys Containment and Sampling Technology

Reading Scientific Services Ltd

SK Pharmteco

Westbourne Global IT Services

R&D

Almac Sciences Ltd

ATG Scientific Ltd

Charles River Microbial Solutions

Chemifloc Ltd

IDA Ireland

Mason Technology

Pharmaceutical Manufacturing Technology

Centre (PMTC)

ProSys Containment and Sampling Technology

Reading Scientific Services Ltd

SK Pharmteco

Synthesis and Solid State Pharmaceutical Centre

REACTORS

Flexachem Manufacturing Ltd

Mason Technology

RECRUITMENT

Chemishield

ICDS Recruitment Consultants

Tandem Project Management ltd.

REFRIGERATION / FREEZING

Ballinlough Pharma Solutions

Cross Technical Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Fisher Scientific Ireland Ltd

Mason Technology

Q1 Scientific

Source BioScience

RENEWABLE ENERGY

Astatine

Dawsongroup | TCS Ireland

Sustainable Energy Authority of Ireland

RESEARCH FUNDING

Pharmaceutical Manufacturing Technology

Centre (PMTC)

Science Foundation Ireland (SFI)

RESPIRATORY PHARMACEUTICALS

Mason Technology

Reading Scientific Services Ltd

Teva Pharmaceuticals Ireland

ROBOTICS

Charles River Microbial Solutions

KUKA Robotics Ireland Ltd

Labplan

Tekpak Automation Ltd

SANITARY TUBING

Flexachem Manufacturing Ltd

SCADA /DCS / MIS

Bonner

Horan Automation

ProSys Containment and Sampling Technology

Tekpak Automation Ltd

SCREENS

Horan Automation

SCRUBBERS

Dawsongroup | TCS Ireland

Flexachem Manufacturing Ltd

SEALS & GASKETS

Flexachem Manufacturing Ltd

Mason Technology

SIEVING

Fisher Scientific Ireland Ltd

Particular Sciences Ltd

SLEEVE / STRETCH WRAPPING

Horan Automation

SOFTWARE

Ballinlough Pharma Solutions

Charles River Microbial Solutions

Chemishield

CMS Chemstore Engineering Ltd

Mason Technology

Westbourne Global IT Services

SOLVENT RECOVERY / SERVICES

Carbon Group

STABILITY STORAGE

Almac Sciences Ltd

ATG Scientific Ltd

Ballinlough Pharma Solutions

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

CMS Chemstore Engineering Ltd

Corcoran Products Ltd

Cross Technical Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Eurofins Biopharma Product Testing

Kuehne + Nagel

Mason Technology

Q1 Scientific

Reading Scientific Services Ltd

SK Pharmteco

Source BioScience

STABILITY TESTS

Charles River Laboratories Ireland Ltd

Eurofins Biopharma Product Testing

Mason Technology

Ortec Inc.

Particular Sciences Ltd

Reading Scientific Services Ltd

SK Pharmteco

STAINLESS STEEL / FITTINGS / PRODUCTS

CMS Chemstore Engineering Ltd

Flexachem Manufacturing Ltd

Foltech Engineering Ltd

Henley Forklift Group Limited

Interpac

Mason Technology

ProSys Containment and Sampling Technology

Quitmann O’Neill

STEAM EQUIPMENT

BS&B Safety Systems Ltd

Flexachem Manufacturing Ltd

Foltech Engineering Ltd

STERILITY TESTING

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

Eurofins Biopharma Product Testing

Reading Scientific Services Ltd

Source BioScience

STORAGE / BUNDING

Ballinlough Pharma Solutions

CMS Chemstore Engineering Ltd

Charles River Microbial Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Interpac

Kuehne + Nagel

Quitmann O’Neill

STORAGE OF HAZARDOUS MATERIALS

CMS Chemstore Engineering Ltd

Corcoran Products Ltd

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Hazchem Training Ltd

Indaver Ireland

Kuehne + Nagel

STRAPPING EQUIPMENT

AbsorboPak

Horan Automation

SUPPLY CHAIN MANAGEMENT

AbsorboPak

Alexion

Ballinlough Pharma Solutions

Chemco Ireland Ltd

DHL Supply Chain

GS1 Ireland

IDA Ireland

Kuehne + Nagel

KWE (Ireland) Ltd

Limerick Packaging

National Chemical Company

Portakabin Ireland

Quitmann O’Neill

Solv-Echem

Ireland Ltd

SURFACE PLASOMON RESONANCE

ATG Scientific Ltd

TABLETING EQUIPMENT

ATG Scientific Ltd

Flexachem Manufacturing Ltd

Horan Automation

TANKS

Complas Packaging Ltd

Flexachem Manufacturing Ltd

Mason Technology

Quitmann O’Neill

TEMPERATURE CONTROL

Ballinlough Pharma Solutions

Bonner

CMS Chemstore Engineering Ltd

Corcoran Products Ltd

Cross Technical Solutions

CRS Pharma Solutions

Dawsongroup | TCS Ireland

DHL Supply Chain

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

KWE (Ireland) Ltd

Labplan

LotusWorks

Mason Technology

Q1 Scientific

Source BioScience

TESTING SERVICES

Almac Sciences Ltd

ATG Scientific Ltd

Bonner

Charles River Laboratories Ireland Ltd

Charles River Microbial Solutions

Chemifloc Ltd

CMS Chemstore Engineering Ltd

Eurofins Biopharma Product Testing

Mason Technology

Reading Scientific Services Ltd

SK Pharmteco

THERMAL IMAGING / THERMOGRAPHY

Ballinlough Pharma Solutions

Reading Scientific Services Ltd

TOOLS

Charles River Microbial Solutions

TRAINING

Hazchem Training Ltd

Reading Scientific Services Ltd

TWi

TRANSPORT & LOGISTICS

AbsorboPak

AQS Environmental Solutions

Ballinlough Pharma Solutions

CRS Pharma Solutions

Dachser Ireland Ltd

Dawsongroup | TCS Ireland

DHL Supply Chain

Hazchem Training Ltd

Kuehne + Nagel

KWE (Ireland) Ltd

Quitmann O’Neill

Skycell AG

UPS Healthcare

TRAY HEAT SEALER

Nelipak Healthcare Packaging

TUBE SETS / DISPOSABLES

Mason Technology

Quitmann O’Neill

VACCINES

Ballinlough Pharma Solutions

Mason Technology

MSD Ireland

VACUUM

SYSTEMS

BS&B Safety Systems Ltd

Fisher Scientific Ireland Ltd

Flexachem Manufacturing Ltd

Horan Automation

Mason Technology

Particular Sciences Ltd

VALVES

Bonner

BS&B Safety Systems Ltd

Flexachem Manufacturing Ltd

Foltech Engineering Ltd

Horan Automation

Mason Technology

VALIDATION

Almac Sciences Ltd

Bonner

Charles River Microbial Solutions

Chemishield

CRS Pharma Solutions

Dawsongroup | TCS Ireland

Horan Automation

LotusWorks

Mason Technology

Pharmalex

Reading Scientific Services Ltd

SK Pharmteco

Source BioScience

Tandem Project Management ltd

Tekpak Automation Ltd

Westbourne IT Global Services

VENTILATION

Cross Technical Solutions

VISION SYSTEMS

Bonner

Horan Automation

KUKA Robotics Ireland Ltd

Particular Sciences Ltd

Tekpak Automation Ltd

WAREHOUSE MANAGEMENT

CMS Chemstore Engineering Ltd

Complas Packaging Ltd

DHL Supply Chain

Horan Automation

Henley Forklift Group Limited

Kuehne + Nagel

Portakabin Ireland

UPS Healthcare

WASTE MANAGEMENT / BALERS / RECYCLING

AQS Environmental Solutions

Indaver Ireland

Quitmann O’Neill

WATER FOR INJECTION

Mason Technology

National Chemical Company

WATER TREATMENT

BS&B Safety Systems Ltd

Charles River Microbial Solutions

Chemco Ireland Ltd

Chemifloc Ltd

Flexachem Manufacturing Ltd

GI Chemicals

InOpSys

Mason Technology

Portakabin Ireland

WEIGHING

Bonner

Fisher Scientific Ireland Ltd

Horan Automation

Mason Technology

Tekpak Automation Ltd

WORKWEAR

O’Flynn Medical Ltd

WORKWEAR MANAGEMENT DISPENSING MACHINE

O’Flynn Medical Ltd

COMPANY LISTINGS

AABBVIE

Address: ABBVIE Sligo – Manorhamilton Road.

Tel: (071) 913 6600

Address: 14 Riverwalk, Citywest Business Campus, D24 XN32.

Tel: (01) 428 7900

Business: Pharmaceutical.

ABSORBOPAK LTD

Address: 6 Main Street, Howth, Dublin, D13P2C1, Ireland.

Tel: +353 (1) 6978733

Email: info@absorbopak.com

Web: www.absorbopak.ie

Business: With our range of desiccants, we help clients all over the world prevent moisture damage.

Contact: Sé O'Leary, Sales / Technical Support

ACTYLIS

Address: Grange Business Park, Skule Hill, Fedamore, Co. Limerick

Tel: (061) 574 404

Email: biopharma@actylis.com

Web: www.actylis.com

Business: Actylis is a global GMP manufacturer of Excipients, APIs and PIs, Process and Cleaning Solutions, Buffers, Cell Culture Ingredients, Amino Acids & Cell and Gene Therapy Ingredients.

Contact: biopharma@actylis.com

ALEXION, ASTRAZENECA RARE DISEASE

Address: College Business & Technology Park, Blanchardstown, Dublin 15, D15 R925.

Tel: (01) 254 6400

Email: julie.carney@alexion.com

Web: www.alexion.com

Business: Pharmaceutical.

Contact: Site Operations Coordinator: Julie Carney

ALMAC SCIENCES LTD.

Address: IDA Technology & Business Park, Garrycastle, Athlone, Ireland, N37 X061.

Tel: +353 (0)90 646 0200

Fax: +353 (0)90 646 0210

Email: almacanalytical@almacgroup.com

Web: www.almacgroup.com

Business: Analytical services provider working in GMP environments across UK, Europe and US with significant experience in the analysis of small and large molecules. Our state-of-the-art labs support drug substance (API) and drug product (finished product) analytics across all phases of clinical development and into commercial release.

Contact: Business Development: Anna Cousens

AMNEAL IRELAND LIMITED

Address: Cashel Road, Cashel, Co. Tipperary.

Tel: +353 (0) 62 27000

Email: careers.cashel@amneal.com

Web: www.amneal.com/cashel

Business: Pharmaceutical Manufacture.

Contact: VP Operations, Ireland: Niall Prendergast

AMTIVO

Address: Block 20A, Beckett Way, Park West Business Park, Dublin 12, D12 P8R2.

Tel: (01) 270 7973

Email: info.ireland@amtivo.com

Web: www.certificationeurope.com

Business: ISO Management Standards Certification body for ISO 9001, 14001, 45001, 50001, 27001, 22301 and 20000-1.

Contact: Holly Fitzpatrick, Sales and Marketing Manager

AQS ENVIRONMENTAL SOLUTIONS

Address: Kiloran, Moyne, Thurles Co. Tipperary.

Tel: +353 (0)504 57800

Email: info@aqssolutions.ie

Web: www.aqssolutions.ie

Business: Provider of drainage, industrial cleaning, waste management and processing services.

Contact: Commercial Director: Stan O’Reilly

ARRAN CHEMICAL COMPANY

Address: Monksland Industrial Estate, Athlone, Co. Roscommon, N37 DN24, Ireland.

Tel: +353 (0) 90 644 5700

Email: info@arranchemical.ie

Web: www.arranchemical.ie

Business: Fine chemical company specialising in the manufacture of products for Pharma, Healthcare, Flavour/ Fragrance & other specialised chemicals & industrial applications.

Contact: Business Development Manager: Gareth Maguire.

ASGARD CLEANING SOLUTIONS

Address: 2E Purcellsinch Industrial Estate, Dublin Road, Kilkenny, R95 D882.

Tel: +353 56 7771771

Email: enquiries@asgardcleanrooms.com

Web: www.asgardcleanrooms.com

Business: Cleanroom Design & Construction.

Contact: Group VP / Director Business Development & Marketing: Jimmy Blaney

ASSOCIATED CHEMICALS LTD

Address: 16D Euro Business Park, Little Island, Co. Cork, Ireland.

Tel: +353 (0) 21 4351014

Email: info@acl.ie

Web: www.associatedchemical.wixsite.com

Business: Chemical Suppliers.

Contact: Managing Director: Sylvester Cotter

ASTATINE

Address: Suite 301, Guinness Enterprise Centre, Dublin 8, D08 T1WY.

Tel: (01) 525 3006

Email: anthony.glynn@astatine.ie

Web: www.astatine.ie

Main Products & Services:

Solar PV and High Temperature Heat Pump Installation.

Contact: Sales and Marketing Director: Anthony Glynn

ASTORIOM

Address: Riverstown 5 Complex, Tramore, Republic of Ireland.

Tel: +353 (0) 51 338435

Web: www.astoriom.com

ATG SCIENTIFIC LTD

Address: Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, United Kingdom.

Tel: +44 (0) 1865 261423

Email: enquiries@atgscientific.co.uk

Web: www.atgscientific.co.uk

Business: Supply of Laboratory Products and Equipment Solutions.

Contact: Andrew Graham

AZELIS IRELAND LIMITED

Address: Unit 23, Sandyford Office Park, Blackthorn Avenue, Sandyford Industrial Estate, Foxrock, Dublin D18 X9X7.

Tel: (01) 295 6977

Fax: (01) 295 8338

Email: graeme.locke@azelis.ie

Business: Chemical Distributor.

Contact: Managing Director: Graeme Locke

B

BALLINLOUGH PHARMA SOLUTIONS

Address: Clondalkin, Dublin, Annacarton Bridge, Co. Cork & Ballinlough, Co. Roscommon.

Tel: Dublin (01) 460 0322 Cork (021) 488 2077 Roscommon (094) 964 0045

Email: info@brltd.ie

Web: www.brltd.ie

Business: Suppliers of Thermo King Pharma Transport Refrigeration. Sales - Service - Parts

Contact: Joe Malone

BARENTZ IRELAND LTD

Address: Block S, Grants View, Greenogue Business Park, Rathcoole, Co. Dublin. Tel: +353 1 4039518

Fax: +353 1 4039519

Email: pharmaireland@barentz.com Web: www.barentz.com

Business: Distributor of excipients, amino acids and APIs to the Pharmaceutical, Nutraceutical & Biopharma industries in Ireland.

Contact: Sales Manager: Storme Delaney

BERKLEY GROUP

Address: 509 the Capel Building, Marys Abbey, Dublin 7. Cork:

3 Watergold, Douglas, Cork.

International Offices: Singapore, London & Dubai. Tel: (01) 872 4666 (021) 428 9600

Email: info@Berkley-group.com

Web: www.berkeley-group.com

BONNER

INSTRUMENTATION, CALIBRATION AND AUTOMATION SOLUTIONS

Address: 35 Western Parkway Business Centre, Ballymount Drive, Ballymount, Dublin 12.

Tel: (01) 450 5050

Fax: (01) 450 5183

Email: contact@bonner.ie

Web: www.bonner.ie

Business: Instrumentation, Calibration and Automation Solutions including calibration, maintenance, temperature mapping and automation systems including SCADA, DCS and MES.

Instrumentation product sales from international manufacturers.

Contact: Managing Director: Patrick M Bonner Service Manager: Roddy Jefferson Automation Solutions: Darren Roche

B. BRAUN MEDICAL

Address: 3 Naas Road Industrial Park, Dublin 12.

Tel: (01) 709 1800

Email: robert.bannon@bbraun.com

Web: www.bbraun.ie

Business: OEM manufacturing.

Contact: Sales Consultant: Susan Cleary

BRENNTAG IRELAND

Address: Unit 405, Greenogue Business Park, Rathcoole, Dublin 24.

Tel: +353 (0) 1 401 3500

Web: www.brenntag.ie

Business: Chemical Suppliers & Distributors.

Contact: Evelyn O'Connor: evelyn.o'connor@brenntag.ie Cole Carroll: colman.carroll@brenntag.ie

COMPANY LISTINGS

BS&B SAFETY SYSTEMS LTD

Address: Raheen Business Park, Limerick, Ireland V94 N4V2.

Tel: (061) 484 700

Fax: (061) 304 774

Email: sales@bsb.ie

Web: www.bsbsystems.com

Business: Design, manufacture and supply of Pressure Relief Devices such as rupture disks, safety heads, custom engineered products, explosion vents, flame arresters, breather valves, safety valves and more.

Contact: Regional Sales Manager: Patrick Murphy

CARBON GROUP

Address: Ringaskiddy, Co. Cork, P43 R772.

Tel: +353 (0)21 437 8988

Mobile: +353 (0) 86 2612 485

Fax: +353 (0)21 437 8950

Email: cork@carbon.ie dublin@carbon.ie

Web: www.carbon.ie

Business: Pharma/biopharma chemicals.

Contact: Area Sales Manager: Carol Deegan

CENTRAL PUMP SUPPLIES

Address: Unit 21, Primeside Park, Kilshane Way, Ballycoolin, Dublin15.

Tel: (01) 861 2326

Email: info@centralpumpsupplies.com

Web: www.centralpumpsupplies.com

Business: Appliances, Electrical, and Electronics Manufacturing.

Contact: Sales/Digital Marketing Assistant: Beatriz Baldiviezo

CAMIDA LTD

Address: New Quay, Clonmel, Co. Tipperary, E91 YV66, Ireland.

Tel: +353 52 6125455

Email: info@camida.com

Web: www.camida.com

Contact: Company Secretary: Deirdre McGrath

Ingredients Sales Manager: Donal O’Neill Mob: 087 7060774

Email: donal.oneill@camida.com

CARA PARTNERS

Address: Little Island Industrial Estate, County Cork.

Tel: (021) 4520500

Email: mkirk@carapartners.ie

Business: Pharmaceuticals.

Contact: Site Head: Michael Kirk

CHARLES RIVER LABORATORIES IRELAND LTD

Address: Carrentrila, Ballina, Co. Mayo, F26 D786, Ireland.

Email: askcharlesriver@crl.com

Web: criver.com/biologics

Business: Biologics Testing Solutions.

CHARLES RIVER MICROBIAL SOLUTIONS INTERNATIONAL

LTD

Address: 49, Greenogue Business Park, Jordanstown Ave, Jordanstown, Rathcoole, Co. Dublin, D24 NF21, Ireland.

Email: askcharlesriver@crl.com

Web: criver.com/microbial

Business: Micro QC.

CHARLES TENNANT & CO LTD

Address: Unit J, Aerodrome Business Park, Co. Dublin.

Tel: (01) 451 4099

Email: info@ctennant.ie

Web: www.charlestennant.com

Business: Chemical and Packaging supplier.

CHEMCO IRELAND LIMITED

Address: Unit 2, Stadium Business Park, Ballycoolin, Cappagh, Dublin 11, D11 X205.

Tel: +353 (0)1 829 3600

Email: info@chemco.ie

Web: www.chemco.ie

CHEMIFLOC GROUP: CHEMIFLOC, GI CHEMICALS, CHEMILABS

Address: Smithstown Ind Est, Shannon, Foynes Port, Limerick.

Tel: 061 708699; 069 65318 (GI)

Fax: +353 61 708653

Email: info@chemifloc.ie info@gichemicals.ie

Web: chemifloc.ie; gichemicals.ie

Business: Chemifloc: Water Treatment GI: Industrial Chemicals

Chemilab: Technical Services

Contact: Gary Palmer, Business Development

CHEMISHIELD

Address: Arc Labs, Carriganore, Waterford.

Tel: +353 (0)51 576 025

Email: sales@chemishield.com

Web: www.chemishield.com

Business: Software & Life Sciences Consultancy.

Contact: Commerical Director: Kevin Walsh

CMS CHEMSTORE ENGINEERING LTD.

Address: Clondrinagh Industrial Estate, Ennis Road, Limerick, V94 XT27.

Tel: (061) 327 792

Email: sales@chemstore.ie

Web: www.chemstore.ie

Business: Solutions provider for the safe storage and management of Hazardous Materials.

COM-PLAS INTERNATIONAL

Address: Southern Link Business Park, Naas, Co. Kildare.

Tel: (045) 874 088/9

Email: sales@complas.ie

Web: www.complas.ie

CORCORAN CH EMICALS LTD

Address: 17 Parkgate Street, D08 NRP2.

Tel: (01) 633 0400

Fax: (01) 679 3521

Email: info@corcoran-group.com

Web: www.corcoran-group.com

Business: Distributors of raw materials for the food, pharmaceutical, polymer & chemical industry.

Contact: Sales

CORCORAN PRODUCTS (IRL) LTD

Address: Unit 12, Northern Cross Business Park, Finglas, D11 DC67.

Tel: (01) 864 4422

Email: info@corcoran-group.com

Web: www.corcoran-group.com

Business: Suppliers of packaging to the food, pharmaceutical and chemical industry.

Contact: Derek Lennon

CPI TECHNOLOGY

LTD

Address: 1-5 Eastgate Drive, Eastgate Retail Park, Little Island, Co. Cork, T45 A433.

Tel: (021) 435 4690

Email: info@cpitechnology.com

Web: www.cpitechnology.com

Business: Providers of Process Equipment.

Contact: Managing Director: Adrian Giltinan

CPL

Address: Groun d Floor, One Haddington Buildings, Haddington Road, Dublin 4, D04 X4C9.

Tel: (01) 614 6000

Email: hello@talentevolutiongroup.com

Web: www.cpl.com/ie

Business: Specialised talent and recruitment solutions company.

CROSS TECHNICAL SOLUTIONS

Address: 9/10 Broomhill Road, Tallaght, Dublin 24.

Tel: (01) 405 6777

Fax: (01) 413 6932

Email: sales@ctsolutions.org

Web: www.crosstechnicalsolutions.ie Business: Refrigeration.

Contact: Technical Director: Jonathan McGrath General Manager: Jason Keating

CRS PHARMA SOLUTIONS

Address: Ireland HQ: Summerhill Enterprise Centre, Summerhill, Co. Meath, A83 XE40. UK HQ: Unit 3, Thornton Park, North Road, Ellesmere Port, CH65 1AB.

Tel: Ireland: +353 (0) 46 943 5000 UK: 0800 085 2298

Email: info@crspharmasolutions.ie

Web: www.crspharmasolutions.ie

Business: Climate controlled storage specialists. Internal coldroom and freezer installations with temperatures ranging from -65°C to +60°C. Close control temperature and humidity stores, stability chambers, incubators, Atex cold stores, dual redundant cooling systems with integral back-up generators, blast freezers, freezers for fast freezing of phase change materials (Eutetic plates and gel packs).

Contact: Technical Director: Patrick Tyrrell

D

DACHSER IRELAND LTD

Address: Blackchurch Business Park, Rathcoole, Co. Dublin, D24 C796. Tel: +353 1 401 3333

Email: dachser.dublin@dachser.com

Web: www.dachser.ie

Business: Founded in 1930, DACHSER is a global market leader in logistic services with a revenue of €7.1 billion. With our comprehensive European road transport network of system and charter service, as well as a homogeneous structure of branches, subsidiaries and partner companies, we will support you in fulfilling your logistics requirements reliably, cost-effectively and on time. We transport your groupage, your full or partial loads and manage your procurement and distribution, both Europe-wide and national, to the highest level.

COMPANY LISTINGS

DAWSON GROUP | TCS

IRELAND

Address: Unit JB, Beech Avenue, Naas Enterprise Park, Newhall, Naas, Co. Kildare.

Tel: (045) 448 810

Email: christianvisser@dawsongroup.ie

Web: www.dawsongroup.ie

Business: Temperature Controlled Solutions. Clean rooms, Stability chambers -70c to +60c, ATEX Modular Solutions, Humidity control, Test Chambers, Blast Freezers (gel packs / Eutectic plates), Hybrid Generators.

Contact: Business Development: Christian Visser

DHL SUPPLY CHAIN

Address: Unit 1 Quantum Distribution Park, Kilshane Cross, Dublin, D11 KV1W, Ireland.

& Unit B1 Horizon Logistics Park, Harristown, Co. Dublin, K67 N5C3, Ireland.

Tel: 086 0665865

Email: john.halpin@dhl.com

Web: http://www.dhl.com/globalen/home/our-divisions/ supply-chain/sectors-overview/ life-sciences-and-healthcare.html

Business: Supply Chain & Logistics.

Contact: Business Development Manager, Life Sciences: John Halpin

DORNAN ENGINEERING LTD

Address: 10 Eastgate Ave, Eastgate, Little Island, Cork, T45 PC63.

Tel: 00353 212 330 900

Email: alyson.murphy@dornangroup.com

Web: www.dornan.ie

Business: Dornan Group is a wellestablished mechanical, electrical and HVAC engineering and construction company, with major project experience across a wide range of sectors in Europe.

Contact: Business Development Coordinator: Alyson Murphy

ELI LILLY KINSALE

Address: Dunderrow, Kinsale, Co. Cork

Tel: 085 878 3827

Email: ezara.ahern@network.lilly.com

Web: www.lilly.co/ie

Business: Pharmaceutical.

Contact: External Communications: Ezara Ahern

ELLAB

Address: Ellab Ireland, Whitegate Cross, Virginia Co Cavan, A82 TFF9

Tel: 0818 250 250

Email: ireland@ellab.com

Web: www.ellab.com

Business: Complete solutions provider to the Biotech and Pharma sectors offering validation & calibration services, monitoring solutions & product sales.

Contact: Director of Business Development: Kevin Davis

ENDRESS+HAUSER (IRELAND) LTD.

Address: Exchequer House, Embassy Office Park, Kill, Co. Kildare.

Tel: (045) 989 200

Email: info.ie@endress.com

Web: www.ie.endress.com

Business: Leading supplier of products, services and solutions for industrial process measurement and automation industry.

Contact: Sales Manager: Brian O’Connell

EUROFINS BIOPHARMA PRODUCT TESTING

Address: Clogherane, Dungarvan, Co. Waterford, X35 T628, Ireland.

Tel: +353 (0) 58 48300

Email: EurofinsBPT-IE@eurofins.ie

Web: www.eurofins.ie/biopharma-services

FISHER SCIENTIFIC IRELAND LTD

Address: Blanchardstown Corporate Park, Ballycoolen, Dublin 15.

Tel: (01) 885 5854

Email: fsie.sales@thermofisher.com

Web: www.ie.fishersci.com

Business: Laboratory supplies, Chemicals, Consumables, Reagents, Equipment & Instruments.

Contact: Portfolio Manager: Gerry Fitzmaurice

FLEXACHEM MANUFACTURING LTD

Address: Donnybrook Commercial Centre, Douglas, Cork, T12 X68Y. Tel: (021) 461 7200

Email: sales@flexachem.com

Web: www.flexachem.com

Business: Mechanical Process Equipment Supplier - Pumps, Seals, Valves, Process Equipment, Biotech and Pharma Equipment and Technical Support.

Contact: Commercial Manager: Michael Bradley

FOLTECH ENGINEERING LTD

Address: The Store House, Charleston Maltings, Midleton, Co. Cork. Tel: (021) 463 9592

Email: info@foltech.ie

Web: www.foltech.ie

Business: Mechanical Engineering.

Contact: Director: John Foley

COMPANY LISTINGS

GRAHAM HART (PROCESS TECHNOLOGY) LTD

Address: Friars Industrial Estate, Bradford Road, Idle, Bradford, BD10 8SX, UK.

Tel: (0044) 1274 617021

Email: post@graham-hart.com

Web: www.graham-hart.com

GREENFIELD GLOBAL

Address: IDA Business & Technology Park, Mountrath Road, Portlaoise, Co. Laois.

Tel: +353 (0) 57 8671400

Email: Portlaoise.info@greenfield.com

Web: www.greenfield.com

Business: Excipients, Buffer Solutions and CIP Solutions producer.

Contact: Business Development Manager: Johnny Geraghty

HAZCHEM TRAINING LTD

Address: G10, Maynooth Business Campus, Maynooth, Co. Kildare.

Tel: (01) 629 1800

Fax: (01) 629 1822

Email: info@hazchem.ie

Web: www.hazchem.ie

Business: Training and Consultancy Services.

Contact: Manager: Michelle Cleere

HENLEY FORKLIFT

GROUP LIMITED

Address: Henley Industrial Park, Killeen Road, Dublin 10.

Tel: (01) 620 9200

Web: www.henley.ie/pharma

Business: Forklift and warehousing equipment, sales, service, hire, parts, driver training, thorough examinations.

GS1 IRELAND

Address: Second Floor, The Merrion Centre, Nutley Lane, Donnybrook, Dublin 4.

Tel: (01) 208 0660

Email: healthcare@gs1ie.org

Web: www.gs1ie.org/healthcare

Business: Global Supply Chain Standards Body.

HORAN

HORAN AUTOMATION AND ROBOTICS LIMITED

Address: Drangan, Thurles, Co Tipperary, E41 DA36.

Tel: (052) 915 2208

Email: sales@horan.ie

Web: www.horan.ie

Business: Automation, Integration, Service, Packing, Palletising, Filling machinery, Robotics, Consulting, Design, Prototyping, Medical device assembly, Sub Component assembly.

Contact: Sales & Marketing Director: Gary Monks

HALEON

Address: Clogherane, Knockbrack, Dungarvan, Co. Waterford

Tel: 086 4081878

Email: gillian.m.power@haleon.com

Web: www.haleon.com

Business: Healthcare manufacturer.

Contact: Business Manager/Comms & Engagement Lead: Gillian Power

HOVIONE LTD

Address: Loughbeg, Ringaskiddy, Co. Cork, Ireland.

Tel: +353 21 451 2856

Fax: +353 21 437 8697

Email: hello@hovione.com

Web: www.hovione.com

Contact: General Manager: Dr. Paul Downing

HUBBCAT

Address: Block 2, Newtown & Business Enterprise Park, Newtownmountkennedy, Co. Wicklow.

Tel: +353 89 700 3476

Email: niall.otoole@hubbcat.com

Business: Telecommunications.

Contact: COO: Niall O'Toole

ICDS RECRUITMENT CONS ULTANTS

Address: Connacht House, 24 Upper Fitzwilliam Street, Dublin 2.

Tel: +353 1 632 1200

Email: info@icds.ie

Web: www.icds.ie

Business: Specialist Recruitment Consultants to the Pharmaceutical, Life Science, Chemical, Medical Device, Food and Technology sectors.

IDA IRELAND

Address: Three Park Place, Hatch Street Upper, Dublin 2.

Tel: (01) 603 4000

Email: idaireland@ida.ie

Web: www.idaireland.com

Business: Investment Promotion & Development Agency.

INDAVER IRELAND

Address: The Highline, 1st Floor, Bakers Point, Pottery Road, Dun Laoghaire, Co. Dublin, A96 KW29.

Tel: (01) 697 2900

Fax: (01) 633 5464

Email: info@indaver.ie

Web: www.indaver.ie

Business: Hazardous & nonhazardous waste disposal and recovery ensuring full compliance.

COMPANY LISTINGS

INOPSYS NV

Address: Maanstraat 9B, 2800 Mechelen, Belgium.

Tel: +32495653821

Email: thomas.windels@inopsys.eu

Web: www.inopsys.eu

Business: Providing circular side stream solutions. Purifying water and recovering materials with mobile & modular installations.

Contact: Sales Manager: Thomas Windels

INTERPAC

Address: 67E Heather Road, Sandyford Industrial Estate, Sandyford, Dublin D18 NV90.

Tel: (01) 294 0600

Fax: (01) 294 0602

Email: ian@interpac.ie

Web: www.interpac.ie

Business: Supplier of packaging to the pharmaceutical, hazardous waste, food and dairy industries.

Contact: Director: Ian Sutton

INVEST NORTHERN IRELAND

Address: Bedford Square, Bedford Street, Belfast, BT2 7ES.

Tel: (0044) 800 181 4422

Web: www.investni.com

Business: Economic development agency.

KUEHNE + NAGEL IRELAND

Address: Unit D2 Horizon Logistics Park, Harristown, Swords, Co. Dublin, K67 A5W6.

Tel: (01) 823 9777

Email: Seamus.keane@kuehne-nagel.com

Web: ie.kuehne-nagel.com

Business: Global Freight Forwarding & Supply Chain Management.

Contact: Seamus Keane, VPPharma&Healthcare - Europe Mob: +353 85 8666646

KUKA ROBOTICS IRELAND

LTD.

Address: Unit 16, Brewery Business Park, Ardee Rd, Cambrickville, Dundalk, Co. Louth, A91 ATX4, Ireland.

Tel: (042) 939 5034

Email: sales.ie@kuka.com

Web: www.kuka.com

Business: Industrial robotics & automation.

Contact: Managing Director KUKA IE: Brian Cooney

Your trusted Global Logistics Par tner

KWE (I reland) Ltd

GDP Wholesale Licence Holder

Dublin Head Office & Temperature Controlled

Warehouse Facility

Address: Horizon Logistics Park, Harristown, Swords, Co. Dublin.

Tel: (01) 823 9600

Email: kwedub@kwe.com

KELSIUS

Address: Ballyconnell Industrial Estate, Falcarragh, Co. Donegal

Tel: (074) 916 2982

Email: sales@kelsius.com

Web: www.kelsius.com

Business: Wireless Temperature Monitoring

Contact: Sales Manager: Ciaran Gallagher

Web: www.kwe.com

Cork Regional Office & Warehouse Facility

Address: South Ring West Business Park, Tramore Road, Cork.

Tel: (021) 497 5722

Email: kweork@kwe.com

L LABPLAN

Address: Allenwood Enterprise Park, Allenwood, Naas, Co Kildare.

Tel: (045) 870 560

Email: info@labplan.ie

Web: www.labplan.ie

Business: Lab supplier of analytical instrumentation, services, technical support.

LENNOX LABORATORY SUPPLIES LTD

Address: John F. Kennedy Drive, Naas Road, Dublin, D12FP79.

Tel: (01) 460 7600

Email: customerservice@lennox.ie

Web: www.lennox.ie

Contact: Padraig Callan, Head of Business Development

LIMERICK PACKAGING

Address: Eastlink Business Park, Ballysimon Rd., Limerick.

Tel: (061) 400 035

Email: info@lmkpkg.ie

Web: www.limerickpackaging.ie

Business: Packaging manufacturers, Distributors, Designers and Auditors.

Contact: Sales Director: Mike Boland

LISTER MACHINE TOOLS LTD

Address: PO Box 838, Bluebell Industrial Estate, Dublin 12.

Tel: (01) 450 8866

Email: sales@listermachinetools.com

Web: www.listermachinetools.com

Business: Supply of machine tools and ancilliary equipment, service and support.

Contact: Sales: Ryan McGrath

LOTUSWORKS

Address: Building 3, Finisklin Business Park, Sligo, F91 KAP2.

Tel: (071) 916 9783

Email: contactus@lotusworks.com

Web: www.lotusworks.com

Business: Engineering & Technical Solutions Provider.

M

MACLACHLAN & DONALDSON

Address: Unit 10, 4075 Kingswood Road, Citywest Business Campus, D24

Tel: (01) 676 3465

Email: mail@maclachlan.ie

Web: www.maclachlan.ie

Business: Intellectual Property Attorneys.

MSD IRELAND

Address: Red Oak North, South County Business Park, Leopardstown, Dublin 18.

Tel: +353 (0)1 299 8700

Email: info@msd.ie

Web: www.msd.ie

MASON TECHNOLOGY

Address: 228 South Circular Road, Dublin, D08 DX8P

Tel: (01) 453 4422

Fax: (01) 415 4492

Email: info@masontec.ie

Web: www.masontechnology.ie

Business: Provider of scientific and laboratory equipment, and technical services including installation and calibration.

Contact: Strategic Marketing Manager: Eilish Sutton

MICRO-BIO IRELAND LTD

Address: Industrial Estate, Fermoy, Co. Cork

Tel: (025) 31388

Fax: (025) 32458

Email: info@micro-bio.ie

Web: www.micro-bio.ie

Business: Chemical Manufacturer.

Contact: Sales Director: Tom Tobin

Business: MSD Ireland is one of the country’s leading healthcare companies, having first established here over 50 years ago. We have a dynamic and diverse team of over 2,800 employees currently across six sites in Ballydine, Co Tipperary, Brinny, Co Cork, Dunboyne, Co Meath, Carlow and Dublin, and, in addition, operate substantial Human Health and Animal Health businesses. At MSD Ireland, we work at the forefront of science and technology to advance manufacturing excellence and R&D across our Irish sites and global company network. With a long-standing footprint in Ireland, our Irish sites manufacture approximately half of MSD’s top twenty products, helping save and enhance lives in over sixty countries around the world.

Contact: Mairead McCaul

MSD Ireland (Human Health) LTD

COMPANY LISTINGS

NELIPAK HEALTHCARE PACKAGING

Address: Galway: Unit 6D, Mervue Business Park, Mervue, Galway, H91 C9D0, Ireland.

Tel: (091) 757 152

Address: Offaly: Kilbeggan Road, Clara, Co. Offaly, R35 F583, Ireland.

Tel: (057) 933 1888

Address: Derry: 1 Acorn Road, Campsie Industrial Estate, Derry, BT47 3GQ, Northern Ireland.

Tel: 0044 28 7181 4000

Email: info@nelipak.com

Web: www.nelipak.com

Business: Innovative packaging solutions and complementary products and services for the healthcare market serving the medical and pharmaceutical sectors.

Contact: Director of Global Marketing: Sean Egan

NPP GROUP LTD

Address: Unit 2, Vantage Business Park, Coldwinters, Dublin 11.

Tel: (01) 880 9299

Email: sales@npp.ie bmcmahon@npp.ie

Web: www.npp.ie

Business: Flexible packaging suppliers & distributors.

OCON CHEMICALS LTD

Address: Unit 3, M.F.T. Business Park, Doughcloyne Ind. Estate, Sarsfield Road, Co. Cork.

Tel: (021) 431 8555

NATIONAL CHEMICAL COMPANY

Address: NCC House, 42 Lower Leeson St., Dublin 2, D02 FX39.

Tel: (01) 613 1400

Fax: (01) 634 0132

Email: sales@ncc.ie

Web: www.ncc.ie

Business: Supply Chain PartnerLife Sciences Industry.

Contact: Product Manager: Christy Smith

Email: info@oconchemicals.com

Web: www.oconchemicals.ie

O’FLYNN MEDICAL LTD

Address: Macroom Environmental Park, Bowl Road, Macroom Co. Cork, P12 YD92.

Tel: (029) 21 799

Email: info@oflynnmedical.com

Web: www.oflynnmedical.com

Business: Distributor of OSL “Automated Protective Clothing Distributor”.

Contact: Conor O’Flynn

COMPANY LISTINGS

ORTEC INC.

Address: Newcastle West Business Park, Station Road, Newcastle West, Limerick, V42 E765.

Tel: +353 87 7752914

Email: jgeraghty@ortecinc.com

Web: www.ortecinc.com

Business: Contract Manufacturing.

Contact: Business Development Manager: John Geraghty

PH ARMACEUTICAL MANUFACTURING

TECHNOLOGY CE NTRE (PMTC)

Address: Bernal Institute, University of Limerick, Co. Limerick, V94 T9PX.

Tel: 086 8530310

Email: pmtc@ul.ie

Web: pmtc.ie

Business: Research and development.

Contact: Centre Director: Sarah Hayes

PHARMALEX

Address: Suite 2, Stafford House, Strand Road, Portmarnock, Co. Dublin, D13 H525.

Tel: +353 1 846 4742

THE PACKAGING CENTRE LTD

Address: Fox & Geese House, Naas Road, Dublin 22.

Tel: (01) 450 8759

Email: sales@thepackagingcentre.ie

Web: www.thepackagingcentre.ie

Contact: Managing Director: Ivan Powell

PARTICULAR SCIENCES LTD

Address: 2 Birch House, Rosemount Business Park, Ballycoolin Road, Finglas, Dublin D11 T327.

Tel: (01) 820 5395

Fax: (01) 822 8813

Email: info@particular.ie

Web: www.particular.ie

Business: Supply, service and support of laboratory equipment.

Contact: Business Development Manager: Donnchadha Quilty

Web: www.pharmalex.com/ireland

Business: An award winning EU and US Quality, Technical & Compliance consultancy to the life science industry.

Contact: Commercial Manager: Anne Marie Purcell

PORTAKABIN IRELAND

Address: Roseville Business Park, Turvey Avenue, Donabate, Co. Dublin.

Tel: (01) 960 9482

Web: www.portakabin.ie

Business: Portakabin is the pioneer of modular construction in Europe, delivering interim and permanent bespoke buildings, of any size and to fulfil almost any application, site and design. Portakabin has provided award-winning off-site built environments of outstanding quality, with unrivalled on time and on budget performance, for over 50 years.

PPD, INC.

Address: Building C, Athlone Business & Technology Park, Garrycastle, Athlone, Co. Westmeath.

Tel: (0906) 460 300

Web: www.ppd.com

Business: Contract Research Organisation.

PBC BIOMED

Address: 4D, Western Business Park, Shannon, Co. Clare, V14 RW92

Tel: +353 86 1280618

Email: bronagh@pbcbiomed.ie

Business: Medical device consultancy

Contact: Ms Bronagh O'Doherty

PROSYS CONTAINMENT AND SAMPLING TECHNOLOGY

Address: IDA Business Park, Carrigtohill, Co. Cork, Ireland, T45 AP82.

Tel: +353 21 4853900

Email: info@prosysgroup.com

Web: www.prosysgroup.com

Contact: Head of Global Sales: Michael Hennessy

Q1 S CIENTIFIC

Address: 87 Westside Business Park, Co. Waterford.

Tel: (051) 355977

Email: info.cqw@cambrex.com

Web: www.q1scientific.com

Business: Stability Storage (ICH/GMP).

Contact: Stephen Delaney, MD

QUITMANN O’NEILL PACKAGING LTD

Address: St. Brendan’s Road, Portumna, Co. Galway, H53 HX51. Tel: (090) 9741148

Email: sales@quitmannoneill.com

Web: www.quitmannoneill.com

Business: Packaging Disributor and Stockist.

Contact: David O’Neill

READING SCIENTIFIC SERVICES LIMITED

Address: The Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, Berkshire, RG6 6LA, UK.

Tel: +44 (0) 118 918 4076

Web: www.rssl.com

Business: Analytical Testing Laboratory.

COMPANY LISTINGS

RED ENGINEERING DESIGN LTD

Address: Sobo Works, 2 Windmill Lane, Sir John Rogerson's Quay, Dublin Docklands, Dublin 2, D02 K156.

Tel: (01) 661 4420

Web: www.red-eng.com

Business: Engineering & Project Management Company.

Contact: Director: Simon Young

SCIENCE FOUNDATION IRELAND (SFI)

Address: 3 Park Place, Hatch Street Upper, Dublin 2.

Tel: (01) 607 3200

Email: info@researchireland.ie

Web: www.sfi.ie

Business: Government funding agency for research.

Contact: Director - Strategy and Communications: Dr. Ruth Freeman

SCIENTIFIC INSTRUMENTS IRELAND

Address: Oulart House, Cullagheerva, Clonsilla, Dublin 15.

Tel: 086 833 1056 (Jenny)

Email: info@siireland.ie

Web: www.siireland.ie

Business: Distribution and Service Support of Sample Preparation and Analytical Equipment.

Contact: Jenny Egan

SK PHARMTECO

Address: Watery Lane, Swords, Co. Dublin.

Tel: (01) 813 9000

Email: skpharmteco@sk.com

Web: www.skpharmteco.com

Business: Contract Development Manufacturing Organisation.

Contact: Director Business Development &

Marketing: Brian Fairley

SKYCELL AG

Address: Bahnhofplatz 6300, Zug, Switzerland.

Tel: 00 4144 533 2300

Email: info@skycell.ch

Web: skycell.ch

Business: Pharmaceutical Logistics & Supply Chain Solutions.

Contact: Sales Department: sales@skycell.ch

SMURFIT KAPPA IRELAND

Address: Ballymount Road, Walkinstown, Dublin 12.

Tel: (01) 409 0000

Email: info@smurfitkappa.ie

Web: www.smurfitkappa.ie

Business: Packaging.

SSPC,

SFI RESEARCH CENTRE FOR

PHARMACEUTICALS

Address: Bernal Institute, University of Limerick, Limerick, Ireland.

Web: www.sspc.ie

Business: Pharma Research Centre.

Contact: Chief Operating Officer, Dr. Sarah Hayes

SUSTAINABLE ENERGY AUTHORITY OF IRELAND

Address: 3 Park Place, Hatch Street Upper, Dublin 2.

Tel: (01) 808 2100

Email: info@seai.ie

Web: www.seai.ie

Business: Energy advice & information.

SOLTEC (IRELAND) LTD

Address: Zone C, Clonmore, Mullingar Business Park, Mullingar, Co. Westmeath.

Tel: (044) 933 5133

Email: info@soltec.ie

Web: www.soltec.ie

Business: Solvent Recovery and Hazardous Waste Management

Contact: Managing Director: Michael Corcoran

SOLV-ECHEM IRELAND LTD

Address: Great Island Industrial Park, Ballincollig, Co. Cork.

Tel: (021) 487 7066

Email: info@solvechem.com

Web: www.solvechem.com

Business: Chemical distribution, chemicals, solvents, water treatment, warehousing.

TANDEM PROJECT MANAGEMENT LTD.

Address: 11 Nessan House, Mahon Industrial Estate, Blackrock, Cork, T12 XN4V.

Tel: (021) 2038130

Email: info@tandempm.ie

Web: www.tandempm.ie

Business: Tandem is an expert project management and engineering design consultancy successfully delivering to life science clients in Ireland, the UK and Europe. Tandem’s results orientated services include project management, project controls, multi-disciplined engineering design, construction management, energy & carbon reduction and CQV.

Tandem also provide client representative teams, operational readiness consultancy and talent solutions.

Contact: Customer Relations Manager: Linda Nugent 0876897995 linda.nugent@tandempm.ie

TEK PAK AUTOMATION LTD.

Address: Whitemill Industrial Estate, Wexford, Y35 A620, Ireland.

Tel: +353 (0)53 9163033

Email: info@tekpak.ie

Web: www.tekpakautomation.com

Business: End-of-Line Automated Packaging Line Design, Manufacture, and Integration for High-Speed Retail Packaged Products and Pharmaceuticals. Tekpak Automation is Focused on the Life Sciences Industry range of pharmaceutical, biomedical, medical device, biotechnology, and cosmeceutical products. With Clients across Ireland, the UK, Europe, North America, Asia and the Middle East, Tekpak Automation can produce customised packaging machinery for product manufactures at any size or scale. Automated Applications include Robotic Pick and Place Systems, Vertical and Horizontal Cartoning, Brite Stock Loading/Unloading from Trays, Stacking, Nesting and Collating, Feeding Product to a Flow Wrapper Infeed, Labelling (TE, Print and Apply, or Thermal Transfer), Batch Data Printing with Camera Verification, Carton and Case Erectors/Closers, Case Packing and Palletising, Machine Linking Conveyors with Signal Exchange, Integration of Serialisation and Aggregation Systems, 21 CFR Part 11 Ready Machines, GAMP 5 Project Management, GMP Design Features and Full Validation Documentation. Tekpak also offers a complete range of after-sales support and service packages to reduce machine downtime and disruptions to maximise the return on investment. Contact us today to assist with your next end-of-line automated packaging project.

Contact: Managing Director: John Kehoe

THERMO FISHER SCIENTIFIC CORK LTD

Address: Currabinny, Carrigaline, Co Cork, P43 AY66.

Tel: (021) 437 8800

Email: contactcork@thermofisher.com

Web: thermofisher.com/patheon

Business: Active Pharmaceutical Ingredient Contract Development and Manufacuring.

T Wi

Address: West Building, Carrigaline Industrial Park, Carrigaline, Co. Cork, Ireland, P43 HK76.

Tel: +353 (0)21 242 8800

Email: info@technicallywriteit.com

Web: www.technicallywriteit.com

Business: TWi is a team of content strategists and content creators supporting leading technology and life sciences companies to streamline their content processes.

Contact: Business Development Director: Emmet Kearney

WESTBOURNE IT GLOBAL SERVICES

Address: The Rubicon Centre, MTU, Bishopstown, Co. Cork.

Tel: (021) 431 4310

Email: dennis.blanck@westbourneit.com

Web: www.westbourneit.com

Business: General IT and Laboratory IT Service

Provider to the pharmaceutical industry in Ireland.

Contact: Business Development Manager: Dennis Blanck

WRENTECH LTD

UNIVAR SOLUTIONS

Address: 536 Grants Crescent, Greenogue Business Park, Rathcoole, Co. Dublin.

Tel: (01) 401 9800

Email: irelandsalesoffice@univarsolutions.com

Web: www.univarsolutions.com/pharma Business: Chemical Distribution.

Contact: Key Account Manager: Carla Byrne

UPS HEALTHCARE

Address: Unit 3, Mygan Park, Jamestown Road, Finglas, Dublin 11.

Tel: +44 7979 704423

Email: ukiehealthcare@ups.com

Web: www.ups.com/ie/en/healthcare/Home.page

Business: Transport & Logsitics.

Contact: Healthcare Marketing Manager: Paul Scott

Address: Unit 3, Innovation Park, Carrigaline Ind. Estate, Kilnagleary, Co. Cork.

Tel: (021) 483 2644

Email: mwren@wrentech.ie

Web: www.wrentech.ie

ACADEMY OF CLINICAL SCIENCE AND LABORATORY MEDICINE

Tel: (01) 905 9730

E-mail: mail@acslm.ie

Web: www.acslm.ie

AN BORD PLEANALA

Tel: (01) 858 8100

E-mail: bord@pleanala.ie

Web: www.pleanala.ie

BIOPHARMACHEM

IRELAND

Tel: (01) 605 1500

E-mail: info@ibec.ie

Web: www.biopharmachemireland.ie

CHAMBERS IRELAND

Tel: (01) 400 4300

E-mail: info@chambers.ie

Web: www.chambers.ie

COMPANIES

REGISTRATION OFFICE

Tel: (01) 804 5200

LoCall: 0818 452 000

E-mail: cro.info@enterprise.gov.ie

Web: www.cro.ie

DEPARTMENT OF THE ENVIRONMENT, CLIMATE ACTION AND COMMUNICATIONS

Tel: (01) 678 2000

E-mail: customer.service@decc.gov.ie

Web: gov.ie/decc

DEPARTMENT OF ENTERPRISE, TRADE AND EMPLOYMENT

Tel: (01) 631 2121

LoCall: 0818 302 121

E-mail: info@enterprise.gov.ie Web: enterprise.gov.ie

DEPARTMENT OF HOUSING, LOCAL GOVERNMENT AND HERITAGE

Tel: (01) 888 2000

E-mail: qcsofficer@housing.gov.ie

Web: www.housing.gov.ie

ELECTRICITY SUPPLY

BOARD

Tel: (01) 676 5831

E-mail: esbnetworks@esb.ie

Web: www.esb.ie

ENTERPRISE

IRELAND

Tel: (01) 727 2000

Web: www.enterprise-ireland.com

ENVIRONMENTAL HEALTH ASSOCIATION OF IRELAND

Tel: (01) 276 1211

Web: www.ehai.ie

ENVIRONMENTAL PROTECTION AGENCY

Tel: (01) 268 0100

Web: www.epa.ie

HEALTH AND SAFETY AUTHORITY

Tel: (01) 614 7000

LoCall: 0818 289 389

E-mail: contactus@hsa.ie Web: www.hsa.ie

HEALTH PRODUCTS REGULATORY AUTHORITY

Tel: (01) 676 4971

E-mail: info@hpra.ie Web: www.hpra.ie

HEALTH RESEARCH BOARD

Tel: (01) 234 5000

E-mail: hrb@hrb.ie Web: www.hrb.ie

HIGHER EDUCATION AUTHORITY

Tel: (01) 231 7100

E-mail: info@hea.ie Web: www.hea.ie

IDA - INDUSTRIAL DEVELOPMENT AGENCY

Tel: (01) 603 4000

E-mail: idaireland@ida.ie Web: www.idaireland.com

INSTITUTE OF CHEMISTRY OF IRELAND

USEFUL REFERENCES

E-mail: secretary@instituteofchemistry.org Web: chemistryireland.org

INTELLECTUAL PROPERTY OFFICE OF IRELAND

Tel: (056) 772 0111

E-mail: ipinfo@ipoi.gov.ie Web: https://www.ipoi.gov.ie/en/

INTERNATIONAL SOCIETY FOR PHARMACEUTICAL ENGINERING (ISPE)

Tel: +1 (813) 960 2105

E-mail: ask@ispe.org Web: www.ispe.org

INVEST NORTHERN IRELAND

Tel: 0800 181 4422 Web: www.investni.com

IRISH BUSINESS & EMPLOYERS CONFEDERATION (IBEC)

Tel: (01) 605 1500

E-mail: info@ibec.ie Web: www.ibec.ie

IRISH CLEANROOM SOCIETY

Web: www.cleanrooms-ireland.ie

IRISH COSMETICS, DETERGENT & ALLIED PRODUCTS ASSOCIATION

Tel: (01) 605 1500

E-mail: kevin.maher@ibec.ie Web: www.icda.ie

IRISH EXPORTERS ASSOCIATION

Tel: (01) 661 2182

E-mail: contact@irishexporters.ie Web: www.irishexporters.ie

IRISH MEDTECH ASSOCIATION

Tel: (01) 605 1500

E-mail: info@irishmedtechassoc.ie Web: www.irishmedtechassoc.ie

IRISH NATIONAL ACCREDITATION BOARD

Tel: (01) 614 7182

E-mail: info@inab.ie Web: www.inab.ie

IRISH PHARMACY UNION

Tel: (01) 493 6401

E-mail: info@ipu.ie

Web: www.ipu.ie

IRISH VENTURE CAPITAL ASSOCIATION

Tel: (01) 276 4647

Web: www.ivca.ie

Email: ciara@ivca.ie

MANDATE TRADE UNION

Tel: (01) 874 6321

E-mail: mandate@mandate.ie

Web: www.mandate.ie

NATIONAL INSTITUTE FOR TRANSPORT & LOGISTICS (NITL)

Tel: (01) 402 3898

Web: www.nitl.ie

PARENTERAL DRUG ASSOCIATION (PDA)

Tel: +1 (301) 656 5900

Web: www.pda.org

PHARMACEUTICAL SOCIETY OF IRELAND

Tel: (01) 218 4000

E-mail: info@psi.ie

Web: www.thepsi.ie

REPAK

Tel: (01) 467 0190

E-mail: info@repak.ie Web: www.repak.ie

SCIENCE FOUNDATION IRELAND

Tel: (01) 607 3200

E-mail: info@sfi.ie

Web: www.sfi.ie

UCD SCHOOL OF CHEMICAL & BIOPROCESS

ENGINEERING

Tel: (01) 716 1825

E-mail: SCBE.enquiries@ucd.ie

Web: www.ucd.ie/chembioeng

ENSURING UNINTERRUPTED PATIENT SUPPLY

• Global distribution of investigational medicines and finished products

• Time critical, temperature sensitive patient supply

• Supporting the needs of Irish Manufacturing Plants

• Established GDP & GMP capacity in Dublin to help futureproof your supply chain

Learn more about how our expertise and resilience can help you with your supply chain needs:

John Halpin, Business Development

john.halpin@dhl.com

+ 353(0)86 0665865

DHL Supply Chain – Excellence. Simply delivered. www.dhl.com/gb-en/home/our-divisions/supply-chain.html

PharmaChem Yearbook 2025

CONTENTS

Future-proofing our Biopharma Industry

RECOMMENDATIONS FOR GOVERNMENT

1. Priority 1: Establish a National Life Sciences Strategy

2. Priority 2: Invest in Skills and Talent

RECOMMENDATIONS FOR GOVERNMENT

Let’s outdo cancer

Taking cancer on

RECOMMENDATIONS FOR GOVERNMENT

Cara Partners 40 Years and Growing

Manufacturing Sector Performing Strongly Despite Rising Costs

MANUFACTURING

A Critical Role in the Economy

Priorities for Government

MANUFACTURING REPORT

The Challenges Ahead

The Impact of AI

Spiralling Costs

Helping Irish business go global

MANUFACTURING REPORT

Case Study: MSD

INNOVATIVE PLASMA THERAPIES

BioPharmaChem Impact 2025: Realising the Potential of the Ecosystem

Leaders Conference, Awards & Gala Dinner, 08 May 2025

Where Innovation Thrives

BIOPHARMACHEM IMPACT CONFERENCE & AWARDS

BioPharmChem Awards 2025

Seeking Partners to Support BioPharmaChem Impact 2025

Apprenticeship Programme a Massive Success

Bridging Skills Gaps

Level 8 Programme Launched

McCann FitzGerald LLP

STEM ENGAGEMENT

STEM-ming the Skills Gap

National Training Fund

Surveying BPCI Members on STEM Engagement

STEM ENGAGEMENT

Targeting Primary and Post-Primary Schools

Further Engagement Opportunities

Ireland Continues to Punch above its Weight

Ibec's KeepWell Mark - National Standards for Workplace Wellbeing

Addressing Modern Challenges with Practical Solutions

Case Study: Sterling Pharma Solutions

Create the Conditions for a Culture of Sustained Wellbeing

Beyond Responsible Care: A Sustainable & Prosperous Society

The Carbon Challenge

A Collaborative Framework

Data & Standards:

Energy & Infrastructure:

Culture, Communication & Mindset:

Scope 3:

Conclusion

A Year of Growth and Innovation at BioPharmaChem Skillnet

Highlights of 2024: Building Momentum

Innovative Programmes: Meeting Industry Needs

Looking Ahead to 2025: Driving Excellence

Bridging Skills Gaps through Talent Development

Ireland’s Role in Biopharma

Future Workforce Needs in Biopharma

NIBRT

NIBRT’s role in Biopharma Skills Development

The Importance of Competency Training in Biopharma

The Future Remains Bright

ALEXION IRELAND IS HOME TO

Managing Medicine Shortages

EMA’s Extended Remit

HEALTH PRODUCTS REGULATORY AUTHORITY

Advancing our National Systems

Pharmaceutical Strategy

Conclusion

Cutting-Edge Research at SSPC

Innovative Industry Collaborations

PMTC: Anticipating Your Needs

Landscape

Meeting your R&D Needs

Partnership is

Your Pathway to Success

SETU Wins Top Research Award

Diverse Research Activity

SPECIALIST REFRIGERATION ENGINEERING